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Abstract: 
Background: 
Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer however 
chemoresistance can be a major obstacle in ER+ cancers. Using comparative proteomic approaches 
(antibody microarray/AbMA and 2D-PAGE with MALDI-TOF/TOF MS) to investigate a pilot series of 
breast cancer samples our research group recently identified 14-3-3 theta/tau, tBID and BcL-XL as 
putative biomarkers of response to neoadjuvant chemotherapy (Hodgkinson et al J Prot 2012, 75:1276-
1283 and 75:2745-2752). Here we aimed to analyse further samples using the AbMA approach and to re-
analyse the combined data. 
Methods: 
Samples from chemoresistant and chemosensitive breast cancers were selected following anthracycline-
taxane chemotherapy and 4 experiments were performed using ductal ER+ tumours. Differential protein 
expression was compared between chemoresistant and chemosensitive samples using the Panorama 
XPRESS Profiler725 AbMA kit. The combined data from 9 AbMA assays and 3 2D-PAGE/MS 
experiments was then analysed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems). A pilot 
series of archival samples was used for clinical validation of putative predictive biomarkers. 
Results: 
89 differentially expressed proteins (DEPs) were seen in the 4 further AbMA experiments. In the 
combined dataset (12 experiments from 2 proteomic platforms), 8 DEPs were seen in at least 3 
experiments. These were 14-3-3 theta, 14-3-3 epsilon, 14-3-3 gamma, Bcl-xl, Bid, Phosphokinase B, 
Vimentin and FAK. 121 DEPs from the combined data were analysed using IPA; 13 DEPs were mapped 
onto the PI3K/AKT pathway. Clinical validation in a pilot series of archival samples revealed AkT-1 
Ser473 and FAKY397 alongside the previously identified and validated 14-3-3 theta/tau, and tBID to be 
significantly associated with chemotherapy resistance. 
Conclusion: 
We have now identified at least 8 proteins which could play a role in breast chemoresistance. We propose 
a potential role for AkT-1, FAK, 14-3-3 theta/tau and tBID as predictive biomarkers of neoadjuvant 
chemotherapy resistance in breast cancer. Further validation in a larger sample series is now required.  
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Chapter 1.   
1.1 BREAST ANATOMY: 
The mammary gland is a modified sweat gland situated in the superficial fascia on the anterior 
wall of axilla. It overlies the pectoralis muscles. It is rudimentary in males, in females it start 
enlarging at the age of puberty. The primary function of mammary glands is to produce milk 
during lactation; milk is produced in the glandular acini of the lobules and transferred via the 
intralobular ducts into the extralobular and finally the lactiferous duct. The contraction of 
myoepithelial cells at the basement membrane of the acini ejects the milk into the intralobular 
ducts. 
1.1.1  Gross Anatomy: 
A well developed female adult breast is conical in shape; its base extending transversely from the 
lateral border of the sternum medially to the mid axillary line laterally. Vertical extension is from 
the 2
nd
 to 6
th
 rib on the anterior chest wall (Figure 1). The breast has an extension directed 
towards the axilla called the axillary process of spence or axillary tail. This is important 
clinically because it can contain abnormal breast masses. 
1.1.2 Breast Structure: 
The fibrous connective tissue that forms the breast fascia extends between skin and pectoral 
fascia through the substance of the gland and is called the suspensory ligaments of Astley 
Cooper. This provides internal support to the gland and divides it into 8-10 radially arranged 
lobules. Each lobule is drained by a lactiferous duct which converges to the nipple like spokes of 
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a wheel; lobules produce milk during breast feeding which is transported by lactiferous ducts. 
There are 8-10 openings depending on the gland lobulation on the surface of the nipple, the duct 
presents as dilatation under the areola called lactiferous sinus (Figure 1).  
 
 
GROSS ANATOMY OF THE BREAST 
 
 
 
Figure 1: Gross anatomy of the breast showing division of the gland into lobules. Each of the 
breast lobule is drained by its own lactiferous duct and all the ducts from different lobules join to 
form a mammary duct. Atlas of Anatomy.com (c) (2004) J Artner MD. 
 
1.1.3 The Terminal Ductal Lobular Unit: 
The distal terminus of the ductal network is the terminal ductal lobular unit (TDLU). Each of the 
lobes in the breast contains thousands of TDLUs, which form the functional secretory unit. The 
secretory units produce milk, which drains via the branching ducts to their terminus as the 
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ampullae at the surface of the nipple (Figure 2). The TDLU is complex and consists of the 
extralobular and intralobular terminal ducts, and the blindly ending lobules (or ductules). Each 
TDLU is lined by an inner layer of secretory cells and an outer layer of myoepithelial cells 
containing contractile fibers that eject the milk into the ducts during lactation (Shaaban AM 
2002).  
 
 
THE TERMINAL DUCTAL LOBULAR UNIT (TDLU) 
 
 
 
Figure 2: show an illustration of terminal ductal lobular unit. Each TDLU is made up of distal 
terminus of the duct and a breast lobule. It is lined by inner secretory and outer myoepithelial 
cells and produce milk during lactation.  Hindle, W, Mokbel, K, Glob. Libr. Women’s med., 
(ISSN: 1756-2228) 2009. 
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1.2 CLINICAL INTRODUCTION TO BREAST CANCER: 
1.2.1 Epidemiology:   
Breast cancer accounts for about 31% of all cancer cases in women worldwide and is the second 
most common cancer in the UK. The UK Department of Health (DoH) Office of national 
statistics data from 2010 shows, 49,961 new cases of breast cancer diagnosed that year. About 
99% of them were in women and less than 1% in men (2011). In the year 2008, the estimated 
worldwide incidence of breast cancer was 1.38 million. This accounted for around a tenth 
(10.9%) of all new cancers and nearly 23% of all female cancer cases (Westlake S 2008).  
1.2.2 Aetiology: 
The aetiology of breast cancer is multi factorial and poorly understood as various risk factors 
modulate the development of breast cancer in women through reproductive age and after 
menopause (Dumitrescu and Cotarla 2005). This section summarizes breast cancer risk 
associated with each factor in detail (summarised in the Table 1). 
1.2.3 Breast Cancer Risk Factors: 
1.2.3.1 Age: 
Breast cancer risk increases with age. Nearly 80% of diagnosed cancers occur in women 50 and 
over (Figure 3). The estimated lifetime risk of developing breast cancer for women in the UK is 
1 in 10 below 65 years and 1 in 8 between 65 to 80 years (2005; Glass AG 2007). 
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Table 1:                    Summary of Breast Cancer Risk Factors 
                                            (Adapted from Dumitrescu and Cotarla 2005) 
 
  
Breast Cancer Risk Factors 
 
Magnitude of Risk 
 
 
 
Well confined Risk 
Factors 
 
 
 
 
 
 
 
 
 
 
 
Probable Factors 
 
 
 
Increasing age  
Geographical region (western countries)  
Family history of breast cancer  
Mutations in BRCA1 and BRCA2 genes  
Mutations in other high-penetrance genes (Li 
Fraumeni syndrome, ATM, NBS1, LKB1)  
Ionizing radiation exposure (in childhood)  
History of benign breast disease  
Late age of menopause (>54)  
Early age of menarche (<12)  
Nulliparity and older age at first birth  
High mammographic breast density  
Hormonal replacement therapy  
Oral contraceptives recent use  
Obesity in postmenopausal women  
Tall stature  
Alcohol consumption (~1 drink/day)  
 
 
High insulin-like growth factor I (IGF-I) levels  
High prolactin levels 
High saturated fat and well-done meat intake  
Polymorphisms in low-penetrance genes  
High socioeconomic status  
 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
 
 
 
 
 
++ 
+ 
+ 
+ 
+ 
++ (moderate to high increase in risk);                     -- (moderate to high decrease in risk); 
+ (low to moderate increase in risk)                           - (low to moderate decrease in risk) 
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AGE RELATED INCIDENCE RATE OF BREAST CANCER 
 
 
 
Figure 3: The graph shows an age related specific incidence rate for breast cancer between 
2006 and 2008. As shown from the figure the incidence of breast cancer increase after age 50 
with a peak in the rates of breast cancers at 65 years. Adapted from The Office of National 
Statistics, 2008. 
 
1.2.3.2 Hormonal factors: 
Long uninterrupted exposure to Oestrogen and Progesterone hormones can affect the chance of 
developing breast cancer (Farquhar C ; 2003). Individual hormonal factors that increase the risk 
include: 
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 Hormone replacement treatment containing oestrogen and progesterone over several years 
 Nulliparity or late motherhood 
 Absence of breastfeeding or breastfeeding for less than a year 
 Early menarche (under 12) or late menopause (after 50)  
1.2.3.3 Familial Breast Cancers: 
Hereditary or familial breast cancers accounts for 25% of all breast cancer cases. Germline gene 
mutations in BRCA1, BRCA2, CHEK2, PTEN and TP53 increase the risk of both breast and 
ovarian cancers by 5-7%. Higher prevalence is noted in women with a family history of breast or 
ovarian cancer at a young age or multiple tumours and in certain ethic groups such as Ashkenazi 
Jews. The mutant protein cannot carry out the normal cell functions of cell regulation growth, 
DNA repair and apoptosis. As a result, cells grow in an uncontrolled fashion increasing the 
chances of malignant transformation.  
1.3 BREAST CANCER CLASSIFICATIONS: 
Breast cancers can be classified under four different classification schemes, or groups. Each type 
of classification is based on different criteria and serves a different purpose.  The most 
commonly used classification systems are based on: 
 Histological appearance  
 Tumour Grade 
 Protein and Gene expression status   
 Tumour Stage 
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1.3.1 Histological Classification: 
The classification of breast cancer into different histological sub-types is based on the 
microscopic anatomy and tumour spread. Breast cancers can be broadly divided into two major 
histological subtypes: ductal and lobular (summarised in the Table 2). Ductal disease originates 
from milk ducts and lobular disease from breast lobules. Further, depending on the spread of 
tumour cells beyond the basement layer, it can be invasive or non-invasive.  
1.3.1.1 Invasive Breast Cancer: 
Invasive breast cancers by definition spread beyond the basement layer and can be divided into 
ductal and lobular sub-types. Invasive ductal carcinoma (IDC) no-specific type is the most 
common form (80%) of all the invasive sub-types. Invasive lobular carcinoma is less common 
and account for only 10% of invasive cancers.   
Table 2:        Histological Classification of Breast Cancers 
 
 
    Type 
 
           Invasive 
 
Non-Invasive (In-situ) 
 
Ductal 
 
Invasive Ductal Carcinoma 
(IDC) 
 
Ductal Carcinoma In-situ 
(DCIS) 
 
Lobular 
 
Invasive Lobular Carcinoma 
(ILC) 
 
Lobular Carcinoma In-situ 
(LCIS) 
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1.3.2 Breast Cancer Histological Grade Classification: 
Histological grade in breast cancer has an independent prognostic significance, as it, along with 
other predictive factors such as receptor status, guides patient treatment management (El-Sayed 
et al. 2008). The three commonly used prognostic determinants for breast cancer include: 
axillary node (LN) status, primary tumour size, and tumour histologic grade. The most widely 
used histologic grading system of breast cancer is the Nottingham combined histologic grade 
(Elston-Ellis modification of Scarff-Bloom-Richardson grading system), also known as the 
Nottingham Grading System. Originally proposed by Bloom-Richardson in 1957, it is a 
numerical grading system categorizing breast tumours into three pathological grades of grade 1 
to 3 based on the degree of tubule formation, nuclear pleomorphism and hyperchromatic mitotic 
nuclei.  This classification system is more commonly used in Europe, including the UK. 
1.3.2.1 Prediction of Prognosis based on Histological Grade: 
The Nottingham Grading System has undergone a rigorous validation in number of other 
independent studies to determine its usefulness in predicting cancer. Furthermore, NGS has been 
combined with lymph nodal status and tumour sizes to develop a prognostic index. One such 
index created by the Nottingham Study Group is called Nottingham Prognostic Index (NPI) 
taking into account tumour size, grade and lymph node status. The histological grade and lymph 
node status are awarded an equal weighting in the NPI scoring them similarly on a scale of 1 to 
3. The combined score from the above two is then added to the multiplied score of 0.2 and 
tumour size (in centimetres). Cut-off points of 2.4, 3.4, 4.4, 5.4and 6.4 can be used to stratify the 
patients into groups excellent, good, moderate I, moderate II, poor and very poor prognosis 
respectively. 
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NPI = 0.2 x tumour size in cm + Tumour grade + Lymph node status  
 
Despite the usefulness of histological grading in predicting the prognosis, tumour gene 
signatures have been found to have superior predictive and prognostic powers (Sotiriou, Wirapati 
et al. 2006; Peppercorn, Perou et al. 2008). For histological grading, factors such as subjectivity 
of histologic technique, reproducibility and inter/ intra-observer variability can all preclude its 
applicability at all times (Rakha, Reis-Filho et al. 2010). 
1.3.3 Breast TNM classification: 
The tumour node metastasis (TNM) staging system is a universally accepted staging system for 
breast cancer. This classification is based on a retrospective analysis of diverse population 
groups representing all stages of disease and correlation of tumour characteristics with survival 
data. TNM classification is periodically updated to incorporate changes from evolving imaging 
and treatment options which impact patient survival.  The American Joint Committee on Cancer 
(AJCC) outlines TNM staging, which is also accepted by International Union Against Cancer 
(UICC). In this classification, breast cancers are classified based on extent of tumour (T); spread 
to the lymph nodes (N) and presence of distant Metastasis (M). A numerical designate is added 
against each letter to indicate the size of primary tumour or its extent and the extent of cancer 
spread. The updated version (7
th
 edition) of the breast cancer TNM staging was proposed by 
AJCC in 2003. In this edition, amendments were made to incorporate nodal micro-metastasis 
with a size-based discrimination between micro-metastases and isolated tumour cells. Also a 
classification of lymph node status by the number of involved axillary lymph nodes and 
inclusion of metastasis to the infraclavicular, internal mammary, and supraclavicular lymph 
nodes were included (Cancer). With the quantification of nodal metastasis with new 
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classification, it was expected that there could be a raised possibility of finding more evidence of 
nodal micrometastases than before thereby creating a discrepancy between the clinical axillary 
nodal status and its pathological state. Therefore, in the revised TNM staging the pathological 
staging system has been reorganized to classify patients with one to three positive axillary lymph 
nodes (with at least one tumour deposit > 2.0 mm and all tumour deposits > 0.2 mm) as pN1a; 
patients with four to nine positive axillary lymph nodes as pN2a, and patients with 10 or more 
positive axillary lymph nodes as pN3a. Furthermore, the infraclavicular disease was staged as 
pN3a in the revised version following evidence from the  Newman et al. study of 146 locally 
advanced breast cancers showing poor correlations of disease free and overall survivals with 
infraclavicular metastasis (Newman, Kuerer et al. 2001). 
1.4 MANAGEMENT OF BREAST CANCER: 
Triple assessment is a formalized clinical approach undertaken to diagnose breast cancer. This 
approach consists of three key assessments: clinical breast examination, radiological examination 
(e.g. mammogram, ultrasound, magnetic resonance imaging) and pathological assessment (e.g. 
biopsy or cytology). 
1.4.1 Treatment of Breast Cancer: 
Breast cancers treatment involves combination of medical (e.g. chemotherapy) and hormonal 
therapies with surgery. Surgical options for breast cancers depend on the patient age, tumour 
size, grade and location. Breast Conserving Surgery (BCS) options include: lumpectomy and 
wide local excisions. For locally advance breast cancers, administration of neo-adjuvant 
treatment before surgery may increases the chances of BCS and avoid mastectomy (Steger and 
Bartsch 2011). At the time of surgery, axillary staging is performed by taking a sentinel lymph 
37 
 
node biopsy or axillary node sampling following the injection of a radioactive tracer and blue 
dye. In the event of finding a sentinel lymph node(s) positive for macro-metastasis (> 2 mm), the 
National Institute of Clinical Guidance (NICE) breast management guidelines of 2009, 
recommend axillary therapy in the form of clearance or radiotherapy (2009). In order to further 
reduce the chances of local recurrence, all patients treated with BCS are offered radiotherapy to 
the breast as adjuvant treatment. 
1.5 BREAST CANCER CHEMOTHERAPY: 
Breast cancer chemotherapy was first administered in mid 1970s as an adjuvant treatment 
following mastectomy and radiotherapy (DeVita and Chu 2008). Since then, the long term 
benefits of breast cancer adjuvant chemotherapy have been demonstrated in the meta-analysis of 
different adjuvant chemotherapy regimens by the Early Breast Cancer Trialist Collaborative 
Group (EBCTCG) (2005). Of the different combination used, anthracycline-based poly-therapy 
with 5-flurouracil, adriamycin and cyclophosphomide (FAC) or 5-flurouracil, epirubicin and 
cyclophosphomide (FEC) was found to show the highest rates of overall (15 years) and disease 
free (5 year) survival. Breast chemotherapy consists of different chemotherapeutic agents. A 
short summary of some of the popular regimens is illustrated in the Table 3. 
1.5.1 Breast Cancer Chemotherapeutic Agents: 
Anthracyclines:  
Anthracyclines (or anthracycline antibiotics) are a class of drugs derived from Streptomyces 
bacterium species and are commonly used for cancer chemotherapy (Fujiwara 2000). Drugs from 
this that are used in breast cancer chemotherapy regimens include: doxorubicin and epirubicin. 
The mechanism of action of anthracyclines agents is via multiple pathways and include, 
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inhibition of cytoplasmic proteases activity leading to the inhibition of degradation of proteins 
involved in cell growth and metabolism thereby inducing apoptosis; inhibition of DNA and RNA 
synthesis by intercalating between base pairs of the DNA/RNA strand, preventing the replication 
of rapidly-growing cancer cells (Takimoto CH 2008). 
 
Table 3:        Breast Cancer Chemotherapy Regimens 
 
      
Chemotherapeutic  agent 
 
 
 
Combination Regimens 
 
Cyclophosphamide 
 
 
Epirubicin 
 
Fluorouracil (5FU) 
 
 
 
 
 
Doxorubicin (Adriamycin) 
 
Methotrexate 
 
Mitomycin 
 
Mitozantrone 
 
 
Docetaxel (Taxotere) 
 
CMF- Cyclophosphamide, Methotrexate, Fluorouracil 
 
 
FEC- Epirubicin, Cyclophosphamide, Fluorouracil 
FEC-T- Epirubicin, Cyclophosphamide, Fluorouracil and 
Taxotere 
 
E-CMF- Epirubicin followed by CMF 
EC- Epirubicin and Cyclophosphamide 
 
 
AC- Doxorubicin (Adriamycin) and Cyclophosphamide 
 
MMM- Methotrexate, Mitozantrone and Mitomycin 
 
MM- Methotrexate and Mitozantrone 
 
 
 
 
EC- Docetaxel 
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Cyclophosphamide: 
Cyclophosphomide is a nitrogen mustard alkylating agent, from the oxazaphorines group. It 
comes as a ‘pro-drug’ and is converted to its active metabolite in liver by the action of 
Cytochrome P4503A4. The formed active metabolite, 4-hydroxycyclophosphamide exists in 
equilibrium with its tautomer, aldophosphamide. Most of the aldophosphamide is oxidised by the 
enzyme aldehyde dehydrogenase (ALDH) to produce carboxyphosphamide and a small 
proportion is converted into phosphoramide mustard and acrolein. The main effect of 
cyclophosphomide comes from its metabolite phosphoramide mustard which forms DNA 
crosslinks both between and within DNA strands at guanine N-7 positions that are irreversible 
and lead to cell death  (Takimoto CH 2008).   
5-Flurouracil: 
5-fluorouracil (5-FU) is a pyrimidine analog belonging to the family of drugs called 
antimetabolites. 5-FU acts in several ways, but principally it is a prodrug for FdUMP which acts 
as a thymidylate synthase inhibitor. Interrupting the action of this enzyme, blocks synthesis of 
the pyrimidine thymidine, which is a nucleoside required for DNA replication. Thymidylate 
synthase methylates deoxyuridine monophosphate (dUMP) into thymidine monophosphate 
(dTMP). Therefore in the presence of 5-FU, dTMP levels are decreased resulting in cell death 
(Longley, Harkin et al. 2003). 
Taxanes: 
The taxanes are class of anticancer drugs, originally derived from the bark of the Pacific yew, 
Taxus brevifolia. The cytotoxic action of taxanes is exerted principally by inhibition of mitosis. 
Taxanes disrupt the microtubule function by stabilizing the GDP-bound tubulin in the 
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microtubule which then inhibit the process of cell division in rapidly growing cells (Miller and 
Sledge 1999).  
1.5.1.1  BREAST NEOADJUVANT CHEMOTHERAPY: 
Neo-adjuvant chemotherapy (NACT) has become a standard treatment for locally advanced 
breast cancers.  It was introduced in the last ten years to treat locally advanced breast cancers 
with an aim to facilitate breast conserving surgery and improve 5 year survival. However, 
compared to adjuvant treatment it offers no added survival benefits (Steger and Bartsch 2011). 
Multiple chemotherapeutic regimens were studied in combination for the neo-adjuvant setting; 
however, desired clinical benefits from a particular specific ‘tailored’ regimen could not be 
established (Hudis and Modi 2007). Hence, tested and standardized adjuvant breast 
chemotherapy regimens with established safety profiles were introduced for the neo-adjuvant 
setting (Mauri, Pavlidis et al. 2005). The clinico-pathological criteria to give neo-adjuvant 
chemotherapy treatment rest solely on the local advancement of breast cancer, tumour size (large 
operable breast cancer) and/or proven lymph node metastases (Fisher, Bryant et al. 1998). 
Tumours showing a complete pathological response to neo-adjuvant treatment were found to 
show better clinical outcomes than to those with residual disease (Wolmark, Wang et al. 2001).  
The major advantage of breast neo-adjuvant chemotherapy in locally advanced breast tumour is 
that it down-stages the disease and allows breast conservation surgery (BCS). The National 
Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial assessing clinical and operative 
outcomes of women receiving pre-operative chemotherapy with operable breast cancers showed 
neo-adjuvant treatment reduce tumour bulk thereby allowing 12% more lumpectomies in  
tumours >=5 cm (Fisher, Brown et al. 1997). Further, a pathological complete response (pCR) to 
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neo-adjuvant treatment was found associated with an improved disease free (DFS) and overall 
survival (OS) at nine years of follow-up (Wolmark, Wang et al. 2001). Furthermore, the ability 
to monitor therapy responses on treatment with imaging (e.g. MRI) allows adjustments to 
chemotherapy regimen and/or drug dosages according to responses (Loo, Teertstra et al. 2008). 
Another major gain from neo-adjuvant approach is that it identifies non-responders early in the 
course of treatment and spares them from the unnecessary side effects of chemotherapeutic drugs 
for no obvious clinical gains. Therefore using this approach, non-responders can be streamlined 
early in the course of the treatment to receive alternative treatments minimizing the risk of 
disease becoming inoperable. Taxanes were added to anthracycline–based regimens to improve 
their clinical effectiveness and achieve pathological complete response (pCR) (Bonneterre, 
Dieras et al. 2004). 
1.5.1.2 Advantages of adding Taxanes: 
Taxanes have been assessed in three randomized controlled trials B-27, CVAP and GEPARDUO 
(Bear, Anderson et al. 2003; von Minckwitz, Kummel et al. 2008) for early-stage breast cancer 
neo-adjuvant chemotherapy in combination (Taxane with Anthracyclines) or sequential regimens 
(Taxanes after Anthracyclines). Docetaxel was used in all three trials; while B-27 and CVAP 
used docetaxel in sequential regimens with anthracyclines, GEPARDUO assessed it in both 
combination and sequential regimens. Results from all the three trials confirmed a significantly 
higher clinical and pCR rates after adding taxanes to anthracyclines The objective and complete 
pathological response rates (ORR and CpR) of 90% and 26% was seen in B-27 trial with AC and 
Taxane sequential therapy in 805 patients (Crown, O'Leary et al. 2004). In the GEPARDUO trial 
with AC and Taxane sequential therapy in 458 patients ORR and pCR were found to be 87% and 
22.4% respectively.  
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The results from NSABP-27 randomised phase III trial showed higher rates of pathological 
complete response with 4 cycles of anthracycline-cyclophosphomide (AC) and 4 cycles of 
docetaxel (Bear, Anderson et al. 2006). Furthermore, docetaxel when used in sequential regimen 
with AC was found to increase the disease-free survival in patients who have had partial 
response to AC regimen (DFS: Hazard ratio [HR] = 0.71; 95% CI, 0.55 to 0.91; p = .007; OS: 
HR = 0.33; 95% CI, 0.23 to 0.47; p < .0001). The National Comprehensive Cancer Network 
Guidance following the evidence, favoured using AC-docetaxel in sequential regimen for neo-
adjuvant treatment (2012). Keeping in with the above guidance, the neoadjuvant regimen used 
within the Hull and East Yorkshire Hospitals NHS trust includes a sequential administration of 4 
cycles of epirubicin/cyclophosphomide followed by 4 cycles of docetaxel.  
1.5.1.3 Assessing Response to NACT: 
Response to chemotherapy is generally assessed by clinical examination and/or radiological 
imaging. Several guidelines to define tumour response on radiological imaging have been 
proposed. Among these, the criteria validated by the Response Evaluation Criteria in Solid 
Tumours (RECIST) group (Therasse, Arbuck et al. 2000) and the UICC (International Union 
Against Cancer) are widely accepted and frequently used. Based on these guidelines, responses 
can be classified as a complete response, partial response, stable disease and progressive disease 
(Table 4). 
In general, 60-90% of breast cancers show clinical response (complete or partial) to neo-adjuvant 
therapy (Wolmark, Wang et al. 2001). A complete clinical response is defined as a complete 
disappearance of tumour following NACT; a 30% reduction in size of tumour from the baseline 
measurement is considered a partial response.  
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Table 4:                        RECIST CRITERIA  
                            (Adapted European Journal of Cancer 45 (2009) 228-247) 
 
A pathological complete response (pCR) as defined by some studies is absence of invasive 
disease from breast only. However, majority of others report pCR as absence of invasive disease 
from both breast and axillary lymph nodes thereby leading to variation in pCR reporting rates (3-
30%) between various studies (Jones and Smith 2006). Furthermore, a pCR in axillary nodes 
after NACT is shown to correlate with improved overall (OS) and relapse free survival (RFS) 
(OS and RFS: 93% and 87% vs 72%) at 5 years in contrast to patients not achieving axillary pCR 
 
 Response 
 
 
        Definition 
 
Complete Response (CR) 
 
 
Partial Response (PR) 
 
 
 
Progressive Disease (PD) 
 
 
 
 
 
 
 
 
 
 
 
 
Stable Disease (SD) 
 
 
 
Disappearance of all target lesions 
 
 
At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters 
 
 
At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study) 
 
In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5mm 
 
OR 
 
 Appearance of one or more new lesions 
 
 
 
Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference 
the smallest sum diameters 
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(OS and RFS: 72% vs 60%; p<0.001) (Hennessy, Hortobagyi et al. 2005). Therefore, a 
pathological complete response to neo-adjuvant therapy may be considered as a surrogate for 
prognosis based on the above evidence. However, different tumour subtypes are associated with 
different responses to neoadjuvant therapies. Generally, tumours containing high levels of Ki67, 
ER- and HER2+ status respond effectively to anthracycline and taxane-containing neoadjuvant 
chemotherapy but tend to have a poor clinical  outcome (Yoshioka, Hosoda et al. 2013).  
1.5.1.4 Monitoring Neo-adjuvant Therapy Response: 
As defined by the RECIST criteria (section 1.5.1.3), a complete radiological response to NACT 
is defined as disappearance of all target lesions on imaging. Traditionally, a NACT therapy 
response has been monitored on clinical examination, mammogram and ultrasound. Dynamic 
contrast enhanced-magnetic resonance imaging (DCE-MRI) has recently emerged as another 
useful investigating modality to monitor responses to NACT (Garimella, Qutob et al. 2007). 
Compared to mammogram and ultrasound, the DCE-MRI has higher sensitivity and specificity 
and hence is a good investigation tool to monitor therapy responses (Partridge, Gibbs et al. 2002; 
Bhattacharyya 2008). However, the predictive value of DCE-MRI is found to depend on 
patient’s age, tumour histology and receptor status (Hsiang et al. 2007; Chen, Feig et al. 2008).  
1.5.2 Predicative Markers of Therapy Response: 
Many clinical markers have been identified that help predict response to neo-adjuvant 
chemotherapy.  This section highlights briefly some of the most commonly used clinical markers 
to predict therapy responses. These markers although more routinely used, are not absolute, as 
molecular sub-typing and axillary staging are also important predictors of therapy responses.  
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1.5.2.1 Tumour Size and stage: 
Similar to age and menstrual status, tumour size and stage is found to have an inverse 
relationship with therapy response. High stage (nodal involvement) disease and/or large size 
tumours (> 5 cm) have less likelihood of a complete response compared to smaller tumours and 
lower stage disease (Stage IIA, IIB and IIIA) (Keam, Im et al. 2007). 
1.5.2.2  Hormone Receptor Status: 
Oestrogen (ER) and Progesterone (PR) receptor status can independently predict pathological 
complete responses following neo-adjuvant therapy (Guarneri, Broglio et al. 2006). This effect, 
independent of type of neo-adjuvant regimen employed, has been found consistently across 
many studies.  Response (pCR) rates can vary between ER+ and ER- tumours and are generally 
found to be superior with ER- sub-types. The European Cooperative Trial in Operable breast 
cancer (ECTO) study from their analysis of 1355 patients showed, 42% of ER- tumours had pCR 
compared to 12% of ER+ tumours (Gianni, Baselga et al. 2005). Similarly, Guarneri et al.; in 
their  retrospective analysis of 1731 patients had 24% of ER – tumours showing pCR with 
different neoadjuvant regimens compared to 8% of ER+ tumours  (Guarneri, Broglio et al. 2006). 
Ring et al.; in their retrospective analysis of 435 patients treated with anthracycline-combination 
regimen and mitoxantrone achieved pCR in 21.6% of ER- tumours compared to 8.1% of ER+ 
tumours (p < 0.001). In the same study, ER- tumours with pCR were found to have superior 5 
year overall survival thereby confirming the prognostic significance of pCR in ER- tumours 
(Ring, Smith et al. 2004). The therapy responses in the PR- tumours have been observed to 
follow a similar trend to ER- tumours. Daidone et al. from their study of 231 T2 tumours 
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reported, a higher response rate with PR- tumours compared to PR+ (86% vs. 68%) (Daidone, 
Veneroni et al. 1999). 
1.5.2.3 Tumour Proliferation Marker ( The Ki67 Index Status): 
The Ki-67 nuclear antigen is expressed in rapidly proliferating cells in all phases of cell cycle 
and is a marker of cellular proliferation. Many studies have been carried out to determine the 
relationship between tumour cell proliferation, analysed by Ki67 expression, and chemotherapy 
response. A 25% decrease in proliferation fraction as assessed by Ki-67 staining of the fine 
needle aspirates in 51 patients receiving antharcycline neo-adjuvant treatment was found to be 
associated with decrease risk of cancer recurrence (Pathmanathan and Balleine 2013). Burcombe 
et al. from their study of 118 patients treated with anthracycline based NACT found an increased 
likelihood of achieving pCR from >75% reduction in Ki-67 index from the pre-treatment 
baseline (Burcombe, Makris et al. 2005). From a study of 119 breast tumours, a >20% 
expression of Ki-67 was found to predict pCR in patients treated with anthracycline based neo-
adjuvant chemotherapy (Petit, Wilt et al. 2004). However, there is currently no evidence based 
protocol established to derive a reliable and informative Ki67 score for routine clinical use. In 
this circumstance, pathologists must establish a standardised framework for scoring Ki67 and 
communicating results to a multidisciplinary team. 
1.6 MOLECULAR INTRODUCTION TO BREAST CANCER: 
The molecular aetiology of tumourigenesis is multi-factorial and thought to result from a series 
of progressive changes such as activation of oncogenes, inactivation of tumour suppressor genes 
and loss of DNA repair genes. Therefore, in order to fully understand the natural progression of 
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tumours and their responses to chemotherapy, cellular processes that trigger, regulate and affect 
cell proliferation and apoptosis (programmed cell death) has to be clearly understood. 
1.6.1 Cell Cycle: 
A eukaryotic cell cycle is divided into a series of sequential phases; the G1, S, G2 and M phases 
with a G0 resting phase between M and G1. A cell progresses through various phases, in response 
to growth factors or onco-proteins. This transition occurs by inactivating distinct checkpoints at 
G1 and G2 stages so that the cell growth occurs in favourable environment and with genetic 
integrity (Hilakivi-Clarke, Wang et al. 2004). The DNA replication and cell mitosis occur in 
occurs in S and M phases of the cell cycle. The cells enter G0 resting phase from G1 when fully 
differentiated or in the presence of DNA damage, which otherwise precludes cell cycle 
progression. Two classes of regulatory molecules belonging to family of serine threonine 
kinases, cyclin and cyclin-dependent kinases (CDK) drive cell cycle progression (Nigg 1995). 
Effector proteins that include cyclin-dependent kinase inhibitors (CDKIs) drive cell progression 
through checkpoints and can reversibly halt cell cycle progression in event of an aberrant cell 
cycle event (Bartek, Lukas et al. 2004).  
Figure 4 gives a graphic illustration of the cell cycle with the cyclin/CDK regulators and CDKIs. 
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THE MAMMALIAN EUKARYOTIC CELL CYCLE PATHWAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The mammalian cell cycle progresses sequentially through G1 S G2 and M phases. 
Cell preparation to progress through different phases occurs at the G1 phase. This occurs in 
response to growth factors such as cyclin and cyclin-dependent kinases (CDK). There is a 
G1Checkpoint that can detect DNA damages and halt cell progression. This is controlled by 
cyclin-dependent kinase inhibitor proteins belonging to INK and Cip/Kip family. The DNA 
synthesis occurs in the S phase controlled by cyclin A-CDK2. The cell progresses to G2phase 
where further growth in preparation to cell division occurs. The cell has to go through the 
G2Checkpoint at this stage which act as another filter to any DNA damages occurred during the 
DNA synthesis. In the M phase cell division occurs and two sister chromatids are formed by the 
process of meiosis. Following cell division the cell enters either the G1 to complete another cycle 
or a G0 resting phase. (Courtesy V.C.Hodgkison, PhD thesis) 
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1.6.2 Cellular Apoptosis: 
Apoptosis is a genetically controlled mechanism of cell death, it is important for the regulation of 
tissue homeostasis. In cancers this mechanism is commonly associated with aberrations, thereby, 
allowing cancer cells to continually proliferate and proceed unregulated with damages to DNA. 
Apoptosis occurs via two major pathways, the extrinsic and the intrinsic pathway. The extrinsic 
pathway is activated in response to external stimuli (e.g. hypoxia, infection, toxins etc.) and is 
initiated by the binding of extracellular death ligands with Fas and tumour necrosis factor 
receptor (TNFR) super family proteins. The intrinsic mitochondrial pathway is initiated in 
response to an internal stimulus (e.g. stress) and on activation releases cytochrome C from the 
mitochondria. The execution of both pathways is mediated through the activation of caspases, a 
family of cysteine proteases present in the cytosol as inactive precursors (pro-caspases). 
Activation of caspases cleaves regulatory and structural molecules of the cell, culminating in cell 
death. 
 
 At the initiation of the intrinsic pathway, internal (DNA damage and reactive oxygen species) 
and external (chemotherapeutic drugs, radiation, infection etc) apoptotic stimuli form a 
mitochondrial apoptosis-induced channel (MAC) to trigger the release of cytochrome C (Dejean, 
Martinez-Caballero et al. 2006). Further, in response to these stimuli, mitochondrial proteins 
called small mitochondria-derived activator of caspases (SMACs) are released into the cytosol to 
bind with the inhibitor of apoptosis proteins (IAPs). This binding of SMACs with IAPs 
deactivates IAPs, which in turn activate pro-caspases to continue the process of apoptosis (Fesik 
and Shi 2001). Released cytochrome C  binds with the Apoptotic protease activating factor - 1 
(Apaf-1) and adenosine triphosphate (ATP), which then bind to the pro-caspase-9 to create a 
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protein complex known as an apoptosome. The apoptosome cleaves the pro-caspase to its active 
form of caspase-9, which in turn activates caspase-3, the final effector enzyme of the apoptotic 
cascade. The active caspase-3 cleaves an inhibitor of caspase activated DNAase lamins, several 
cytoskeleton binding proteins and poly (ADP-ribose) polymerase (PARP). Cleavage of these 
proteins causes DNA fragmentation, inhibition of DNA synthesis and repair, nuclear membrane 
disruption, chromatin condensation, and cytoskeleton collapse (Chaudhry and Asselin 2009). 
 
The extrinsic or direct signal transduction pathway is triggered when the tumour necrosis factor 
released in response to external stimuli binds with the TNF-Receptor 1. This binding initiate a 
signalling cascade via the intermediate membrane proteins, the TNF receptor-associated death 
domain (TRADD) and Fas-associated death domain (FADD) (Chen and Goeddel 2002). Further, 
a second independent extrinsic pathway involving Fas- Fas ligand (FasL) also activates caspase-
8 by forming the death-inducing signalling complex (DISC) which contains FADD, caspase-8 
and caspase-10. The activated caspase-8 feeds directly into caspase-3 activation which in turn 
contributes to degradation of cellular proteins important for cell survival and integrity (Wajant 
2002) (Figure 5). 
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CELLULAR APOPTOTIC PATHWAYS ( EXTRINSIC AND INTRINSIC) 
 
 
 
 
Figure 5: The apoptotic extrinsic pathway as shown in the figure is activated by the binding of 
TNF with the TNFR1 in response to external stimuli. Upon activation, a death induced signalling 
complex (DISC) is formed which activate caspases 8/10 and 3. In contrast, the intrinsic pathway 
is activated by pro-apoptotic proteins (Bax, Bid, and Bad), hypoxia, and DNA damage by 
radiation exposure. Similarly, activation of intrinsic pathway releases the cytochrome c from the 
mitochondrial membrane that binds with Apoptotic Protease Activating Factor-1 in presence of 
ATP to form apoptosome. The apoptosome in the cytosol binds to pro-caspase 9 to activate pro-
caspase 3 to caspase- 3. The formation of caspase-3, the final effector enzyme that cleaves 
regulatory and structural cell proteins to bring cell death remains the final common pathway for 
both extrinsic and intrinsic apoptotic pathways. (Adapted from David Erikson; Tumour Biol. 
(2010) 31:363–372). 
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1.6.2.1  APOPTOTIC PROTEINS: 
The BCL-2 Protein: 
The Bcl-2 gene (18q21.3) was initially identified at a breakpoint in a chromosomal translocation 
(t14:18)  in human B-cell lymphomas (Tsujimoto, Finger et al. 1984). The gene codes a family 
of proteins that regulate cell apoptosis. Bcl-2 proteins are usually expressed in every tissue 
during the developmental period. However, in adults, their expression is restricted to 
proliferating cells. The Bcl-2 family members can be both pro and anti-apoptotic (Al-Mansouri 
and Alokail 2006). The anti-apoptotic members such as Bcl-2 and Bcl-xL and the pro-apoptotic 
members such as Bax, Bad and Bid exists with different domains.  
A balance between cell proliferation and apoptosis drives the normal development of tissue. In 
normal adult cells, pro-apoptotic members of Bcl-2 family exist as heterodimers with anti-
apoptotic members in order to maintain the cell homeostasis in a resting state. In the pro-
apoptotic conditions an increased cytoplasmic Bax concentration shifts the equilibrium to the 
Bax homodimer formation and increases the mitochondrial permeability to release cytochrome C 
(Quinn, Henshall et al. 2005). Similarly, an increased formation of Bcl-2 homodimer in anti-
apoptotic conditions shifts the equilibrium towards inhibition of apoptosis by blocking the MAC 
activity of Bax protein. 
In breast tissue, Bcl-2 is known to be expressed in normal mammary epithelial cells and in early 
pregnancy but remains undetectable in lactating and involuting glands (Kumar, Vadlamudi et al. 
2000). In breast carcinomas, Bcl2 persistent expression was found in about 61-70% of invasive 
ductal carcinomas, 66% of micro-papillary carcinomas and 2.9% of apocrine carcinoma (Leal, 
Henrique et al. 2001). 
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Studies have shown Bcl-2 protein promotes cell survival but not proliferation in breast cancer 
cells (Kumar, Vadlamudi et al. 2000). Studies analysing mechanisms of anticancer therapies 
have shown phosphorylation of Bcl-2 protein at serine residue in response to anticancer therapy 
renders the protein functionally inactive. This decreases its binding with Bax protein  and confers 
the protective effect (Simstein, Burow et al. 2003). Over- expression of Bcl2 protein has been 
shown to cause resistance to anticancer therapy by inhibiting apoptosis (Olopade, Adeyanju et al. 
1997). Evidence to such a hypothesis, comes from a breast cancer cell line study that showed 
improved responses to breast cancer chemotherapeutic agents including doxorubicin, docetaxel 
and mitomycin C by knocking down the expression of Bcl-2 and Bcl-xL proteins using anti-
sense oligodeoxynucleotides (Nuki and Simkin 2006). Similarly, a loss or down-regulation of 
pro-apoptotic Bcl-2 family member may result in resistance to anticancer therapy (Radetzki, 
Kohne et al. 2002)  as shown by forced expression of pro-apoptotic proteins such as Bak and 
Nbk/Bik showing reversal of chemotherapy resistance by manipulating the downstream 
signalling cascade. 
1.7 BREAST CANCER & SURFACE RECEPTORS: 
Breast tumours show expression of Oestrogen (ER), Progesterone (PR) and Human Epidermal 
Growth Factor-2 (HER2) on their cell surface. These receptors promote tumour growth from 
their interaction with the Oestrogen and Progesterone hormones. Therefore, a thorough 
understanding of these interactions at the molecular level can help develop therapy strategies and 
determine long term cancer prognosis. 
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1.7.1 Oestrogen Receptor (ER): 
The oestrogen receptor (ER) is a nuclear ligand activated transcription factor belonging to steroid 
hormone receptor family. It is an important molecular marker in breast cancer as it promotes cell 
proliferation and differentiation via 17β-estradiol (E2) interaction. There are two types of ERs 
characterised to date: ERα and ERβ.  
Breast tumours express both ER receptors. However, expression of ERβ is reportedly decreased 
with carcinogenesis (Gustafsson 1999). Approximately 70-80% of breast cancers show ER 
positivity (Keen and Davidson 2003) and  ERα plays the predominant mediator of mitogenic 
effects of oestrogen (Hewitt, Harrell et al. 2005). More recently, expression of ERβ has been 
found to be associated with breast cancers in pre-menopausal with high oestradiol levels 
(Murillo-Ortiz, Perez-Luque et al. 2008).  
1.7.2 Progesterone Receptor (PR): 
The progesterone receptor (PR) a member of steroid hormone receptor super family is a protein 
found inside cells. PR exists naturally in two isoforms: PR-A and PR-B. As the majority of ERα 
positive tumours also express PR; presence of normal PR levels in the breast cancer cells 
suggests an intact ER signal transduction pathway (Sandhu, Parker et al. 2010).   
1.8 MOLECULAR CLASSIFICATION OF BREAST CANCER: 
The receptor based breast cancer classification uses immuno-histo-chemistry (IHC) to confirm 
individual cell receptor (ER, PR, and HER) status. Gene expression profiling studies by Perou et 
al. analysed cell receptors and tumour grade alongside the biologic heterogeneity from molecular 
alterations (Geyer, Marchio et al. 2009; Prat and Perou 2011) classifying breast cancers into 
55 
 
distinct molecular sub-types. Even though, similar in morphology, molecular sub-types differed 
markedly in their biologic characteristics  making them a genetically diverse group (Bertucci and 
Birnbaum 2008). 
Using gene expression profiling techniques such as cDNA microarray and oligonucleotide two-
dimensional array, breast tumours, can be clustered into different groups based on differential 
gene expressions (Liu and Sotiriou 2002). Sorlie et al. and Sotiriou et al. were the first to classify 
breast cancers using this technique into 5 distinct subtypes;  Luminal A (ER+); Luminal B 
(ER/PR+); erbB2 over-expressive (HER2+), Basal-like (triple negative); and Normal-like 
(Sorlie, Perou et al. 2001; van 't Veer, Dai et al. 2002; van de Vijver, He et al. 2002; Sotiriou, 
Neo et al. 2003). The dominant factor emerging from these molecular studies showed 
remarkably different gene-expression phenotypes for the ER positive and negative tumours.  
Based on this feature, a further sub-division of molecular subtypes was undertaken by Sorlie et 
al. from a selected intrinsic gene set of 456 cDNA clones based on decrease or absent ER gene 
expression and other additional transcriptional factors. Groups with the lowest ER expression 
were: basal-like, normal epithelial and erbB2 subtypes each with specific expression 
characteristics. The basal-like subtype had a high expression of keratins 5, 17, laminin, and fatty 
acid binding protein 7. The erbB2 showed a high expression of genes in the ERBB2 amplicon 
including ERBB2 and GRB7. The normal breast-like, showed a highest expression of adipose 
tissue and nonepithelial cell types type proteins (Sorlie, Perou et al. 2001). The luminal group, 
with the highest ER gene expression pattern was further categorized into ‘A’ and ‘B’ sub-groups. 
This classification was based on the level of luminal specific genes and ER cluster expression. 
The luminal-A subgroup demonstrated the highest expression of the ER gene. A further division 
of luminal group into two smaller units of luminal B and C was undertaken depending on a 
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moderate to low expression of the luminal specific genes. After the initial molecular 
classification into subtypes of breast cancer, a new intrinsic subtype was identified in 2007 called 
claudin-low subtype (Herschkowitz, Simin et al. 2007). It is characterized by a low expression of 
genes involved in tight junctions and intercellular adhesion such as claudin-3, 4 and 7 cingulin, 
ocludin, and E-cadherin. This subtype is located in the hierarchical clustering near the basal-like 
tumors, suggesting both subtypes may share some characteristic gene expression such as low 
expression of HER2 and luminal gene cluster. 
1.8.1 Breast Cancer Molecular Subtypes & Clinical Outcomes: 
As discussed in the section 1.5.1.3, the clinical and molecular subtypes of breast cancers show a 
wide variation in responses to neoadjuvant chemotherapy and clinical prognosis. The correlation 
of specific gene expressions to the clinical outcomes was first demonstrated from the work of 
van’t Veer and colleagues using the cDNA microarray analysis of 70 core genes (van 't Veer, Dai 
et al. 2002; van de Vijver, He et al. 2002). Further, Sorlie, Perou et al. (2001), analysed clinical 
outcomes for each of the intrinsic breast molecular sub-type in a univariate survival analysis and 
found basal-like and ERBB2 were  associated with shortest relapse-free and overall survival 
(n=49; OS: Luminal A 96 months, Basal like 36 months and ERBB2 72 months; P<0.01; RFS: 
Luminal A 96 months, Basal like 24 months and ERBB2 72 months P<0.01) (Sorlie, Perou et al. 
2001). Similar differences in relapse-free and overall survival between the basal-like, ERBB2 
and luminal sub-types were also found by Sotiriou et al. in a larger study involving 99 breast 
tumours. The luminal subtype was found to show better relapse-free and overall survival 
compared to basal like and ERBB2 sub-types ( RFS: Luminal 3000 vs Basal like 2000 days; P< 
0.013; OS: Luminal 3500 vs Basal like 2200 days; P <0.022)  (Sotiriou, Neo et al. 2003) (Figure 
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6). In conclusion, molecular classification classifies breast cancers into six distinct sub-types 
each with a unique characteristic representing the breast tumour heterogeneity in its entirety.  
KAPLAN MIER CURVE FOR ‘DFS’ AND ‘OS’ FOR INTRINSIC 
MOLECULR SUBTYPES 
                                A                                                               B 
 
Figure 6: The graph illustrates Kaplan–Meier curves of disease-free survival (A) and overall 
survival (B) Dark blue, luminal A; light blue, luminal B; red, basal-like; pink, HER2-enriched; 
yellow, Claudin-low; red. From the above data, Luminal A is found to show the best and HER2 
+ the worse disease free and overall survivals amongst all the molecular subtypes (Herschkowitz, 
Simin et al. 2007).                                                                                                               
1.8.2 Breast Molecular Subtypes & Neoadjuvant Therapy Response: 
The effects of anthracycline-taxane based NACT in different biological phenotypes were 
examined in the GeparTRio study involving 2,072 locally advanced breast cancers (Huober, von 
Minckwitz et al. 2010). Findings from the study showed highest pCR rate of 57%  in patients age 
< 40 years with triple negative (basal-like) status comapared to 35% pCR rate for luminal sub-
types (Table 5).  
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Table 5:    Multivariate analysis for pCR within different biological groups                                                                             
(Adapted from GeparTrio Study; Huober von Minckwitz et al. 2010) 
 
 
Factor Luminal A, pCR 
at surgery 
(n=562) 
Luminal B, pCR at 
surgery (n=462) 
HER2 like, pCR 
at surgery 
(n=193) 
Triple negative, 
pCR at surgery 
(n=351) 
 
 pCR 
(%) 
P 
value 
pCR 
(%) 
P value pCR 
(%) 
P value pCR 
(%) 
P value 
 
Age (years) 
<40 
 
>40 
 
 
10.1 
 
6.6 
 
0.256 
 
24.1 
 
17.8 
 
0.163 
 
 33.3 
 
 28.2 
 
 
0.441 
 
57.0 
 
34.1 
 
    0.01 
Tumour 
Grade 
III 
I + II 
 
 16.2 
 3.8 
 
<0.0001 
 
24.3 
17.8 
 
0.018 
 
31.3 
25.3 
 
0.164 
 
39.5 
30.5 
 
  0.137 
 
Histological 
Type 
 
Ductal/others 
 
Lobular 
 
 
 
 
 
 
7.8 
 
4.3 
 
 
 
 
0.376 
 
 
 
 
20.0 
 
11.9 
 
 
 
 
0.058 
 
 
 
 
31.0 
 
7.7 
 
 
 
 
0.164 
 
 
 
 
 
38.9 
 
39.1 
 
 
 
 
  0.702 
 
Further, Rouzier et al. evaluated the gene expression profiles of 82 breast cancer patients treated 
with anthracycline-taxane NACT and reported pCR rates of 45% for the basal-like and HER2-
positive sub-types and 6% for the luminal sub-types (Rouzier, Perou et al. 2005). Kim et al. from 
their series of 257 patients treated with adriamycin-taxane NACT showed similar findings of a 
higher pCR rates 21.1% vs 10.5% vs 8.9% p=0.001 for basal-like, HER2+ and luminal sub-type 
(Kim, Sohn et al. 2010). Carey et al. from their 107 patients series showed 36% of HER2+ and 
27% of basal-like sub-types acheived pCR (p=0.01) compared to only 7% of luminal tumours 
following anthracycline only NACT (Carey, Dees et al. 2007). Lv et al.from their analysis of 102 
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tumours treated with anthraccyline-taxane-carboplatin NACT regimens found pCR rates of 
24.4% ,22.2% and 8.7% (p=0.041) for basl-like, HER2+ and luminal sub-types respectively (Lv, 
Li et al. 2011). In a more recent follow up study of 512  patients who received anthracycline-
based therapy (epirubicin or doxorubicin) or an antimitotic based-therapy (including taxanes and 
vinca-alkaloids) pCR was shown to be significantly lower in HR+/HER2− tumors (P < 0.0001) 
at 7 year follow up (Guiu, Arnould et al. 2013). Further, in the same study the OS rates at 7 years 
were found to be significantly higher in HR+/HER2− (76.1%) followed by 60.1% (TNBC), 
72.4% (HR+/HER2+), and 49.9% (HR−/HER2). From the above findings, it is safe to conclude 
that luminal, basal-like, normal-like, and erbB2+ subgroups have different responses to 
neoadjuvant chemotherapy and clinical outcomes: basal-like (mostly hormone receptor negative) 
and erbB2+ (mostly HER2 overexpressed/amplified and ER−) respond well to neoadjuvant 
therapy but have the worst outcomes with the shortest DFS and OS rates. At a molecular level, 
the differential chemosenistivies between different molecular subtypes can be explained from a 
lower expression of proliferation cluster genes in the luminal A subtype (Perou, Sorlie et al. 
2000; Sorlie, Perou et al. 2001). 
1.8.3 Why Biomarkers for ER+ (Luminal A) Breast Cancer? 
According to the NCCN breast cancer guidance 2012, patients presenting with a locally 
advanced breast cancer up to the age of 70 years are routinely offered neoadjuvant chemotherapy 
to down stage the disease and facilitate BCS ((Guidelines)
TM
 2012). Currently, this practice 
remains uniform across all the breast cancer molecular subtypes. However, as evidenced from 
the above studies (sections 1.8.1 and 1.8.2), ER+ (Luminal A) breast cancer subtype tend to have 
poor pathological response after neoadjuvant chemotherapy. Therefore, using molecular 
signatures (e.g. gene or protein biomarkers) and/or radiological imaging (e.g. MRI, PET scan) if 
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chemotherapy responses in ER+ (Luminal A) subtype can be predicted, patients unlikely to 
respond to therapy can be selected early in the treatment course. These patients then can be 
streamlined to alternative treatment strategies sparing them from unnecessary side-effects of 
therapies for no therapeutic gains. 
1.9 CHEMOTHERAPY RESISTANCE: 
Drug resistance of tumour cells is a major obstacle in effective neo-adjuvant chemotherapy 
treatment and a common cause of primary treatment failure. Although exact mechanisms of 
resistance to anticancer therapy remain unclear, multiple factors are believed to act in interrelated 
or independent pathways which result in intrinsic and acquired therapy resistance. In general, the 
common mechanisms implicated with chemo resistance include: 
1. Intra-cellular defence factors which decrease the drug concentrations at the target level by 
activating transporter protein and detoxification mechanisms within the cells 
2. Enhanced DNA repair 
3. Resistance to chemotherapy-induced apoptosis 
1.9.1 Intracellular Defence Mechanisms: 
Drug Transporter Protein: 
The intracellular concentrations of a drug are managed by a fine balance of drug influx and 
efflux mechanisms. Changes to drug accumulation in the cell occur by a decrease in drug influx 
or an increase in efflux mechanisms. As most of the cytotoxic drugs enter cells via passive 
diffusion, alterations in the bio-physical properties of the plasma membrane and changes in the 
lipid fluidity due to Ca
2+
 concentration can all decrease the rate of drug uptake into the cells 
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(Liang and Huang 2002; Laura Gatti 2005). This mechanism is primarily implicated in cisplatin, 
and methotrexate drug resistance, but is less effective in preventing lipid soluble drugs such as 
anthracyclines from entering the cell. (Ramu, Glaubiger et al. 1983; Stavrovskaya 2000).  
 
Multi-Drug Resistance Protein: 
The multi-drug resistance proteins (MRP) are a subfamily of the ‘ABC super-family’ of 
transporter proteins. Similar to the P-gp protein, the MRP family is also functionally ATP 
dependent and are mostly involved in the transport of glutathione (GSH)-conjugated derivatives 
of toxic compounds (GS-X pump) (Ishikawa, Kuo et al. 2000). A total of seven protein members 
(MRP-1 to 7) belong to the MRP family. MRP-2 is implicated in antharcycline resistance. The 
MRP-1 protein was detected in 49% of breast cancers (Leonessa and Clarke 2003) using 
immunohistochemical studies and over-expression was associated with reduced overall and 
disease free survival (Filipits, Malayeri et al. 1999). 
  
Breast Cancer Resistant Protein: 
The breast cancer resistant protein (BCRP) is a 72 kDa protein that belongs to the G sub-family 
of ABC super-family proteins. Evidence of BCRP over-expression in multi-drug resistance was 
confirmed in transfection studies involving MCF-7 breast cell lines transfected with BCRP 
cDNA. Collectively, BCRP over-expression was found to confer resistance to mitoxantrone, 
topotecan, and flavopiridol, paclitaxel, cisplatin/ or vinca alkaloids (Allen, Brinkhuis et al. 1999) 
(Doyle, Yang et al. 1998). The BCRP/ABCP mediates mitoxantrone and anthracyclines 
(doxorubicin) cell efflux, an action which is dependent on the presence of threonine or glycine 
substrate at position 482 of the BCRP cDNA (Honjo, Hrycyna et al. 2001). Mutation in the 
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BRCP/ABCP gene causes arginine substitution at position 482 changes the substrate specificity 
and anthracyclines are accumulated in the cells thus conferring drug resistance. 
1.9.2 Enhanced DNA Repair: 
Cytotoxic medications can also activate several other distinct cellular mechanisms that lead to 
drug resistance. One such example is the up-regulation of DNA repair mechanisms which has 
been associated with resistance to alkylating agents in leukaemia and topoisomerase inhibitors in 
breast cancers. The DNA repair mechanisms involve excision or repair of damaged strands. 
Excision of damaged base pairs involves, nucleotide excision repair (NER) and base excision 
repair (BER). The NER pathway is one of the pathways responsible for the removal of DNA 
adducts produced by cytotoxic drugs such as cisplatin and nitrogen mustards (Chaney and Sancar 
1996). Drug resistant cancer cells promote DNA replication to nullifying the cytotoxic effects 
(Selvakumaran, Pisarcik et al. 2003). BER removes damaged base pairs and induce DNA repair 
via endonucleases. This action may lead to resistance to oxidizing (e.g. H2O2) and alkylating 
agents such as cyclophosphomide and nitrogen mustards (Kelley, Kow et al. 2003). The 
mismatch repair (MMR) pathway corrects single base mispairs incorporated by cytotoxic drug 
exposures. A deficient MMR system can confer therapy resistance as cells fail to recognise DNA 
damage and continue to proliferate. Approximately 25% of sporadic breast cancers show a 
deficient MMR system (Fedier, Schwarz et al. 2001) 
1.9.3 Chemotherapy-Induced Apoptosis and Drug Resistance: 
Apoptosis induced cell death, is one of the key mechanisms of action of chemotherapeutic agents 
(Kaufmann and Earnshaw 2000). It is postulated, that defects in the pathways involved in 
apoptosis may result in drug resistance (Reed 1999). In-vitro studies have shown that two protein 
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families: the p53, Bax and BcL-2 are involved in the initiation of apoptosis. In breast cancers, 
loss of p53 is found to confer resistance to DNA-damaging agents such as doxorubicin. The Bcl-
2 apoptotic protein also plays an important role in MDR. The relative amounts of the two 
proteins determine whether apoptosis can be triggered as imbalances in the ratios of anti- and 
pro-apoptotic Bcl-2 family members may be associated with therapy resistance. 
1.9.3.1 P53 Protein and Chemoresistance: 
The TP53 gene known as the ‘guardian of genome’ is located on the short arm of chromosome 
17 and encodes p53 tumour suppressor protein. Normally, low concentrations of the p53 protein 
reside in the cell in an inactive state due to its association with its negative regulator murine 
double minute-2 protein (mdm2). A normal physiological activation of p53 occurs in response to 
cellular stress, e.g. DNA damage, and induces the transcription of genes involved in cell cycle 
control and apoptosis (May and May 1999; Vogelstein, Lane et al. 2000). In a normal adult cell, 
p53 protein binds to mdm2 to remain in an inactive state. In the event of DNA damage, p53-
mdm2 complex disassociates and release the active p53 to induce cell cycle arrest at the G1 
checkpoint. The active p53 then seek to repair the damage DNA by either promoting or 
repressing the expression of target genes (e.g. p53R2 gene, ribonucleotide reductase gene, DNA 
polymerases). In the event of repair not possible, p53 directs the cell towards apoptosis by 
inhibiting cyclin dependent kinase complex activity through p21 protein (Figure 7). This  
mechanism is implicated in anthracycline chemo sensitivity in breast cancer treatment  (Osborne, 
Wilson et al. 2004). 
The p53 status in breast cancer plays an important role in tumour responsiveness to anti-
neoplastic agents. This action, mediated via p53 dependent change in the Bcl-2/Bax ratio occurs 
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through increased expression of Bax and reduced expression of the Bcl-2 protein. Therefore, loss 
of normal p53 function can potentially result in resistance to chemotherapeutic agents due to loss 
of apoptotic properties. Further, the prognostic value of p53 in providing information on tumour 
response following systemic chemotherapy is found to increase when combined with  ER, PR, 
HER2 ,Bcl-2 and Bax expressions (Zheng, Lu et al. 2001; Yamashita, Nishio et al. 2004). 
 
THE p53 MEDIATED APOPTOSIS AND CELL CYLCE ARREST 
PATHWAY 
 
 
Figure 7: The p53 protein known as ‘The Guardian of Genome’ is a tumour suppressor 
protein. As shown in the figure, P53 upon activation interacts with various other cell cycle 
proteins involving different pathways. The end product of such activation is either cell cycle 
arrest or triggering of apoptosis or transcription of DNA repair proteins. The p53 mediated DNA 
repair is carried out via the interaction with p53 R2 gene and is can be responsible for inhibition 
of tumour metastasis and angiogenesis.  
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1.9.4 Alteration of Molecular Pathways & Drug Resistance: 
1.9.4.1 PIP3/AkT-mTOR Pathway: 
Activation of Phosphotidylinositol-3kinase (PI3K) is reported to occur in breast, ovarian, 
pancreatic and oesophageal cancers (Zhou, Liao et al. 2001). PI3K phosphorylates inositol lipids 
at the 3-position of the inositol ring to generate the 3-phosphoinositides PtdIns-3-P, PtdIns-3,4-
P2, and PtdIns-3,4,5-P3. Akt, also known as protein kinase B (PKB), is a major target of PI3K 
and belongs to subfamily of serine/threonine protein kinases with three identified member 
proteins: Akt/AKT1/PKB, AKT2/PKB, and AKT3/PKB. Activation of AkT occurs via PDK1 
through phosphotidylinositol-3kinase (PIP3) after ligands binds to the receptors at the cell 
membrane. This activation depends on the integrity of the PH domain, which binds to PI3K 
products, and on the phosphorylation of Thr308 in the activation loop and Ser473 in the C-
terminal activation domain by PDK1 (Cheng, Jiang et al. 2002). The activity of Akt is negatively 
regulated by PTEN, a tumour suppressor gene. PTEN encodes a dual-specificity protein and lipid 
phosphatase that reduces intracellular levels of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in cells by 
converting them to PtdIns-4-P1and PtdIns-4,5-P2 respectively, thereby inhibiting the PI3K/Akt 
signaling pathway. Activation of AkT, results in different downstream cellular processes such as 
cell survival, cell proliferation and cell migration via the inhibition of pro-apoptotic proteins 
BAD and activation of GSK3β protein and Forkhead protein transcription factor (Figure 8). The 
phosphotidylinositol-3kinase/(AkT) pathway has been implicated in acquired therapeutic 
resistance in breast cancer, through evasion of cell death (West and Dennis 2011).  In breast 
cancers, Akt activation is found to correlate with HER-2/neu over expressions; Akt-induced 
signalling is suggested to increase drug-induced apoptosis resistance in cells over expressing 
HER-2/Neu via Mdm2 phosphorylation (Zhou, Liao et al. 2001).
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REPRESENTATION OF PIP3/AkT-mTOR PATHWAY IN BREAST CHEMOTHERAPY RESISTANCE 
 
 
Figure 8: A general sketch of the PKB/AKT pathway. PIP3 is activated by PI3K and recruits AKT to the cell membrane via 
activation of PDK1. AKT activation stimulates cell cycle progression, survival, metabolism and migration through phosphorylation of 
many physiological substrates. Acquired chemotherapy resistance in breast cancer occurs through cytotoxic drugs mediated activation 
of PIP3/AKT  inhibition of apoptosis via downregulation of BAD protein. 
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1.9.4.2 Role of Integrins in Chemoresistance: 
 Integrins mediate cell to cell interactions and cell attachments to the extracellular matrix (ECM). 
In addition to the above described roles, ligation of integrins with ECM ligands induces a variety 
of intracellular signals and regulates several cellular responses including migration, 
differentiation, proliferation and programmed cell death (Frisch and Francis 1994; Hood and 
Cheresh 2002). Integrins are composed of α and β chain heterodimers which are activated upon 
by ligand binding. Focal adhesion kinase (FAK), Integrin-Linked and Src kinases are example 
integrins which upon binding form clusters on the cell surface called focal adhesions. These 
focal adhesions, then acts as a structural link between the ECM and the intracellular actin 
cytoskeleton for the mediation of signal transductions to the intracellular signalling pathways. It 
has been hypothesised that the integrin-ECM interactions causes chemotherapy resistance by 
activating the downstream signalling survival pathways such as PIP3/AKT and MAPK/ERK 
(Figure 9)  in a complex and tissue specific mannerisms (Mitra and Schlaepfer 2006). The role of 
integrins in breast cancer chemotherapy resistance was first reported by Aoudjit F and Vuori K et 
al; using MDA-MB-231 and MDA-MB-435 breast cancer cell lines (Aoudjit and Vuori 2001). In 
this study, ligation of β1 integrins by their extracellular matrix ligands was found to inhibit the 
release of cytochrome c from mitochondria, preventing apoptosis induction in response to 
paclitaxel and vincristine therapies. The above β1 mediated protection was found to be 
dependent on the activation of the PI3-kinase/AkT pathway. Further, in the same study, other 
integrins such as laminin-1-binding integrin α6β1 and fibronectin were also found to exert 
protective effects against the drug-induced apoptosis via activation of PI3-kinase/AkT 
mechanism and via down regulation of pro-apoptotic Bad protein.  
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THE INTEGRIN-PIP3/AKT MEDIATED THERAPY RESISTANCE AXIS 
 
Figure 9: The PIP3-kinase/AKT pathway in integrin-mediated drug resistance. Integrin/ECM 
interactions lead to the activation of PIP3-kinase/AKT, which then regulates various downstream 
targets including proteins of Bcl-2 family, cyclins and NFkB. Further, activation of the 
transcription factor NFκB, increase the expression of several anti-apoptotic proteins and lead to 
chemoresistance (adapted from Chemotherapy Research and Practice Volume 2012, Article ID 
283181). 
1.9.4.3 The Role of 14-3-3 Mediated Pathway in Chemoresistance: 
14-3-3 proteins are a family of highly conserved proteins that are involved in a wide range of 
cellular processes. Recent evidence indicates that some of these proteins have oncogenic activity 
and that aberrant expression of 14-3-3 promotes tumourigenesis in lung, prostate, ovarian and 
pancreatic tissues (Radhakrishnan, Putnam et al. 2011). The number of proteins in the 14-3-3 
family varies with species. However, in mammals, seven isoforms have been identified namely 
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beta/alpha, gamma, eta, sigma, epsilon, theta/tau and zeta/delta and they function by binding to 
other proteins predominantly through phosphorylated serine residues. Translational studies have 
identified 14-3-3 gamma isoform as a downstream negatively regulated p53 target protein and 
that loss of p53 function leads to over expression of 14-3-3 gamma isoform promoting genomic 
instability in lung cancer (Riley, Sontag et al. 2008; Radhakrishnan, Putnam et al. 2011). The 
above mechanism mainly implicated in lung tumourigenesis and chemoresistance. Further, 14-3-
3 sigma and eta isoforms are known to play a key role in cell cycle arrest and has a role in cell 
death interacting via Mdm4, Chk2 and Cdc25c motif loop (Bustos 2012). Therefore, down 
regulation of these protein isoforms or up regulation of 14-3-3 gamma isoform result in cell 
survival evading cell death from the inactivation of p53 pathway in response to chemotherapy 
induced DNA damage (section 1.9.3.1). Also, 14-3-3 proteins are downstream effectors of the 
PIP3/AkT pathway and have a role in mediating cell survival, proliferation and cell regulation by 
evading apoptosis (section 1.9.4.1). The above outlined mechanisms in combination and/or 
binding of 14-3-3 proteins with disordered ligand partners (e.g. proteins involved in regulation of 
the cytoskeleton; GTPase function; membrane signalling; phases of the cell cycle- apoptosis) 
have been postulated to cause chemoresistance with 14-3-3 family of proteins.   
1.10 PROTEOMICS FOR BIOMARKER DISCOVERY: 
The discovery of biomarkers up until the late 1980s was very much limited to a handful of 
proteins. However, in the last decade, technological advancements in protein separation (e.g. 
sub-bio fractionisation), identification (e.g. mass spectrometry) and enrichment methods have 
lead to the discovery of hundreds of new biomarkers for a range of purposes. Early studies 
utilised cell line models to make novel biomarker discoveries. However, more recently, the use 
of biological samples (e.g. plasma, urine, cerebrospinal fluid, tumour interstitial fluid, and 
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tumour tissues) have gained momentum with both proteomic and non-proteomic based 
approaches ((Olsson, Zetterberg et al. ; Shao, Wang et al. ; Sun, Yang et al. ; Pitteri and Hanash 
2007). 
The aim of this section is to provide an overview of proteomic workflow for biomarker 
discovery and to discuss the challenges of using different clinical samples with proteomics. A 
literature search was conducted on pubmed using the term “challenges of clinical samples with 
proteomics” and 22 articles published in human studies in last 10 years were selected and 
reviewed. 
1.11 BIOMARKER: 
The official National Institutes of Health definition of a biomarker is a substance that is 
objectively measured and evaluated as an indicator of normal biologic processes, pathogenic 
processes or pharmacologic responses to a therapeutic intervention (Diamandis 2010). A 
biomarker can therefore be a mutated gene signature, altered mRNA or a differentially expressed 
protein which can be studied under three “omic” categories of genomics, transcriptomics, and 
proteomics. 
1.11.1 Proteomics Vs. Other Omic Studies: 
Omic' technologies include genomics, transcriptomics, proteomics and metabolomics all of 
which have a significant potential in generating novel biomarkers of exposure, susceptibility and 
response. However, for this review, the discussion as to why proteomics should be preferred over 
other omic studies for the cancer biomarker discoveries will be largely limited to comparing 
proteomics to genomics and transcriptomics studies only. 
71 
 
Proteome study in contrast to genome or mRNA has an inherent advantage for it may allow the 
identification of genomic and transcriptomic modifications, being that the identified proteins are 
itself the biological endpoints. Genomic studies involve analysing a change in the genome 
structure as a marker of response; this usually is a change in the DNA sequence. Genome based 
research in the last decade has transformed with the availability of information on gene 
sequencing and development of high-density DNA microarrays. (Lipshutz, Fodor et al. 1999; 
Shou, Qian et al. 2006). However, genomics compared to the other two ‘omic’ studies, due the 
static nature of human genome and very few mutations altering its functional status may have a 
limited role in cancer biomarker studies. Firstly, genomic studies are dependent on classification 
methods for assessment of differential gene expressions (Moler, Chow et al. 2000). 
Discrepancies are known to exist between high differential gene expressions and the accuracy of 
their classification methods limiting the role of genomics for biomarker studies (Xiong, Fang et 
al. 2001). Further, the gene functioning is affected by alternative splicing; the mRNA transcripts 
of a  single gene can undergo hundreds of alternative splicing events adding or deleting 
functional domains, changing affinities, and/or altering mRNA stability. This produce variable 
transcripts making genome based study alone less specific (Gardina, Clark et al. 2006). 
Furthermore, find a limited role in large  population based studies genomics find a limited role 
due to the lack of comprehensive analytical techniques to evaluate all splice variations, 
individual patient differences and tissue complexities (Furey et al.; 2001). 
 
The transcriptome by definition is a subset of genes transcribed in an organism that link the 
genome, proteome and the cellular phenotype. With the advent of the DNA microarrays platform 
in transcriptomics, measuring  the mRNA expression levels is now possible  (Leder, Merila et al. 
2009). In a normal cell state, besides the post-translational modifications, frequency of mRNA 
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expressions determines the cell protein content. In cancer cells, excessive mRNA turnover occur 
causing a mismatch between the peak mRNA expressions and protein translations. This 
difference up to as high as 20 folds between the cell protein content and mRNA expressions 
limits protein expressions analysis from a quantitative mRNA data using transcriptomics studies 
(Gygi, Rochon et al. 1999).  
In contrast to genomic and transcriptomic studies, studying proteome has an inherent advantage 
for it allows identification of all genomics and transcriptomics modifications, being that the 
identified protein is itself the biological endpoint.  Also, studying proteins allows researchers to 
translate the findings into immunohistochemistry and thus readily translated into clinical practice 
in histopathology labs. 
1.12 PROTEOMICS: 
A global analysis of protein expression, interaction and functional status can be studied under 
proteomics. Proteins via their post-translation modifications acquire stability and functional 
variability (Johann, McGuigan et al. 2004) and therefore give an accurate reflection of cell 
functionality and response. Currently, proteomic technology has been used in two main areas of 
cancer research: early diagnosis and treatment (included prediction of response to treatment and 
targeting novel cancer agents) (Chuthapisith, Layfield et al. 2007). Whilst many proteomic 
techniques exist, studying differential protein expressions using current proteomic methods can 
be grouped into gel based and gel free mass spectrometry (MS) methods and micro-array based 
methods. 
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1.13 Workflow of Proteomic Discovery Pathway: 
The proteomic based biomarker discovery pipeline mainly consists of four stages; discovery 
stage, data mining stage, confirmation stage and validation stage. In the discovery stage proteins 
are identified using MS-dependent or MS-free proteomic methods. The Data mining stage 
involves using a software programme such as Ingenuity Pathway Analysis (IPA) for mapping 
differentially expressed proteins (DEPs) to molecular pathways to understand the relationships 
between proteins and mechanisms of tumourogenesis and therapy resistance. The Confirmatory 
stage involves confirming the differential expression of identified proteins using an 
immunoblotting technique. Following confirmation, in the Validation stage, putative biomarkers 
are validated to assess their clinical relevance using archival series of pre-treatment clinical 
samples in a tissue based-immuno-histo-chemistry (IHC) approach or non-tissue based Enzyme 
Linked Immno Sorbent Assay (ELISA) approach. The proteomic biomarker discovery pipeline 
described above is illustrated in the Figure 10.  
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THE WORKFLOW OF BIOMARKER DISCOVERY PATHWAY 
 
Figure 10: shows the proteomic biomarker discovery pipeline. 1D/2D-PAGE/MS: One and 
two dimensional polyacramide gel electrophoresis/Mass Spectrometry; iTRAQ: iso-baric tag for 
absolute and relative quantification; SILAC: Stable isotope labelling amino acid; ICAT: 
Isotope-coded affinity tagging; AQUA: Absolute quantification; IPA: Ingenuity Pathway 
Analysis; IHC: Immunohistochemistry; ELISA: Enzyme linked immuno sorbent assay; MRM: 
Multi chain reaction. 
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1.13.1 Proteomic Discovery Phase: 
This is the first stage in the proteomic biomarker workflow and involves protein separation using 
gel-based (1D-PAGE, 2D-PAGE and 2D-DIGE) or gel-free techniques (i-TRAQ, ICAT and 
SILAC) followed by protein identification using mass spectrometry (MS) (Zong, Zhang et al. 
2007). However, protein identification and analysis of differential expressions can also be 
achieved using another approach which does not involve use of mass spectrometry called 
microarray. This method is usually preferred if proteins fail to generate a sufficient number of 
peptides with mass spectrometry assisted techniques to gain a significant identification, or if the 
specific form of protein is not represented in the database. Microarray-based proteomic methods 
can be employed in a forward (antibody immobilised) or reverse (protein lysate immobilised) 
phase and offers a range of methods that compliment traditional mass spectrometry-based 
proteomic methods. However, none of the approaches when used on their own can fully analyse 
the whole proteome in a single experiment, therefore using them in combination increases the 
chances of wider proteome coverage.  
1.13.1.1 MS-Assisted Gel Based Methods: 
This is a low-throughput method in which using principles of electrophoresis, proteins are 
separated in polyacramide gel based on molecular weight and iso-electric point following 
extraction from the sample in a suitable buffer (e.g. Laemmli buffer) prior to gel loading. The 
one-dimensional (1D-PAGE) method separates proteins based on molecular weight in a vertical 
plane; separated proteins are then visualized as bands of different molecular weights and 
identified using a ladder of molecular marker proteins from co-electrophoresis. In the two-
dimensional method, protein separation takes place in the horizontal and vertical planes based on 
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the proteins iso-electric point and molecular weights. The first dimension horizontal separation is 
to the iso-electric point based on the net protein charge along an immobilized pH gradient (IPG) 
strip in electric field (Gorg, Weiss et al. 2004). Following electrophoresis, proteins from the IPG 
strip are separated as individual spots on the polyacramide gel which are then visualized by gel 
staining using either silver stain or coomassie blue stain. Using software analysis (e.g. 
RegStatGel) the pattern of gel spots between samples (treatment sensitive and resistant) are 
studied for differential expression. A two-fold differential expression is taken as significant  
(Zhu, Rawe et al. 2008) and protein spots showing this change are then cut and digested into 
their peptide from for identification using MS.  
1.13.1.2 Limitations of Gel based MS based Proteomic Methods: 
In the past, global analyses of protein expression have usually been carried out using 2D-PAGE, 
a well-established but notoriously difficult analytical method. Though unrivalled in its ability to 
resolve thousands of individual proteins, 2D-PAGE demands considerable effort and skill for 
reproducibility. Even in the most experienced hands, the above technique encounters difficulties 
at identifying membrane-bound proteins the targets of several important drugs. Further, more 
than 15% of a cell's proteins with this technique may never be identified because of the proteins 
hydrophobicity. The 2D-PAGE technique also has limitations at detecting low abundance, or 
rarely expressed proteins, a group thought to carry out several critical functions in the cell. 
Therefore, other complementary proteomic techniques such as microarrays (forward or reverse 
phase) and/or gel free MS methods (iTRAQ, ICAT, SILAC and AQUA) are usually employed 
alongside 2D-PAGE/MS in order to achieve a more thorough interrogation of the cell proteome. 
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1.13.1.3 MS based-Gel Free Methods: 
“Gel-free," MS-based, proteomics techniques has emerged as the methods of choice for 
quantitatively comparing proteins levels among biological proteomes, since they are more 
sensitive and reproducible than 2D-PAGE-based methods (Haqqani, Kelly et al. 2008). Protein 
identification from these methods is based on high-throughput ‘shotgun’ analysis of peptides 
from a complex liquid mixture using high performance liquid chromatography (Chen and Yates 
2007). Currently, the MS-based methods utilize mainly stable isotope labels (e.g., ICAT, 
iTRAQ) or “Label-free" methods to identify differentially expressed proteins in two or more 
samples.  
However, despite its superiority over gel-based methods, limitations of the application of 
shotgun proteomics exist and include mainly issues of data analysis. Generally, a single 
multidimensional protein identification technology used to identify proteins with shotgun 
proteomics method generates ≥70,000 spectra in a single experiment. For a complete quantitative 
profiling of proteins, multiple MS runs may be required. As a result, the rapid expansion of 
protein databases, searching this many spectra can pose an enormous computational load making 
real protein identifications versus the false discoveries a challenging and time consuming task 
(Wu and MacCoss 2002). Therefore, due the above limitations, a less complex but a high-
throughput complimentary method such as microarrays that allows screening of multiple proteins 
in a single experiment in a short period of time remains an attractive and favoured approach in 
proteomic translational research. Hence, for this research project, considering the limitations of 
above mentioned proteomic approaches and researcher’s (TH) time constraints, a simpler 
proteomic approach such as antibody microarray was preferred over more complex and time 
consuming gel-based OR gel-free MS methods. 
78 
 
1.13.1.4 MS-free Approach: Forward Phase Antibody Microarray Technique 
Microarrays provide a high-throughput proteomic method that allows screening of multiple 
proteins in the forward-phase approach. However, microarrays with antigen immobilised in a 
reverse-phase can screen only one protein at a given time. In the forward-phase approach, protein 
lysate is screened using multiple immobilised antibodies spotted onto a nitrocellulose coated 
microscope slide. This method is good to compare protein expressions of two samples (e.g. 
therapy sensitive vs therapy resistance) as it allows comparing differential protein expressions 
between the samples as fold changes (Smith, Watson et al. 2006). Following protein extraction 
and quantification, proteins from two samples are labelled with different fluorescent dyes. The 
treatment sensitive sample is labelled with Cy3 fluorescent dye and treatment-resistant sample 
with Cy5 dye. Labelled samples are then incubated with the nitrocellulose slide containing 
immobilized antibodies. There is a range of commercially available microarray kits available 
covering up to 700 antibodies per slide. Differential protein expressions are detected by studying 
the fluorescent signal intensity of the antigen-antibody binding complexes for each sample at the 
wavelength corresponding to dye label (Figure 11). Protein detection using the forward-phase 
microarray method can be used complimentarily with the MS based approaches to enhance the 
credibility of discovered biomarkers.  
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THE FORWARD-PHASE ANTIBODY MICROARRAY WORKFLOW TECHNIQUE 
 
 
 
 
 
 
 
 
 
Figure 11: A graphical illustration of forward-phase antibody microarray technique. Each microarray kit contains a pre-coated 
antibody slide covering up to 700 antibodies.  Sample A is a chemo-sensitive sample extract which is labelled with Cy3 fluorescent 
dye. Sample B is chemo-resistant extract which is labelled with Cy5 fluorescent dye. Both the samples are mixed and incubated with a 
nitrocellulose slide containing up to700 immobilised antibodies. Differential expressions are analysed by studying the fluorescent 
signals of antigen-antibody complexes for each samples at the wavelength corresponding to the dye label. 
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1.14 Clinical Samples in Proteomic Cancer Research: 
Cancer biomarker studies in the past heavily depended on cell line models for novel discoveries. 
However, more recently, different biological samples such as plasma, serum, urine, CSF, tumour 
interstitial fluid, circulating tumour cells, and fresh tumour samples have all been used in 
biomarker discovery research. Using cell lines models and clinical samples have their own 
advantages and disadvantages; however, clinical samples are more preferable over cell lines 
because of their ability to reflect the true tumour environment and attached clinical and 
pathological data with them. However, despite this advantage, a more routine use of clinical 
samples in cancer biomarker studies remain largely restricted due to the issues of tissue 
heterogeneity and a lack of guidance on standardized methods for sample collection, transfer and 
storage (Dihazi and Muller 2007; Ericsson and Nister 2011).  
1.14.1.1 Tumour Samples Proteomics: 
Translational studies have used different clinical samples with various ‘omic’ platforms to study 
therapy responses (Hodgkinson et al. 2012), classify tumours and to investigate tumour biology 
(Zepeda-Castilla, Recinos-Money et al. 2008). Biomarker studies of the early years used 
formalin fixed paraffin embedded (FFPE) tissues with gene expression profiling for making 
novel discoveries. Since then, using smaller amount of protein with high resolution MS, global 
analysis of clinical samples with proteomic methods has been achieved (Zepeda-Castilla, 
Recinos-Money et al. 2008). More recently proteomic studies have used tumour samples with 
MS to monitor and assess responses to cytotoxic therapies (Bauer 2010). Our research group 
have recently published a pilot study using post-treatment resected fresh breast tumour samples 
for the first time with proteomics (antibody microarray and 2D-PAGE-MALDI/TOF/TOF) to 
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discover biomarkers of anthracycline-taxane breast chemotherapy resistance (Hodgkinson et al. 
2012). Clinical tissues commonly employed for biomarker research include both fresh and 
frozen-formalin fixed samples and are by nature complex and heterogeneous. Therefore, utilising 
them for biomarker discovery studies involves overcoming the obstacles of tissue heterogeneity. 
In order to recapitulate the in-vivo molecular interactions that drive disease at the micro-
environment level, analysation of sub-populations of cells from the heterogeneous microecology 
is required. However, a selective seclusion and utilisation of tumour cells from a heterogeneous 
tumour environment can be a challenge. Laser Capture Micro-Dissection (LCM) is one 
technique that isolates histologically pure cancer cells using laser-assisted micro-dissection from 
complex heterogeneous tissues and micro-environments (Braakman, Luider et al. ; Braakman 
2011). Since its advent, genomic and proteomic biomarker studies have witnessed an important 
step forward. Using comparative proteomics (2D-PAGE/MS and LC-MS/MS) with LCM on 
isolated breast cancer cells, proteins of breast cancer metastasis and prognosis have been 
identified (Braakman, Luider et al. ; Braakman 2011). However, protein yield from cancer cells 
using the LCM technique can be usually low. Further, staining methods used in the identification 
of cancer cells with LCM, can pose hindrance with the downstream analysis proteomic technique 
employed. Therefore, for the above reasons, LCM method for isolation of breast tumour cells 
was not considered for this project. A brief overview of the benefits and limitations using 
different tissue for proteomic biomarker discovery are shown in the Table 6. 
 
 
 
82 
 
Table 6:   
 
  Limitations and Benefits of using tissue samples for biomarker discovery 
 
 
  Clinical Tissue 
 
         Benefits 
 
       Limitations 
 
Fresh tissue; biopsy  
samples 
 
 
Pre-treatment sample 
High tumour percentage 
Good sample quality 
May be helpful for predictive 
biomarker discovery 
 
 
Requires ethic approval 
Requires patient consent 
Optimization of techniques 
of protein extraction and 
quantification 
Sample size variations 
 
 
 
Formalin fixed paraffin 
embedded tissues (FFPE) 
 
 
Multiple FFPE cores can be 
assembled in a single block 
and used in tissue 
microarrays- MS analysis to 
collate large information for 
further proteomic analysis 
 
Helpful for predictive 
biomarker discoveries 
 
 
 
Issues of protein 
solubilisation 
Optimization of techniques 
of protein extraction  
Protein modifications from 
formaldehyde fixation 
limiting antigen detection 
Ethical and consent issues 
 
 
 
Fresh tissue; resected 
samples 
 
 
Helpful in assessing therapy 
responses 
Provides markers of therapy 
monitoring 
Provides prognostic markers 
of disease 
 
 
 
 
Tissue heterogeneity 
Variable sample quality and 
amount 
Optimization of techniques 
of protein extraction and 
identification 
Background variations with 
structural proteins  
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1.15 PROJECT AIMS & OBJECTIVES: 
The primary aim of this research project is to expand the list of identified putative biomarkers of 
neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancers using further fresh 
tumour samples and an antibody microarray proteomic approach. Selected proteins from the 
panel will be taken forward for pilot clinical validations using a pre-treatment archival samples 
series to confirm their clinical relevance. Further, this project also aims to optimise a new 
antibody microarray protocol which will enable the use low sample volumes (≤ 1ml) for future 
microarray based proteomic work.  
 
The secondary aim of my project is to undertake immuno-validations of the breast neoadjuvant 
chemotherapy resistance DEPs discovered by Dr.Victoria Hodgkinson (PhD) using comparative 
(AbMA and 2D-PAGE-MS/TOF) proteomics in a larger archival series (Hodgkinson 2012). 
Further, utilising a few clinical samples excluded from the current study, protein extraction and 
quantification methods using smaller tissue volumes will be optimised for the future proteomic 
work involving core biopsy samples. 
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Chapter 2.   
2.1 INTRODUCTION: 
The majority of thesis will focus on application of the antibody microarray proteomic technique 
with fresh tumour samples for the analysis of resistance of breast tumours to anthracycline-
taxane chemotherapy. Further, principles and details of the antibody microarray technique with 
full/standard, half-labelling and modified half-labelling protocols including description of 
Ingenuity Pathway Analysis for data mining will be discussed in detail. Also, protein 
confirmations and clinical validations using immnuoblotting and immunohistochemistry 
techniques will be outlined and discussed in detail. 
All chemicals used in the research study were of the highest quality and purchased from Sigma-
Aldrich unless otherwise stated. The contamination of samples for proteomic analyses was 
minimized by wearing a lab coat, nitrile gloves and a visor where appropriate. Furthermore, 
preparation of clinical samples for experiments was carried out under strict aseptic conditions. 
2.2 STUDY DESIGN: 
The pilot breast cancer research study originally approved by the South Humber Local Research 
Ethics Committee (ref 07/Q1105/43) in 2007 was conducted in two stages by two independent 
researchers Dr.Victoria Hodgkinson (VH) (PhD) and Dr.Tasadooq Hussain (TH) (MD student 
and author of this thesis). For the initial part of the study, VH collected a total of n=38 post-
treatment fresh tumour samples and analysed n=8 samples in four pairs using a comparative 
proteomic approach (Antibody Microarray and 2D-PAGE/MS experiments) to identify 
predictive putative biomarkers of anthracycline-taxane neoadjuvant resistance (Hodgkinson et 
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al.2012). In the second stage of the project, a further fresh set of n=6 samples in three pairs were 
analysed by TH using a newly optimised ‘Half-labelling Antibody Microarray Protocol’. An 
outline of the study design is depicted in Figure 12. Initially, patients who matched the 
requirements of the study were identified by the clinicians in the Breast Unit at Castle Hill 
Hospital. They were informed of the research study, and if patients wished to participate they 
were provided with an information sheet and a signed record of consent was taken. This may 
have been towards the end of the chemotherapy treatment, prior to surgery. During surgical 
resection of the residual tumour, breast surgeons took a small sample of macroscopic tumour, 
which was immediately stabilised by snap-freezing in liquid nitrogen. Tumour samples provided 
by the surgeon varied in size from 2 mm
3
 to 2 cm
3
. Tumour samples were then stored at minus 
80
o
 C until required. After allowing time for histopathological tests and reports to be completed, 
patient notes were accessed by a clinician involved in the study, and relevant data was recorded. 
This included details regarding the type of tumour, the molecular subtype of the tumour, the 
chemotherapy administered tumour sizes pre- and post-treatment from DCE-MRI and US scans, 
as well as the pathology reports from both the core biopsy specimen taken upon diagnosis and 
the tumour resection. 
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A FLOWCHART OF THE STUDY DESGIN 
 
 
Figure 12: The flow chart depicts different stages patient journey from the time of initial clinic 
presentation with breast lump to the point of surgical resection. Patient recruitment for this study 
took place after completing the NACT and before surgical resection. Only samples from tumours 
that were non-responders and/or deemed to have a partial clinical response were collected and 
used for proteomic analysis. 
2.3 SAMPLE COLLECTION AND PATIENT SELECTION: 
The study included patients receiving neoadjuvant chemotherapy for locally advanced breast 
cancer at Hull and East Riding Hospitals NHS Trust, Hull from 2007 to 2011 (5 years). Both VH 
and TH were jointly involved in the sample collection and storage process. A total of 50 post-
treatment fresh breast tumour samples were collected as per the ethical approval. The clinico-
pathological details of all n=50 samples and the determined therapy responses for each tumour 
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are outlined in the Appendix 1 of the thesis. Of the n=50 total samples collected for both studies, 
a total of n=38 tumour samples were collected initially by Victoria Hodgkinson (VH) during her 
PhD study period (2008-2010). Of the 38 samples, four samples were excluded from the VH 
study and used for preliminary optimisations. The remaining 34 samples were pooled and carried 
forward for the proteomic analysis. Of the available n=38 samples, only n=8 samples were 
initially used by VH for the combined antibody microarray and 2D-PAGE/MS analysis grouping 
them into 4 pairs of chemosensitive and chemoresistant. A consort chart as shown in the Figure 
13 outlines how clinical samples were collected (n=38), pooled and used for pilot proteomic 
analysis (n=8) and optimisation experiments (n=4) in the VH project. 
 
A further n= 12 samples were collected by TH between May to July 2011 to bring the final number 
to n=50 before stopping the sample collection. This last set of samples (n=12) were not included in 
the initial VH pilot study and kept frozen at – 80 degrees centigrade for a later use. The clinical data 
for these 12 samples was completed by TH in January 2012. The second consort chart shown in 
Figure 14 outlines the final number of samples collected (n=50), the number of samples that 
were available for proteomic analysis in both the studies (n=26) and the total number of samples 
that were excluded from both the studies (n=24).  
 
The third consort chart as shown in the Figure 15 outlines the samples that were used (n=6) in 
this project for further four antibody microarray experiments and the sample pair that was used 
for western blot analysis. All 6 tumour samples selected for this study and the VH pilot study 
were all ductal ER+ clinical variant of intrinsic Luminal A molecular subtype. This molecular 
subtype was selected for proteomic analysis due to its poor sensitivity to anthracycline-taxane 
neoadjuvant chemotherapy (sections 1.8.1, 1.8.2 and 1.8.3). 
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2.3.1 Response Evaluation From Clinical Samples: 
For the project samples, therapy responses were determined using RECIST criteria (section 
1.5.1.3) with the help of an Oncologist (Dr. Vijay Agarwal) and samples were paired according 
to therapy regimens, therapy responses and tissue availabilities. Responses were categorised into 
chemosensitive (Responders) and chemoresistant (Non-responders). Tumours were classed as 
chemosensitive (Responders) if following neoadjuvant chemotherapy a ≥30% reduction in the 
tumour size was noted at the final histology from the baseline measurements at the pre-treatment 
breast MR and/or if no residual tumour was found at the final resection histology. Tumours that 
progressed following neoadjuvant treatment (≥20% increase in tumour size from baseline breast- 
MR measurement) and/or showed no change in the tumour size from the baseline (stable disease) 
were termed as chemoresistant (Non-responders). The above method, to assess tumour responses 
comparing the pre-treatment MR tumour measurement to the final histology residual tumour size 
and not the post-treatment MR tumour measurement was a novel approach undertaken for the 
first time with the VH samples (Hodgkinson et al. 2012). Assessing therapy response this way, 
eliminated any bias at accurate estimation of a therapy response that could occur as a result of 
tumour fragmentation following taxane therapy on the post-treatment MR (Denis, Desbiez-
Bourcier et al. 2004). To maintain uniformity between the two studies (VH and TH), the same 
therapy assessment strategy and cut-off criteria as described above by our research group were  
used for the response evaluation of tumour samples analysed in this project.  
All patients in the study received neo-adjuvant chemotherapy regimen consisting of 4 cycles of 
EC [epirubicin (90 mg/m2) + cyclophosphamide (600 mg/m2)] and 4 cycles of docetaxel (100 
mg/m2), given at 3-weekly intervals in the order of EC followed by Docetaxel. Following the 
treatment, depending on the patient response, either resection of residual tumour or mastectomy 
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was carried out. The consort chart in Figure 15 and Table 7 outlines all the 6 clinical samples 
used for the antibody microarray analysis in this project. The clinical data of analysed samples (8 
from VH work; 5 from this study) with their neoadjuvant therapy responses is listed in Table 8 
and 9 with the full list of all 50 patients listed in the Appendix 1 of this thesis. 
Table 7:    Samples Selected for the Antibody Microarray Analysis         
 
 
2.3.2 Sample Collection at Surgery: 
At the time of surgery, patients were approached for the sample donation and an informed 
consent was obtained from the willing donors. Samples were taken by the operating surgeon 
(usually a breast consultant) and collected in a micro-centrifuge tube to be snap frozen in liquid 
nitrogen and stored at minus 80
o
C until required. The pieces of solid tumour provided ranged 
between 1 to 3 and the size between 2 mm
3
 to > 2 cm
3
 and the number of pieces of solid tumour 
provided (in separate microcentrifuge tubes) by the surgeon ranged from 1 to 3.  
 
Sample Pairs 
 
Clinical Response 
 
 
 
 
Pair 1 
 
Chemosensitive 
 
Chemoresistant 
 
#16B 
 
 
#1B 
 
 
 
Pair 2 
 
 
#38 
 
 
 
#15B 
 
 
Pair 3 
 
#12B 
 
 
#1 
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At the time of consent, patients were asked for the permission to access their case notes for 
relevant clinical information which included chemotherapy details, radiological and pathological 
results and reports for determination of response and molecular typing (ER/PR/HER2 status).  
.
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AN OUTLINE OF SAMPLE COLLECTION AND UTLISATION FROM VH-PILOT PROJECT 
 
Figure 13: The consort chart outlines the project breast sample collection and utilisation for the VH pilot project. A total of 38 
samples were collected initially of which 34 were taken for proteomic analysis and 4 for initial optimisation work. Of the 34 samples, 
8 samples were paired and analysed using combined antibody microarray (green colour) and 2D-PAGE/MS approaches (purple 
colour). For samples which were included in more than one experiment (2) is shown. 
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FLOW CHART OUTLINING THE SAMPLE COLLECTION, UTILISATIONS & EXCLUSIONS 
 
Figure 14:  The consort chart outlines the utilisation of n=50 samples collected for the breast cancer project. From the 50 samples 
collected, only 26 were taken forward for proteomic analysis and the rest were excluded for the reasons outlined above. For the 
current project, 6 samples were selected from the pool of 26 available and used for the antibody microarray experiments. Of the 6 
samples used, 1/6 sample was selected from the VH 8 sample cohort and the rest (n=5) were all unutilised samples.  
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AN OUTLINE OF CURRENT RESEARCH PROJECT & METHODS 
 
Figure 15: The consort chart outlines the current research project. From the total of 50 breast samples collected, 26 samples were 
eligible for proteomic analysis. VH pilot study used 8/26 samples. For this study, 6 samples in 3 pairs (light blue colour) were selected 
and used for the antibody microarray experiments. Samples were paired as chemosensitive (CS) or chemoresistant (CR) based on 
using RECIST criteria (light orange colour). All 6 samples were ER+ (luminal) ductal sub-type. Only one pair (#38
CS 
vs. #15B
CR
; red 
colour) out of three was successfully confirmed on western blot. In the second part of the project, 14-3-3 isoforms identified in VH 
pilot study and the new DEPs identified in the current study were selected for immuno validations using two archival iFEC & ECD 
pre-treatment core biopsy sample series. 
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CLINICAL AND THERAPY RESPONSE DATA OF SAMPLES USED IN THE CURRENT PROJECT 
 
Table 8:  Table listing clinical tumour samples (n=6), showing the breast carcinoma types, the receptor status (ER/PR/HER2), and 
therapy administered, represented by EC: epirubicin + cyclophosphamide, D: docetaxel with the number of cycles. Response was 
classified as chemo-sensitive (CS) or chemo-resistant (CR) based on RECEIST criteria if the tumour regressed by ≥30% from the 
baseline or showed no response and/or increased by ≥20% from the baseline at pre-treatment MRI 
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CLINICAL AND THERAPY RESPONSE DATA OF SAMPLES USED IN VH-PILOT SERIES 
 
Table 9: Table listing clinical tumour samples (n=8), showing the breast carcinoma types, the receptor status (ER/PR/HER2) and 
therapy administered, represented by EC: epirubicin + cyclophosphamide, D: docetaxel with the number of cycles. Reduced doses are 
indicated* (also see Appendix A) Response was classified as chemo-sensitive (CS) or chemo-resistant (CR) based on RECEIST 
criteria if the tumour regressed by ≥30% from the baseline or showed no response and/or increased by ≥20% from the baseline at pre-
treatment MRI 
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2.3.3 Archival Series Pre-treatment Core Biopsy Patient Selection: 
2.3.3.1 : MRI-iFEC Archival Series: 
The clinical validations of 14-3-3 protein isoforms and Vimentin protein from VH pilot work 
was carried out using a pre-treatment core biopsy archival series (n=35) previously identified and 
characterised (Garimella et al. 2007) and a small pre-treatment core biopsy samples series (n=32) 
collected from the patients selected for this study.  
Ethical approval had previously been granted for the archival series entitled ‘monitoring the 
effects of chemotherapy in breast cancer patients using magnetic resonance imaging and 
molecular markers’ from the Hull and East Riding Research Ethics Committee (ref 03/00/038). 
All patients in this cohort were recruited between 2000 and 2002 from the Hull and East Riding 
NHS trust, and had histologically-proven breast cancer with a primary tumour of ≥ 3cm. In total, 
35 archival tissue samples were obtained from 36 locally advanced breast cancers (one patient 
had bilateral breast cancer). These comprised 75% ER-positive tumours and 69% PR-positive 
tumours. Patient consent was obtained to allow access to pre-treatment core biopsy samples and 
to perform serial DCE-MRI scans (pre-treatment, after 2nd cycle of chemotherapy, and post-
treatment) so that tumour response to therapy could be monitored. Patients were treated with 6 
cycles of 5-fluorouracil (200 mg/m2), epirubicin (60 mg/m2) and cyclophosphamide (600 
mg/m2) (infusional FEC), administered at 3-weekly intervals. Tumour response was assessed 
after the 2nd cycle using DCE-MRI scans. Patients who showed a response continued with the 
full course of treatment, and where no response was observed, chemotherapy was terminated. 
Following this, definitive surgery was performed to remove residual tumour.  
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In order to avoid any confusion and a mix up with the other series used in the validation work, 
this series will be referred as ‘MRI-iFEC’ series. 
2.3.3.2 EC-D Archival Series: 
The second series used for clinical validations included pre-treatment core biopsies of patients 
recruited (n=50) for this study and the VH study. All the patients in this series were treated with 
Epirubicin, Cyclophosphamide and Docetaxel in the doses and regimens as described in the 
section 2.3.1. Therefore, this series was referred as the ‘EC-D’ series. For this series, the tumour 
response was assessed on pre-treatment DCE-MRI scans and final histology using RECIST 
criteria described in the section 1.5.1.3. Patient clinical data was collected from hospital 
computer records and patient notes by the author of this thesis (TH) and Miss Dalia ElFadl 
(previous breast research fellow). Therapy responses were assessed by Dr. Vijay Agarwal 
(Oncologist). Patients who showed a response at the 2
nd
 DCE-MRI scan on treatment continued 
with the full course of treatment, and where no response was observed, chemotherapy was 
terminated and definitive surgery was performed to remove residual tumour. The clinico-
pathological status of tumour samples collected for the study are summarised in the Table 10. 
 
 
 
 
 
 
 
99 
 
 
EC-D SERIES SAMPLE CLINICO-PATHOLOGICAL STATUS 
 
Receptor Status Numbers (n=50) Percentage 
ER+ 37/50 74% 
PR+ 13/50 26% 
Histology   
Ductal 42/50 84% 
Lobular 8/50 16% 
Response Data   
CR 19/50 38% 
CS 28/50 56% 
SD 1/50 2% 
PD 2/50 4% 
Table 10: The clinico-pathological characteristics of tumour samples collected for the study 
showed the majority of tumours were ER+ (74%) ductal (84%) type. The therapy response data 
as determined using the RECIST criteria showed majority of the tumours were CS (56%) and 
38% of tumours showed chemoresistance to anthracycline-taxane therapy. 
CR=Chemoresistant CS=Chemosensitive PD=Progressive disease SD= Stable disease 
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2.4 SAMPLE PREPARATION FOR MICROARRAY ANALYSIS: 
2.4.1 Introduction: 
Sample preparation in proteomics is an important step, as complimentary proteomic studies have 
discovered this process to be end-application specific and size dependant (Gromov, Celis et al. 
2008). Tissue preparation for proteomic studies is carried out in a two step process, tissue 
breaking down and homogenisation. The process of tissue homogenisation is an important step 
and has to be carried out in correct lysis buffer for subsequent protein extraction. Although, 
surgical excision provides large tissue samples allowing classical tissue homogenisation with 
mechanical methods (tissue ruptor, sonicator, grinding in liquid nitrogen and cryostat 
sectioning), optimal methods of homogenisation and protein extraction with smaller tissue 
samples (e.g. core biopsy) are yet to be fully established (Gromov, Celis et al. 2008). 
Furthermore, preparation of lysis buffer for tissue suspension is decided based on the end-
application (array or 2D-PAGE/MS) due to reagent compatibilities as no single ideal 
solubilisation buffer exists for all proteomic applications (Gorg, Weiss et al. 2004; Weiss and 
Gorg 2008). 
2.5  Protein Extraction Methodology: 
The technique of protein extraction with mechnical homogensation using breast tumour samples 
was earlier optimised by VH (for the pilot work). Findings from VH experimental preliminary 
optimisation studies showed a poor correlation between tumour size (by eye), or mass (g) and 
protein yield (mg/ml). This was  mostly due to a high amount of tissue heterogenity between 
tumour samples (Hodgkinson, D et al. 2012). Therefore, all the  breast tumour samples used in 
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this project even though appeared approximately the same size by naked eye examintaion were 
weighed before suspending into the lysis buffer. 
The breast tumour samples used in this project were first resuspensed in antibody microarray 
extraction/labelling buffer (Sigma-Aldrich) and mechanically  homogenised using a hand held 
tissue ruptor. Polypropylene microcentrifuge tubes were used in the tissue extraction to prevent 
any retention of  protein/peptide on the glass surface. Initially, a 10 ml of antibody extraction 
solution was prepared by adding 100 µl of Phosphatase Inhibitor Cocktail, 50 µl of Protease 
Inhibitor Cocktail and 1.2 µl of Benzonase Working Solution. This solution was called as Buffer 
‘A’ and kept on ice until required. The addition of Protease and Phosphatase inhibitors helps 
maintain the protein composition by inhibiting their breakdown in the sample; benzonase 
removes nucleic acid present in the sample. The next few steps from this stage were carried out 
in a Class II Tissue Culture Hood, using a sterile technique. Breast tumour sample was removed 
from -80
o
 C freezer and weighed after defrosting. To avoid protein degradation sample was kept 
on ice when not handled. Individual tumour samples were transferred in a sterile Petri dish on ice 
and cut into pieces using a sterile scalpel knife and washed with cold PBS solution to remove 
any residual blood clots adhered to the tumour tissue. Four times w/v of Buffer A was then added 
to the tissue in a universal tube and the tissue was mechanically homogenised on ice using a 
hand-held homogeniser called Tissue Ruptor (#9001273, Qiagen)  
The hand-held homogeniser has been used commonly for homogenising plant and animal tissues 
(Burden Sept 2008). It consists of an outer stationary tube (stator) and an inner turning shaft 
(rotor) connected to a motor. The working action involves applying tangential shearing force the 
tissues when the shaft is running at 10,000-20,000 rpm. To avoid cross-contamination between 
the samples, we used a disposable shaft (#990890, Qiagen) between each experiment. Each 
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sample was homogenised individually three times, conducting each homogenising action strictly 
for 30 s with a 30 s rest in between. Resting the samples prevented protein denaturisation from 
the heat generated by the Tissue Ruptor at high speeds. After homogenisation, samples were 
centrifuged for 10 s at 10,000 x g in a microcentrifuge tube to remove any fat contained in the 
sample (Figure 16). 
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SAMPLE PREPARATION AND PROTEIN EXTRACTION METHOD 
 
 
Figure 16: Sample preparation and protein extraction from clinical tissue samples for antibody 
microarray analysis. The steps involved in the extraction of protein for clinical samples include 
weighing the tissue first followed by tissue slicing Buffer A suspension. The samples are then 
mechanically homogenised individually and centrifuged repeatedly to obtain a clear supernatant 
which is then used in the Bradford Assay for protein quantification. 
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2.5.1 Mechanical Homogenisation for Small Sample Volumes: 
Tissue Ruptor can be used for homogenising samples varying in sizes from less than 1 ml up to 
40 L. However, this method may not be ideal for smaller tissue samples (e.g. core biopsy 
sample). This is due to an increased risk of  protein denaturisation and tissue entrapment reported 
from an earlier study (Burden Sept 2008). Therefore, for smaller tissue volume alternative 
methods of homogenisation are recommended to avoid excessive tissue loss and protein 
breakdown. These methods includes: Cryo-Grinding, Vortex-Bead Beating and Sonication 
methods (Burden Sept 2008). Of the above three methods, we employed Sonication for  
homogenisation of smaller size breast tumour sections for the pilot protein extraction and 
quantification optimisation experiments using low tissue volumes.   
The initial sample processing for the Sonicator method was carried out similar to the Tissue 
Ruptor method as described in the section 2.5 A Water-Bath Sonicator (Scientific Laboratories, 
serial #030172) was used for the homogenisation. Firstly, tumour samples were suspended in 
micro centrifuges with four times w/v of Buffer A; micro centrifuges where then  suspended in a 
Water-Bath Sonicator (Scientific Laboratories, serial #030172)  and  sonicated for a total of 5 
min for 3 times. In between each sonication process, samples were rested for 5 min on ice to 
avoid protein denaturisation from the heat generated.  Finally, samples were centrifuged for 10 s 
at 10,000 x g in a microcentrifuge tube in order to remove any fat contained in the sample which 
collects as a supernatant layer at the top of the micro centrifuge. This layer is carefully pipetted 
out and the solution containing the tissue lysate is transferred into a fresh microcentrifuge tube. 
The samples are then placed on an end-over-end rotator set at a slow speed in a cold room at 4
o
 C 
for overnight or at least 16 hours. At the end of the mixing period, samples are centrifuged at 
13,000 x g for 5 min keeping them in the cold room.  Samples after this point are ready for the 
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protein quantification using one of the four spectroscopic protein assay method (e.g. Bradford 
assay). For our samples, protein quantification was carried out using Bradford Protein 
Quantification Assay as it is compatible with the reagents used in antibody microarray analysis. 
2.6  BRADFORD PROTEIN QUANTIFICATION METHOD: 
The Bradford protein assay is a spectroscopic analytical procedure used to measure the 
concentration of protein in a solution. The Bradford Reagent (Kit #128K4340, Sigma Aldrich) 
consists of Brilliant Blue G dye in phosphoric acid and methanol (Table 11). The dye exists in 
three forms: cationic (red), neutral (green), and anionic (blue) under acidic conditions, the dye is 
predominantly in the doubly protonated red cationic form (Amax = 470 nm). However, when the 
dye binds to protein, it is converted to a stable unprotonated blue form (Amax = 595 nm) which is 
then detected at 595 nm in the assay using a spectrophotometer or microplate reader (Sedmak 
and Grossberg 1977). This shift in the absorbance spectrum (Amax = 470 nm to 595 nm) occurs as 
a result of dye-protein complex and is therefore proportional to the amount of protein present in 
the sample. The colour development in Bradford assay is associated with the presence of certain 
basic amino acids (primarily arginine, lysine and histidine) in the protein. Van der Waals forces 
and hydrophobic interactions also participate in the binding of the dye to the protein. The number 
of Coomassie dye ligands bound to each protein molecule is approximately proportional to the 
number of positive charges found on the protein. Free amino acids, peptides and low molecular 
weight proteins do not produce colour with coomassie dye reagents. In general, the mass of a 
peptide or protein must be at least 3000 daltons to be assayed with this reagent.  
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BRADFORD ASSAY COOMASSIE PLUS REAGENT CONTENTS 
 
Bradford Assay Reagent Content List: (950ml) 
Coomassie G-250 dye 
Methanol 
Phosphoric acid 
Solubilising agents in water 
 
Table 11: Bradford assay reagent consists of Brilliant blue G dye in phosphoric acid and 
methanol. In the acidic state the dye remain stable in red cationic form (Amax = 470 nm). 
However, when binded to protein in the sample, the dye convert to stable unprotonated blue 
anionic form (Amax = 595 nm). The colour development in the assay remains proportional to the 
amount of protein in the sample. 
 
2.6.1 Determination of Protein Concentration: 
The protein concentration of the tumour sample is determined by comparison to that of a series 
of protein standards known to reproducibly exhibit a linear absorbance profile in this assay. 
Although different protein standards can be used, the two most commonly employed protein 
standards are the Bovine Serum Albumin (BSA) and Bovine Serum Globulin (BSG). For this 
project quantification experiments, we chose Bovine Serum Albumin as our standard as it is the 
most widely used protein with a greater dye-protein colour developing property with majority of 
the commercially available assay reagents.  
Eight BSA protein standards were prepared, ranging from concentrations of 0.1 to 1.4 mg/ml 
diluted in Buffer A in microcentrifuge tubes. A 5 μl volume of each standard concentration in 
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duplicates was placed in separate wells in a 96-well plate. Tissue extracts of unknown protein 
concentration at a similar volume of 5 μl were also placed into separate wells in the 96-well in 
undiluted and diluted concentrations (e.g. 1:5. 1:10 and 1:20). Bradford Reagent was mixed 
gently and brought to the room temperature and 250 μl was added to each protein standard and 
each sample concentration. The 96-well plate was then mixed for 30 s on the spectrophotometer 
(Multiscan MS plate reader, Labsystems) and incubated at room temperature for 5 min. 
Absorbance was subsequently measured at 595 nm. 
2.6.2 Plotting BSA Standard Protein Curve: 
The unknown protein concentration in the sample is determined by plotting a BSA protein 
standard curve against the absorbance at 595 nm (Figure 17). The protein concentration of the 
tissue extracts is then calculated using the equation of the line y = mx + c; protein concentration 
x is determined from the equation as x = y-c/m. The ‘y’ in the equation represents the protein 
concentrations values obtained at 595nm from the undiluted (neat) and diluted samples before 
any corrections for dilutions are applied. Figure 20 is an example of BSA standard curve at 
595nm absorbance. The equation for the line of best fit is show R
2
 as a correlation between 
protein concentrations in the standards and absorbance at 595nm. A R
2
 value of 1 or near 1 
represents a strong correlation. 
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THE BSA PROTEIN STANDARD CURVE 
 
 
 
Figure 17: is an example of how protein standards curve for BSA at concentrations 0.1 to 1.4 
mg/ml measured at 595nm absorbance looks like. The equation of the line y=mx + c is 
represented in this example by y =0.2493x + 0.3595, x in the equation represent the protein 
concentration to be determined and is calculated from the equation x = y-0.3595/0.2493 where y 
is the protein concentration value obtained from the neat sample and before correction for the 
dilution. R
2
 from the equation represent correlation between protein concentrations in the 
standards and absorbance at 595nm. A  R
2
 value of 1 or near 1 represents a strong correlation 
which is an indirect indication that similar standard volumes were pippetted into each well. 
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2.7 ANTIBODY MICROARRAY: 
2.7.1 Panorama® Antibody Microarray-XPRESS Profiler 725 Kit: 
For this research project, the Panorama
®
 Antibody Microarray-XPRESS Profiler 725 Kit 
(SIGMA-ALDRICH) was exploited in order to study the differential protein expression between 
chemosensitive and chemoresistance breast cancers. The Panorama
®
 Antibody Microarray- 
XPRESS Profiler 725 contains 725 different antibodies each spotted in duplicate on a 
nitrocellulose-glass slide (Figure 18). These antibodies represent families of proteins known to 
be involved in a variety of different biological pathways (Cell signalling, Apoptosis, P53 family 
of proteins and Transcriptional factors). The Panorama
®
 Antibody Microarray XPRESS Profiler 
kit has been previously exploited in many proteomic studies to assess differential protein 
expressions for various tumours (e.g. breast and colorectal) and cell line studies and has been 
found to be a useful proteomic method providing a large amount of high quality data for analysis 
(Celis, Moreira et al. 2005; Kopf, Shnitzer et al. 2005; Madoz-Gurpide, Canamero et al. 2007).  
The differential protein expressions by this method are detected when proteins binds to their 
corresponding antibodies spotted on the slide. Each slide contains 725 antibodies spotted in 32 
sub-arrays each containing duplicate spots of 23 antibodies, as well as duplicate positive control 
spots for Cy3 and Cy5 (monoclonal antibody that recognises Cy3 and Cy5), and 11 negative 
controls (Appendix 2). The differential protein expressions with Panorama
®
 Antibody 
Microarray are analysed by labelling each sample (chemosensitive and resistant) with a different 
Cyanine DyeTM (CyTM 3 or Cy5). Fluorescent signal intensity for each sample is then recorded 
individually at the wavelength corresponding to the dye label of the sample and compared. The 
fluorescence intensity detected on the array with each antibody depends on this binding affinity; 
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therefore, signal intensity comparison can be performed only within the same antigen/antibody 
system and not between different antibodies. 
The Panorama
®
 Antibody Microarray- XPRESS Profiler 725 is an accurate and robust protein 
expression profiling technique which is easy to learn and perform. Usually a single experiment 
can be completed within a day. Antibodies spotted on the slide are in high density to ensure 
strong signals. The proprietary treatment of the slide coating minimizes background staining, 
thereby, maximising the signal-to-noise ratio for accurate analysis (Kopf, Shnitzer et al. 2005).   
 
 
THE PANORAMA XPRESS PROFILER 725-KIT 
                         A                                                               B 
                  
 
 
Figure 18: The picture A on the above shows an unscanned antibody microarray slide. Each 
slide comes with multiple printed spots each representing one antibody. On the Panorama 
XPRESS Profiler 725 array slide there are 725 printed antibody spots. The picture B on the right 
hand side shows a representation of the antibody microarray slide with printed protein library 
and labelled proteins together. The labelled protein samples are added to the slide and incubated 
before scanning.   
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2.8 ANTIBODY MICROARRAY EXPERIMENT PROTOCOL: 
Following Bradford protein quantification, protein concentrations from the breast tumour 
samples were determined as described in the section 2.6.1. Only those samples that had protein 
concentrations ≥ 1mg/ml were selected for antibody microarray analysis. This was keeping in 
line with the SIGMA recommendations of using the Panorama
®
 Antibody Microarray-XPRESS 
Profiler-725 kit with a minimum protein concentration of 1mg/ml for array analyses.  
For all the six samples used in the project, the protein concentrations were determined and found 
to be ≥ 1mg/ml required protein concentration for microarray analysis. Therefore, all 6 samples 
were eligible for the microarray analysis. Individual sample concentrations found at the Bradford 
Protein Assay from our research samples will be discussed in the detail in the results chapter of 
the thesis. 
The antibody microarray experiment protocol will be discussed under 4 main headings: 
1. Sample Dilution and Protein Labelling 
2. Determination of dye/protein molar ratio 
3. Microarray slide incubation 
4. Slide scanning and Data analysis 
2.8.1 Sample Dilution and Protein Labelling: 
In the standard microarray protocol, sample dilution with Buffer A is carried out to bring the 
final volume to an ml at 1mg/ml sample concentration. Protein labelling using the above dilution 
is termed as ‘Full-Labelling Microarray Protocol’. A second protocol using 0.5 ml of final 
sample volume at 1mg/ml protein concentration termed as ‘Half-Labelling Microarray Protocol’ 
has been optimised in this research project for the first time. The optimisation details of the 
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‘Half-Labelling Microarray Protocol’ will be discussed in the subsequent sections of this 
chapter. With the optimisation of the new protocol, researcher will now be able to use low 
sample volumes (0.5 ml) at 1mg/ml protein concentration technically advancing the antibody 
microarray proteomic research.  
2.8.1.1 Standard or Full-Labelling Microarray Protocol: 
Extracts with protein concentrations >1.0 mg/mL were used for fluorescent labeling. The range 
of concentrations used in this study was 1.0 to 8 mg/ml. A dual fluorescent-labeling assay 
analogous to that exploited in cDNA microarray experiments was used. Extracts were labelled 
separately using Cy3 or Cy5 dyes (GE Healthcare). Each protein sample (1 mL) was added 
directly to one vial of either Cy3 or Cy5 and mixed thoroughly by inversion. The labeling 
reaction was allowed to proceed for 30 minutes at room temperature in the dark. During this 
period, samples were mixed every 10 minutes. Labelled samples were purified from free excess 
Cy dye using the Sigma-Spin columns supplied with the antibody microarray kit. The columns 
were centrifuged for 2 minutes at 4,000 rpm before 150 µL of labelled protein sample were 
pipetted onto the centre of the column. A further centrifugation at 4,000 rpm was done for 4 
minutes. The eluate was retained, and protein concentration was estimated using the Bradford 
assay as described in section 2.6.1. Labelled protein was stored at -20
o
C until hybridization. For 
the purpose of this study, chemosensitive sample was labelled with Cy3 and chemoresistant 
sample was labelled with Cy5 (Figure 19). 
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WORKFLOW OF THE FULL-LABELLING MICROARRAY PROTOCOL 
 
 
Figure 19:  The workflow of the full-labelling Microarray Protocol is shown above. At first, one ml of 
sample (CS and CR) volume at 1mg/ml concentration is directly mixed with dyes. The labelled protein 
lysates are then loaded onto spin-columns at 150 µl volume and D/P ratios determined. Finally an equal 
amount of protein load is calculated and the samples are loaded onto the array slide. 
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2.8.1.2 Determination of Dye/Protein Molar Ratio (D/P Ratio): 
The Dye to Protein Molar Ratio (D: P ratio) is determined by measuring the absorbance of the 
Cy3-labelled and Cy5-labelled protein samples at 552 nm and 650 nm respectively after diluting 
the samples to 1:150 (15 μl of labelled sample + 135 μl of Buffer A) and blanking the UV 
spectrometer machine with Buffer A or water and using the calculations supplied with the 
microarray kit. As specified in the microarray kit, to use the labelled samples in a microarray 
experiment, D/P ratio of ≥ 2 is required. A lower ratio (≤ 2), doesn’t stop the array assay being 
carried forward; however, at this ratio a higher than normal background interference should be 
expected at the slide scanning stage. After this step, antibody microarray slides are washed by a 
brief submersion in PBS. The Cy3 and Cy5 labelled sample pairs are added at equal protein 
concentrations to 5 mL of Array Incubation buffer (antibody microarray kit component). The 
resulting solution is mixed by inversion and added to a well of the quadriPERM Cell Culture 
Vessel supplied with the antibody microarray kit. The antibody microarray slide is added to the 
well containing the labelled samples. The Vessel is protected from exposure to light with 
aluminium foil and incubated on an orbital shaker (30 rpm) at room temperature for 45 minutes. 
Subsequently, 5 mL of wash buffer (antibody microarray kit component) is added to the 
remaining wells of the Vessel and the slide is washed on an orbital shaker for 5 minutes in each 
well. The wash buffer is decanted from well 4 and replaced with 5 mL of proteomics grade water 
(Bio-Rad, Hemel Hempstead, United Kingdom) for a final wash for 2 minutes. The hybridized 
antibody microarray slide is removed from the well and air dried in the dark. After this step, the 
microarray slide is scanned for final analysis. 
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2.8.1.3 Slide Hybridization, Fold Change Cut-off & Quality Control: 
The hybridized antibody microarray slide is scanned using a GenePix Personal 4100A 
Microarray Scanner (Axon Instruments, Union City, CA) with 532 and 635 nm lasers (Figure 
20). Primary analysis is done with the GenePix Pro (version 4.1) software package (Axon 
Instruments). Images of scanned antibody microarrays are gridded and linked to a protein print 
list. Absent spots are flagged automatically by GenePix Pro; however, all spots are manually 
reviewed. Further analysis is done using Acuity (version 4.0) software (Axon Instruments) for 
the identification of differentially expressed proteins. Microarrays are normalized based on the 
Lowess method due to a slight skew in data distribution. The log ratios of Cy5 to Cy3 are 
determined for each spot to estimate the relative concentrations of each protein in the two 
independently dye labelled samples of each experiment. Unreliable data is removed from 
analyses by applying quality control criteria. Such criteria were set to include only those spots 
with a small percentage (<3%) of saturated pixels, spots that were not flagged as absent, spots 
with relatively uniform intensity and uniform background, and those spots that were detectable 
above background levels. Proteins showing a ≥ 1.8 fold differences in expression in 90% of 
individual microarrays are deemed significant.  
In microarray analysis, as indicated by previous studies, a fold change of ≥1.3 to ≥1.8 has been 
considered significant to represent differential protein expression (Ghobrial, McCormick et al. 
2005; Smith, Qutob et al. 2009). Previously, our research group, using a total of 13 independent 
antibody microarray experiments encompassing a range of oncology-related research on human 
tissue, cells or cell lines from 5 distinct sample groups set a fold change of ≥1.8 and a substance 
match of ≥90% to represent a significant differential expression and a high quality microarray 
experiment (Hodgkinson, ElFadl et al. 2011). Therefore, this cut-off and substance match criteria 
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was taken as a standard reference to analyse data obtained from the six microarray experiments 
performed in this project. However, using  the same sample set, if multiple experiments are 
performed, differentially expressed protein data showing a fold changes ≥ 1.5 but ≤ 1.8 is 
considered as supporting evidence and proteins are taken to the next stage (confirmation and 
validation) only if the value of  ≥1.8 is reached in at least one experiment. 
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SCANNED IMAGES OF THE PANORAMA-XPRESS PROFILER-725 
 
 
Figure 20: shows a scanned image of the Panorama® Antibody Microarray- XPRESS Profiler 
725 slide; each slide contains 725 antibodies spotted in 32 sub-arrays each containing duplicate 
spots of 23 antibodies, as well as duplicate positive control spots for Cy3 and Cy5 (green spots). 
The above image displayed is a hybridised slide image when the array slide is scanned at two 
different wavelengths (532nm and 653nm). From the above image the relative intensity of two 
dyes can be determined for each antibody. If the difference in the relative intensity of each dye is 
>1.8 fold, this represent a significant fold change for a differential protein expression of that 
particular protein. (Courtesy V.C.Hodgkison, PhD thesis) 
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2.9 OPTIMISATION OF HALF-LABELLING PROTOCOL: 
2.9.1 Introduction: 
For the first time, tumour lysates in this research project were analysed using 0.5 ml of sample 
volume with Panorama-XPRESS Profiler Antibody Microarray Kit. Previous to this study, all 
breast tumour samples used in the VH pilot study were analysed using the ‘Standard/Full-
Labelling Protocol. Optimisation of this new protocol for microarray analysis is therefore, a 
technical advancement from the previously used and only available protocol to-date for the 
microarray analysis.  
2.9.2 Half-Labelling Microarray Protocol: 
In this protocol, the sample dilution with Buffer A is carried out to bring the final volume to 0.5 
ml at 1mg/ml sample concentration.  
2.9.3 Protein Labelling for the Half-Protocol: 
Similar to the ‘Standard/Full-Labelling Microarray Protocol’, protein lysates in the ‘Half-
labelling Microarray protocol’ are also labelled with fluorescent dyes (Cy3 and Cy5). However, 
as in this protocol, only a 0.5ml of the final sample volume is used for the experiment, cyanine 
dyes supplied to be used for a ml of sample volume require a prior dilution with an non-aqueous 
based solution (e.g. DMSO) prior to mixing with the protein lysate. The above step is the first 
modification to the standard/full labelling protocol. 
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1
st
 Modification from the Standard Protocol: 
Firstly, the cyanine dyes (Cy3 and Cy5) are diluted in 50 µl of freshly prepared Dimethyl-
Sulfoxide (DMSO) solution instead of directly mixing the 0.5 ml of sample lysates. A 25 µl of 
the dye-DMSO volume is then mixed with the respective sample lysate and the final volume is 
brought to 525 µl for each sample (Figure 21). The above modification was carried out to allow 
utilising only half the dye volumes for protein labelling with this protocol. Following 
consultations with the GE Healthcare Consortia and SIGMA, issues of poor dye solubilisation 
with aqueous based solutions were ironed out and freshly prepared DMSO solution was used for 
the dye dilution. 
2
nd
 Modification from the Standard Protocol: 
At this step, instead of adding 150 μl of labelled sample volume onto the Sigma spin-columns as 
in the standard protocol, 300 μl of labelled sample is added to the spin-columns to have a 
maximum protein (150 µg) available to load onto the microarray slide at the final step. Similar to 
the standard protocol, second protein quantification is undertaken using labelled samples and the 
protein concentrations are checked before going ahead with the experiment. 
2.9.3.1 D/P Ratio, Slide Hybridisation & Quality Control: 
Before hybridization, the dye-to-protein molar ratio was determined following the calculations 
supplied with the antibody microarray kit. Only samples with a dye-to protein molar ratio >2 
were applied to the antibody microarray as recommended in the antibody microarray kit 
protocol. Antibody microarray slides were washed by a brief submersion in PBS and the slide 
incubation, scanning and application of quality control was performed as described in sections 
2.8.1.3 and 2.8.1.3 
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WORKFLOW OF THE HALF-LABELLING MICROARRAY PROTOCOL 
             
Figure 21: The workflow of Half Labelling Microarray Protocol. As shown in the figure 0.5 
ml of both the samples (CS and CR) are not mixed directly with cyanine dyes but after DMSO 
dilution. Secondly, a total of 300 µl of sample and not 150 µl as in standard protocol is loaded 
onto spin-columns for protein quantification and to determine D/P ratios.  
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2.10 DATA MINING: 
2.10.1 Introduction: 
The DEPs identified and selected from the antibody microarray experiments are carried forward 
to the confirmation phase. However, selection of DEPs that will go the next stage from the 
bigger cohort of identified DEPs has to be performed in a logical and meaningful way. A useful 
tool to aid the prioritization of proteins, which are to be carried forward, is software (e.g. Array 
Unlock and Ingenuity Pathway Analysis) which analyses and interprets the data using knowledge 
bases (Jimenez-Marin, Collado-Romero et al. 2009). For our samples array data analysis we used 
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc., USA).  Protein lists were uploaded 
into IPA software, where they were mapped against the Ingenuity Knowledge Base, to highlight 
direct relationships between candidate proteins using networks and canonical pathways.  The top 
five canonical pathways to which maximum DEPs are matched along with other pathways to 
which DEPs are matched in decreasing order highlights and prioritizes the proteins of most 
interest. DEPs associated with pathways (e.g. apoptosis inhibiting, DNA repair inhibition) aid 
understanding and presenting potential hypotheses (Chemoresistant in our samples), giving 
researchers’ informative direction for downstream confirmation. 
2.10.2 Ingenuity Pathway Analysis:  
The data generated by antibody microarray analysis was analysed using IPA (Ingenuity Systems, 
www.ingenuity.com). Each set of data, containing a list of gene symbols, which had been 
checked against the IPI and NCBI databases, was uploaded into IPA software online. The 
Ingenuity Knowledge Base is the core facility and repository behind IPA, holding all the 
biological and chemical information, functional annotations and model relationships for genes, 
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proteins, complexes, disease states, cells, tissues etc in a well-structured and accessible manner. 
The Ingenuity Knowledge Base is a comprehensive database containing manually reviewed, 
accurate information. Within the Ingenuity Knowledge Base there are four types of information, 
including both experimental- and literature-based 104 sources, which is all manually reviewed: 
(1) Ingenuity® Expert Findings, which contains experimentally-demonstrated information; (2) 
Ingenuity® Expert Assist Findings, from recently published journal abstracts; (3) Ingenuity® 
Expert Knowledge, containing signalling and metabolic pathway information, which is curated 
from a team of Ingenuity experts ; (4) Ingenuity® Supported Third Party Information, which is 
selected from a range of specific sources and databases including Entrez Gene, Gene Ontology 
and RefSeq.  
For network generation, each gene was mapped to the corresponding gene within the Ingenuity 
Knowledge Base, and an ‘annotated dataset’ was generated. Genes which were successfully 
mapped into the Ingenuity Knowledge Base were called ‘network eligible’ molecules, and were 
subsequently overlaid onto a global molecular network developed from the information 
contained within the Ingenuity Knowledge Base. During analysis of data, networks of ‘network 
eligible’ molecules were then algorithmically generated based on their connectivity. The general 
settings allowed the maximum number of ‘molecules per network’ and ‘networks per analysis’ to 
be included, to highlight direct relationships between human molecules which had been reported 
in both tissues and cell lines.  
Canonical pathway analysis of the dataset involved the identification of pathways within the IPA 
library of canonical pathways that were most significant to the dataset. All molecules mapped 
within the dataset were considered for canonical pathway analysis. The significance of the 
association between the dataset and the canonical pathway was measured by two factors; 1) A 
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ratio of the number of molecules within the dataset that can be mapped into a pathway, divided 
by the total number of molecules involved in that pathway, 2) Fisher’s exact test was performed 
to determine the probability that the association between the dataset and the canonical pathway 
identified had occurred by chance, which was displayed as a p-value. 
2.11 IMMUNOBLOTTING: 
Before taking any interesting DEPs forward to the validation stage, their presence is confirmed 
using a second independent technique such as immunoblotting. 
2.11.1 Western Blotting: 
The western blot (sometimes called the protein immunoblot) is a widely accepted analytical 
technique used to detect specific proteins in the given sample of tissue homogenate or extract. It 
uses gel electrophoresis to separate native proteins which are then transferred to a membrane 
(typically nitrocellulose), where they are probed with antibodies specific to the target protein. 
2.11.2 Protein Extraction and Quantification: 
The samples (cell line lysates or tissue extracts) used for Western blot ideally should have their 
protein extraction and quantification carried out using Western blot extraction and quantification 
methodology. However, breast tumour samples from this study for Western blotting had protein 
extraction and quantification using antibody extraction/labelling buffer and Bradford 
quantification assay as described in the sections 2.5 and 2.6.1. The tissue protein extracts where 
then diluted into a Western extraction sample buffer containing 4ml of DH2O, 1ml of 0.5M 
TRIS: HCL at pH 6.8, 0.8 ml glycerol, 1.6ml of 10% SDS and 200 µl of 0.05% bromophenol 
blue. To every 190 µl of extraction sample buffer a further 10 µl of 5% β mercaptoethanol is 
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added to allow a full denaturisation of the proteins. Sample extracts are used at 10 µg and 20 µg 
protein concentrations to achieve a final dilution volume of 25 µl with sample extraction buffer. 
2.11.3 One-Dimensional Electrophoresis: 
After diluting the protein extracts with WB extraction buffer, proteins in the extracts were then 
denatured by heating at 95
o
C in a thermocycler for 5 min. They were then placed on ice to 
prevent reversal of protein denaturation, vortexed and centrifuged at maximum speed (~12,000 x 
g) for 30 s. Twenty microlitre of extract was then loaded into appropriate wells in a 12% Precise 
Protein Gel (Thermo Scientific) with Tris-HEPES-SDS running buffer, alongside 10 μl of 
Precision Plus Protein Western C Standard (#161-0376, Bio-Rad), as a marker of molecular 
weight. The gel was run at a constant voltage of 140V for 40 min. 
2.11.4 Transfer of Proteins to Nitrocellulose Membrane: 
Proteins that had been separated by molecular weight were transferred onto a nitrocellulose 
membrane using the iBlot dry transfer system (Invitrogen) with ‘iBlot gel transfer stacks, 
nitrocellulose’ (Serial#793403, Invitrogen) (Figure 22). Whilst using the stack, firstly, the 
‘bottom’ disposable transfer stacks containing membranes were placed in the machine following 
which, gels were placed on top of the membrane in the required orientation. Filter paper soaked 
with dH2O was then placed on top of the gels and air bubbles were removed using a roller. The 
‘top’ disposable pack containing the cathode was placed on top of the membrane followed by a 
sponge containing an electrode. The standard transfer, as recommended by the manufacturer was 
used, which ran for 7 min, and transferred the proteins from the gel onto the nitrocellulose 
membrane. 
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THE i-BLOT DRY TRANSFER SYSTEM FOR IMMUNOBLOTTING 
                         A                                                                                 B 
 
                                                
                                                              C 
Figure 22: Invitrogen i-blot dry transfer system is shown in figure A and B. Figure C 
illustrates the stack arrangement for the transfer system. The anode (red) stack is placed at the 
bottom, above this there is a layer of PVDF membrane. The 1D-PAGE containing proteins spots 
is placed above the anode to allow protein transfer onto the PVDF membrane below. Finally, a 
cathode stack with the shiny surface facing front is placed over the gel with a filter paper in 
between the two layers.             
 
126 
 
2.11.5  Blocking Non-specific Binding Sites on Membrane: 
Once the proteins had been transferred onto the membrane, the free binding sites on the 
membrane were blocked by incubating the membrane with ‘blocking solution’ (5% low-fat milk 
powder (Marvel), diluted in TBS-Tween20) in a Nalgene staining box on an orbital shaker for 1 
hour at RT or 16 hours at 4
o
 C. This was necessary to prevent unwanted binding of antibodies to 
the membrane when probing for a specific protein.  
2.11.6 Adding Primary and Secondary Antibodies: 
The primary antibody to the protein of interest was optimised and diluted to its optimum 
concentration in blocking solution. It was incubated with the membrane for 2 hours at RT on an 
orbital shaker. Following this, the membrane was washed 3 times with TBS-Tween20 (5 min per 
wash) on an orbital shaker, to remove any unbound antibody. The membrane was then incubated 
with a HRP-conjugated secondary antibody to the animal the primary antibody was raised in. 
This was diluted to its optimum concentration in blocking solution and incubated with the 
membrane for 1 hour at RT on an orbital shaker. For visualisation of the Precision Plus Protein 
Western C Standard molecular weight marker, 1 μl of Precision Protein StrepTactin-HRP 
conjugate (#161-0381, Bio-Rad) was also added to the blocking solution containing secondary 
antibody. Three washes of 5 min each with TBS-Tween20 were carried out on an orbital shaker. 
2.11.7 Loading Control: 
Loading control is added to the membrane to test for accurate loading of extract proteins into the 
gel, thus allowing fair comparisons to be made between samples. For this, proteins which should 
be present in all cells at equal concentrations called ‘housekeeping proteins’ (example β actin, α 
tubulin or GAPDH) are used.  
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2.11.8  Protein Detection: 
Protein detection is carried out by incubating the membrane with equal amounts of Supersignal 
West Pico Stable Peroxide Solution and Supersignal West Pico Luminol Enhancer Solution from 
the Supersignal West Pico Chemiluminescent Substrate Kit (#34078, Thermo Scientific) for 5 
min with frequent gentle manual agitation in the dark. The membrane is then developed by  
placing it between transparent plastic sheets in an intensifying cassette with CL-XPosure Film 
(#34090; Lot# 85140102; Thermo Scientific) and gentle manual agitation in 250 ml each of 
GBX Developer (#, Sigma Aldrich) until bands appeared. This is followed by 30 s incubation in 
250 ml 5% Acetic Acid and then 250 ml GBX Fixer (Lot#061M1859), with gentle manual 
agitation in a plastic tray. The developed films were then allowed to air-dry before scanning and 
densitometry 
2.11.9 Densitometry:  
Densitometry was used to quantify the density of bands on films, representing expression of a 
particular protein in the chosen protein extract. The film was scanned using a GS-800 Calibrated 
Densitometer (Bio-Rad) and Quantity One software (Bio-Rad) was used to normalise the protein of 
interest against the loading control (Beta-actin). The normalised optical density of the target bands 
was then given allowing for the target protein expression to be compared between both the 
chemosensitive and chemoresistant samples. This then allowed for the optical density of the target 
band to be recorded and the subsequent fold-change to be calculated.  
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2.12 IMMUNOHISTOCHEMISTRY 
Immuno-histochemistry (IHC) technique is a combination of immunological, histological and 
biochemical methods for the identification of specific tissue components. It is one of the most 
common techniques used for the validation of proteins confirmed on immunoblotting. The 
visualization and localization of the cellular components is achieved by means of a specific 
antigen/ antibody reaction using a labelled antibody.  
2.12.1 Archival Samples used in Pilot Clinical Validations: 
As described before in the section 2.3.3, two different archival pre-treatment series (MRI-iFEC 
and EC-D) were selected for clinical validations. The IHC validations for the 14-3-3 protein 
isoforms (alpha/beta, zeta/delta and epsilon isoform) were carried out using the MRI-iFEC series 
and rest of the other proteins (14-3-3 theta/tau, Vimentin, AkT1, FAK) were validated using the 
EC-D series (Figure 23). 
2.12.2 Blocking and Antigen Retrieval Methods: 
The principles of the IHC procedure can be studied under the following headings: 
Blocking phase:  
In this phase, the endogenous RBC peroxidase, biotin activity and the background specific (from 
diffused proteins) and non-specific binding is blocked by using methanol with hydrogen 
peroxide and a blocking serum (e.g. R.T.U.Horse serum). 
Antigen retrieval phase: 
The aim of this step is to release proteins or expose antigenic sites by using heat (steamer, 
pressure cooker, or microwave) in Heat Induced Epitope Release (HIER) method or using an 
enzyme in the Protein Induced Epitope Release (PIER) method.  
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SELECTED PROTEINS FOR IMMUNOHISTOCHEMICAL 
VALIDATIONS & THE USED ARCHIVAL SERIES  
 
 
Figure 23: shows the proteins selected for the immuno-histochemical validations using MRI-
iFEC and EC-D series. In total four 14-3-3 isoforms were validated using the MRI-iFEC series 
and two new proteins and two proteins (14-3-3 theta/tau and Vimentin) from VH study were 
validated using the EC-D series. 
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2.12.2.1 Cutting Tissue Sections: 
The formalin-fixed, paraffin-embedded tissues are sectioned into slices as thin as 4 to 5μm with a 
microtome. These sections are then mounted onto glass slides that are coated with an adhesive. 
After mounting, the sections are dried in an oven or microwave in preparation for 
deparaffinization. 
2.12.2.2 De-waxing and rehydration: 
In this step the tissue sections are first de-waxed by incubating in warm (~50 °C) Histoclear II 
(#HS-200, National Diagnostics) for 10 min. This step is followed by two further 10 s 
incubations (with a gentle shaking of the rack) in separate solutions of Histoclear II (#HS-200, 
National Diagnostics). Sections are then rehydrated by incubating for 10 s in three separate 
100% ethanol solutions shaking the rack gently at each step. The sections were then rinsed in 
running tap water for 1 min.  
2.12.2.3 Blocking of endogenous peroxidase:  
The endogenous peroxidase activity of red blood cells is blocked by incubating the tissue 
sections with 400 ml of methanol containing 30% hydrogen peroxide for a period of 20 min.  
2.12.2.4 Antigenic site retrieval:  
Antigenic site retrieval is achieved by applying the principles of the HIER method; slides are 
boiled in a stainless steel pressure cooker at 15 psi pressure with 1500 ml of distilled water and 
15 ml of Vector Antigen Unmasking Solution (1:100) (#H-3300, Vector Laboratories) at a full 
pressure of 3 min.  Slides are then transferred into a pot containing Tris Buffer Saline (TBS). 
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2.12.2.5 Blocking of non-specific binding sites: 
For this step, the slides are arranged serially onto a sequenza system (Shandon, Basingstoke, 
UK) using cover plates. An accurate slide assembly ensures that there are no air bubbles between 
the slides and the cover plate using TBS-washes. Non-specific binding sites within sections are 
blocked by incubating slides with 100µl (3 drops) of pre-diluted blocking serum (normal horse 
serum) from Quick Kit (Vector #PK-7800) for 10 min.  At the end of 10 min incubation, a 2 x 5 
min TBS rinses are performed and slides as slides are prepared for antigen detection. 
2.12.2.6 Antigen detection: 
For this step, a diluted antigen-specific primary antibody, a secondary antibody and conjugated 
streptavidin-peroxidase complex is used. The blocking solution (TBS + 1.5% blocking serum) 
and the diluted primary antibody solution (TBS + 1.5% blocking serum + primary antibody) are 
prepared and applied to the slides sparing the negative of the primary antibody solution. Slides 
are then incubated for 2 hrs at room temperature and rinsed with 2 x 5 min TBS thereafter. 
Finally, slides are incubated with 100µl (3 drops) of pre-diluted biotinylated pan-specific 
universal secondary antibody from Quick Kit (Vector #PK-7800) for 20 min before incubating 
slides with 100µl (3 drops) of conjugated streptavidin-peroxidase complex reagent (Vector #PK-
7800) for 10 min.  
2.12.2.7 Antibody Visualisation: 
Antibody visualisation is achieved using 0.02% diaminobenzidine (DAB) in 400 ml of TBS 
containing 0.125% hydrogen peroxide (30% w/w solution).  DAB is commonly employed in 
enzyme- mediated immuno detection as a substrate for the Horse Radish Peroxidase (HRP) 
enzyme. Slides when incubated with the DAB solution (DAB + H2O2) develop a brown-coloured 
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polymeric oxidation product which stains the tissue sections.  DAB staining can then be 
visualized directly by bright-field light microscopy. The underlying chemical process in the 
colour development involves oxidation of hydrogen peroxide (H2O2) by HRP enzyme and 
formation of free oxygen radical which then oxide diaminobenzidine to a complex polymeric 
compound. The incubation time with DAB is strictly controlled to 30 min or else DAB starts 
precipitating on to the tissues.  
          
Step 1:  H2O2        HRP Enzyme         H2O + (O)
-
  
   
Step 2:  (O)
 -
 + DAB    Oxidation               Polymeric Compound (Brown Coloured) 
2.12.2.8   Colour Enhancement, counterstaining and differentiation: 
The contrast of the staining  is enhanced by incubating slides in 0.5% copper sulphate in 0.9% 
sodium chloride solution for 5 min. Sections are counterstained by incubating  with filtered 
Harris’ Haematoxylin (#HHS32, Sigma Aldrich) gently shaking the rack  for 20 s. Excess 
haematoxylin is removed by washing the slides in running tap water and the differentiation of the  
counterstaining  is produced by incubating slides in acid alcohol (70% alcohol, 1% HCl (conc) ) 
with gentle shaking for 10 s. Slides are then washed in running tap water and prepared for 
mounting following  rehydration. 
2.12.2.9 Rehydration, clearing and mounting:  
In this final step, tissue sections are rehydrated by taking slides through 100% ethanol solutions 
three times with gentle rack shaking for 10 s in each solution. Sections are finally dipped into 
three clearing Histoclear II (#HS-200, National Diagnostics) solutions with gentle rack shaking 
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for 10 s in each solution. All slides are then mounted onto cover-slips using Histomount (#HS-
103, National Diagnostics) and left to dry overnight. 
2.12.2.10 Scoring of immunostained tissue sections: 
The scoring system was developed by Victoria Hodgkinson (PhD) for the breast cancer 
proteomic-pilot study. Slides were scored after observation of all slides across the sample series 
based on the percentage of stained tumour cells and the intensity of tumour cell staining. For the 
cytoplasmic staining, slides were scored ‘positive’ if > 50% tumour cell coverage was found 
showing a moderate to strong intensity staining.  If the staining was noted in less than 50% 
tumour cells in weak or weak-moderate intensity slides were scored ‘negative.’ For the nuclear 
membrane staining, slides were scored ‘positive’ if in a single cluster > 20% tumour cells were 
found to be stained.  If the cell staining in the cluster was found to be involving < 20% of tumour 
cells the slides were scored ‘negative.’  Similarly, for the cell membrane staining, a 50% of 
membrane staining in at least 50% of tumour cells was scored ‘positive’. If the staining involved 
<50% of membrane and/or <50% of cells the slides were scored ‘negative.’  (Tables: 12, 13 and 
14). The scoring was performed by two observers (VH and TH) independently, after consultation 
with a consultant histopathologist (Dr. Ann Campbell).  In the event of disagreement between the 
two observers, we decided to involve a third observer (Dr. Ann Campbell) to score the slides 
inorder to minimize the inter-observer variability. 
For the immuno validation work in this project, the tissue staining noted with the breast cores 
(EC-D series) using AkT Phospho Ser473, Vimentin and FAK phosphoY397 protein antibodies 
and with 14-3-3 protein family (beta/alpha, zeta/delta and epsilon) antibodies using the MRI-
iFEC series was similar in location and intensity to the one described by our research group 
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previously (Hodgkinson et al. 2012). Therefore, the same scoring method and scores were used 
for the six proteins assessed in the pilot validation work from this research study. 
 
Table 12:            IHC scoring system for the cytoplasmic staining 
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Table 13:       IHC scoring system for the cell membrane staining 
 
 
 
Table 14:        IHC scoring system for the Nuclear membrane staining 
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2.12.2.11 Statistical Correlation of IHC scoring: 
The statistical significance between histological scores and responses to breast cancer 
chemotherapy (chemosensitivity or chemoresistance) was assessed using a two-tailed Fishers 
exact test. A  P value of ≤ 0.05 was considered significant. Statistical calculations were 
performed using the online software programme (GraphPad 116 software Inc (USA) at 
 http://www.graphpad.com/quickcalcs/contingency1.cfm). The clinical response data and IHC 
scores were entered in a 2 x2 contingency table as shown below in Figure 24. 
 
 
FISCHERS EXACT TEST CONTINGENCY TABLE 
 
 
 
Figure 24:  shows a 2 x 2 contingency table for Fischer’s exact test. The values (x) is entered for the  
number of patients that show a chemo-sensitive or chemo-resistant response against a positive or a 
negative IHC score for a particular staining localization. 
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Chapter 3.   
3.1 INTRODUCTION: 
This chapter will cover the results of protein extraction/quantification and antibody microarray 
experiments carried out using chemoresistant and chemosensitive sample pairs. The six samples 
(3 pairs of chemosensitive and chemoresistant) used in this project were selected after matching 
them on the basis of the chemotherapy regimens, number of chemotherapy cycles, 
immunohistochemical receptor (ER, PR and HER2) status, chemotherapy responses and tissue 
availability (section 2.3). Protein extraction and quantification from the selected sample pairs 
was carried out using the protein extraction and quantification techniques as described in 
sections 2.5 and 2.6.1. The information on the sample weights and the dilution volumes of the 
extraction/labelling buffer (4 times weight/volume) used for the suspension of research samples 
is provided in the Table 15 below. The technique of recording sample weights, volume dilutions, 
mechanical homogenisation and protein quantification has already been illustrated in Figure 19 
and described in the section 2.4. 
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Table 15: Project samples Recorded Weights and Dilution Volumes for 
Protein Extraction 
 
 
 
3.1.1 Results from the Bradford Quantification Assay: 
Using protein lysates from the above listed 6 research samples, protein quantification 
experiments was carried out with the Bradford assay (section 2.6.1. A total of two quantification 
experiments were carried out using the same sample lysates independently by TH and VH (post-
doc) to accurately analysis the samples and eliminate any confounding bias (e.g. individual 
pipetting errors) influencing the experiment findings. The individual Bradford quantification 
results from two experiments (TH and VH) using all 6 research samples are listed in Tables 16 
and 17. The final protein concentrations for all 6 samples were decided by taking an average 
reading of TH and VH protein concentrations. The results of the combined average protein 
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concentrations (TH + VH) for all 6 samples are listed in the Table 18. For the microarray 
analysis, the calculations of individual sample dilutions were based on the combined average 
quantification values from the TH and VH data. 
 
Table 16:  Final Protein Concentrations for 6 Clinical Samples: TH analysis 
 
Sample # Sample Absorbance 
Protein 
concentration        
(x) 
Correct for 
dilution Average 
Final 
Concentration 
(mg/ml) 
#16B/CS 
1(1:5) 0.167 0.794117647 3.970588235 
4.105219553 
4.345484673 
1 (1:5) 0.18 0.847970174 4.23985087 
1(1:10) 0.096 0.5 5 
4.585749793 1 (1:10) 0.076 0.417149959 4.171499586 
#1B/CR 
2(neat) 0.169 0.802402651 0.802402651 
0.783761392 
1.19400718 
2 (neat) 0.16 0.765120133 0.765120133 
2 (1:5) 0.029 0.222452361 1.112261806 
1.153686827 2(1:5) 0.033 0.23902237 1.195111848 
2(1:10) 0.013 0.156172328 1.561723281 
1.644573322 2(1:10) 0.017 0.172742336 1.727423364 
#38/CS 
3(1:5) 0.109 0.553852527 2.769262635 
2.531068766 
3.071665286 
3(1:5) 0.086 0.458574979 2.292874896 
3(1:10) 0.048 0.301159901 3.011599006 
3.612261806 3(1:10) 0.077 0.421292461 4.212924606 
#15B/CR 
4(neat) 0.256 1.162800331 1.162800331 
1.218724109 
1.874067937 
4(neat) 0.283 1.274647887 1.274647887 
4(1:5) 0.069 0.388152444 1.94076222 
1.951118476 4(1:5) 0.07 0.392294946 1.961474731 
4(1:10) 0.05 0.309444905 3.094449047 
2.452361226 4(1:10) 0.019 0.181027341 1.810273405 
#12B/CS 
5(1:5) 0.144 0.698840099 3.494200497 
3.483844242 
3.931234466 
5(1:5) 0.143 0.694697597 3.473487987 
5(1:10) 0.079 0.429577465 4.295774648 
4.37862469 5(1:10) 0.083 0.446147473 4.461474731 
#1/CR 
6(1:5) 0.317 1.415492958 7.077464789 
7.004971003 
8.177299089 
6(1:5) 0.31 1.386495443 6.932477216 
6(1:10) 0.199 0.926677713 9.266777133 
9.349627175 6(1:10) 0.203 0.943247722 9.432477216 
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Table 17:      Final Protein Concentrations for 6 Clinical Samples: VH analysis 
 
 
 
 
 
 
Sample Absorbance 
Protein  
concentration 
(x) 
Correct for 
dilution 
Average 
Protein  
concentration 
(mg/ml) 
Samples # 
1 (1:5) 0.255 0.916963996 4.584819981 
4.517515407 
 
 
#16B/CS 
1 (1:5) 0.261 0.93642556 4.682127798 
1: (1:10) 0.111 0.449886474 4.498864742 
1: (1:10) 0.105 0.430424911 4.304249108 
2 (neat) 0.277 0.988323062 0.988323062 
1.333198184 
 
 
 
 
#1B/CR 
2 (neat) 0.273 0.975348686 0.975348686 
2 (1:2) 0.133 0.52124554 1.04249108 
2 (1:2) 0.12 0.479078819 0.958157639 
2 (1:5) 0.055 0.268245216 1.341226078 
2 (1:5) 0.058 0.277975997 1.389879987 
2 (1:10) 0.04 0.219591307 2.195913072 
2 (1:10) 0.027 0.177424586 1.774245864 
3 (1:5) 0.171 0.644502108 3.222510542 
3.386312034 
 
 
#38/CS 
3 (1:5) 0.164 0.621796951 3.108984755 
3 (1:10) 0.085 0.365553033 3.655530328 
3 (1:10) 0.082 0.355822251 3.558222511 
4 (1:2) 0.193 0.715861174 1.431722348 
1.782246729 #15B/CR 
4 (1:2) 0.192 0.71261758 1.425235161 
4 (1:5) 0.08 0.349335063 1.746675316 
4 (1:5) 0.075 0.333117094 1.665585469 
4 (1:10) 0.049 0.248783652 2.487836523 
4 (1:10) 0.032 0.193642556 1.93642556 
5 (1:5) 0.175 0.657476484 3.28738242 
3.491728836 
 
 
#12B/CS 
5 (1:5) 0.172 0.647745702 3.238728511 
5 (1:10) 0.081 0.352578657 3.525786572 
5 (1:10) 0.093 0.391501784 3.91501784 
6 (1:10) 0.219 0.800194616 8.001946156 
7.969510217 
 
#1/CR 6 (1:10) 0.217 0.793707428 7.937074278 
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Table 18:             TH/VH Combined Average Protein Concentrations 
 
 
 
3.2  HALF PROTOCOL OPTIMISATION EXPERIMENTS USING 
BREAST TUMOUR SAMPLES: 
3.2.1 Introduction:  
In this section of thesis, three “Half-labelling Microarray Protocol” optimisation experiments 
using breast tumour lysates are highlighted and discussed. The initial results from the first two 
failed optimisation experiments using the new protocol and a third experiment that passed the 
quality-control are provided and discussed in detail.  
 
As mentioned above, the ‘Half-labelling Microarray Protocol’ was optimised in three 
experiments using breast tumour lysates. The sample lysates used in the three optimisation 
experiments were chosen randomly from the 6 study samples. The three optimisation 
experiments were called experiment # 1, #1b and #2b. The sample pairs used for experiments #1 
and #1b were sample #16 (chemosensitive) vs #1B (chemoresistant). For experiment #2b, sample 
#38 (chemosensitive) vs 15B (chemoresistant) were used. All the three optimisation experiments 
were carried out using protocol as described in the section 2.9.  
Samples # 
TH Average 
(protein conc. 
mg/ml) 
VH Average 
(protein conc. mg/ml) 
Averages of TH and VH 
(protein conc. mg/ml) 
#16B 4.34548 4.51751 4.4314977 
#1B 1.194 1.333 1.2635991 
#38 3.07166 3.38631 3.228986 
#15B 1.87406 1.78224 1.8281534 
#12B 3.93123 3.49172 3.7114794 
#1 8.177299 7.96951 8.0734046 
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3.3  EXPERIMENT # 1: SAMPLE #16B (CS) vs. #1B (CR) 
Protocol Used: ‘Half-Labelling Microarray Protocol’ 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #089K4791 (2009 Stock Kit)  
3.3.1  Introduction: 
This was the first experiment in the series using samples #16B (CS) and #1B (CR). The sample 
receptor status, therapy response summary along with the final protein concentrations and 
volume dilution summaries are provided in Tables 19 and 20 below: 
 
 
Table 19:   The Summary of Samples Characteristics and Therapy Response    
 
 
 
Samples Receptor Status NACT Response 
 
#16B(CS) 
 
 
ER +; PR & HER 2- 
 
 
EC X4; D X 1 
 
PR 
#1B(CR) ER +; PR & HER2- EC X4; D X2 PD 
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Table 30:    Final Sample and Dilution Buffer Volumes (µl) for Sample #16B vs #1B 
 
 
 
Samples Final Bradford Conc. 
(mg/ml) 
Final Sample volumes 
in µl 
Final Buffer A 
volumes in µl 
 
#16B (CS) 
 
4.431977 
 
112.8287 
 
387.1713 
#1B (CR) 1.263599 395. 6951 104.3049 
 
3.3.2 Sample Dilutions and Protein Labelling: 
The samples at final concentrations were diluted with Buffer A to bring the final volume up to 
500 µl.. The chemosensitive (CS) sample #16B was labelled with Cy3 (pink colour) and the 
chemoresistant (CR) sample #1B with Cy5 (blue colour) fluorescent dyes after diluting cyanine 
dyes with 50 µl of aqueous solution Buffer A. The steps following from this stage were as 
described in sections 2.9.2 and 2.9.3. The results from the protein concentrations on the 2
nd
 
Bradford assay are listed below in the Table 21. 
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Table 41:    Results from 2
nd
 Bradford Quantification using Labelled Samples 
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#16B Cy3; CS 0.165 0.765473527  
0.791573 #16B Cy3; CS 0.179 0.817673378 
#1B Cy5; CR 0.18 0.821401939  
0.810216 #1B Cy5; CR 0.174 0.799030574 
 
 
3.3.3 D/P Ratio, Slide Hybridisation & Quality Control:  
The dye-protein molar ratio for the experiment was calculated as described in section 2.8.1.2 and 
the values obtained for Cy3 and Cy5 in this experiment were Cy 3; #16B; CS = 3.37 and Cy 5; 
#1B; CR = 4.13. As the ratio obtained for both Cy3 and Cy5 was ≥2, the experiment was taken 
forward and an optimal protein load for each of the sample was calculated from the left over 
sample volume. For this experiment, a protein load of 80 µg (sample volume of 101.6 µl for 
#16B and 98.73 µl for #1B) each sample was decided. The slide was then incubated with equal 
volume of sample lysates and scanned for the final data analysis (Figure 25). The quality control 
percentage for the experiment was determined following manual slide arrangement and 
substance match percentage values of 84 % (TH) and 85% (VH) were obtained at two 
independent analyses at two different times. From the above % match results, the experiment 
was classed as ‘Failed’ and the experiment data was not taken forward for the data mining stage. 
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EXPERIMENT #1 ( SAMPLE #16B vs #1B)  FLOW CHART 
 
Figure 25:  The flowchart for the ‘Half-labelling Microarray Protocol’ is as shown above. 
Prior to sample labelling with the dyes, the dyes are diluted with 50 µl of Buffer A. A 25 µl of 
the dye-Buffer A solution is then added to samples to reduce the volume of dye used for the low 
sample volume in this protocol. 
147 
 
3.3.4 Discussion: 
The experiment #1 was analysed and the possible reasons of the failure were determined. 
Discussions were carried out with SIGMA and the GE Healthcare Consortia and the steps that 
were different in the ‘Half labelling Microarray Protocol’ (e.g. the dye dilution step and the spin 
column protein load) were re-analysed. Abnormal spot morphologies (oval shape instead of the 
round) and an excessive background interference (Figure 26) noted at the time of slide analysis 
were explored as potential factors that may have contributed to the failure. Adequacy of protein 
load onto the array slide with low sample volumes and the slide validity were some of the issues 
that were discussed with SIGMA.  
Finally, it was concluded that all the above factors had potential to fail the experiment in 
combination and/or individually. Also, during discussions with SIGMA, it was discovered that 
the Panorama- XPRESS Profiler 725 kit used in this experiment was released from the SIGMA’s 
2009 stock (slide validity up to one year only). Following the discovery, our research group 
decided to repeat the experiment using the labelled lysates of the same sample pair and a new kit 
without making any alterations to the ‘Half labelling Microarray Protocol’. The repeat 
experiment was called experiment #1b. 
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SPOT MORPHOLOGIES FROM THE FAILED MICROARRAY SLIDE 
(EXPT #1) 
                                           A                                                      B 
 
 
                                                          C 
 
Figure 26: The morphology of the spots from the failed slide of the AbMA experiment #1 is 
shown. In the figure A, the spots are not visible due an excessive background staining (yellow 
arrow). In figure B, the visible spots are oval in shape (orange arrow) instead of the normal 
round morphology. The normal rounded spots are illustrated in figure C for comparison. 
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3.4 EXPERIMENT #1b: LABELLED Cy 3 #16B (CS) vs. Cy 5 #1B (CR) 
Protocol Used: ‘Half-Labelling Microarray Protocol’ 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #071M4826 (2012 Stock Kit)  
 
In this experiment, the labelled Cy3 (CS) 16B and Cy5 (CR) 1B samples extracts from the 
previous experiment #1 were used. At the start of the experiment, 150 µl of each of the labelled 
sample was added onto the SIGMA spin-columns and the unbound dye was removed by 
centrifugation. After this, a 2nd Bradford protein quantification was performed using 10 µl of 
each of the labelled sample and the results from the quantification are highlighted in Table 22. 
 
Table 52: Results from 2
nd
 Bradford Quantification using Labelled Samples  
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#16B Cy3; CS 0.222 1.014989293  
1.057816 #16B Cy3; CS 
#16B Cy3; CS 
#16B Cy3; CS 
#1B Cy5; CR 
0.232 
0.244 
0.230 
0.251 
1.057815846 
1.109207709 
1.049250535 
1.139186296 
#1B Cy5; CR 0.247 1.122055675  
1.147752 #1B Cy5; CR 
#1B Cy5; CR 
0.256 
0.258 
1.160599572 
1.169164882 
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3.4.1 D/P ratio, Slide Hybridisation & Quality Control: 
The D/P ratios for each of the labelled sample were as follows: for Cy3 #16B was 2.432 and for 
Cy5 #1B: 3.0534. Based on the above calculation, a protein load of 100 µg for both samples was 
determined to go onto the array slide (Figure 27). The slide was then incubated and finally 
scanned for the data analysis. A substance match percentage of 82% was obtained on TH and 
81% on VH analysis. This experiment too failed to pass the quality control of ≥90% substance 
match and the data was not taken forward for interpretation. 
3.4.2 Discussion: 
The possible reasons for the experiment failure were discussed with SIGMA and the GE 
Healthcare consortia again. The microarray slide used in this experiment was a new replacement 
kit issued by SIGMA. Following discussions, issues of inadequate protein load on to the array 
slide and dye solubilisation compatibility with aqueous based solution (e.g. Buffer A) came to 
light. Therefore, a few alterations to the existing ‘Half-labelling Microarray Protocol’ were 
considered. In order to achieve a maximum protein load of 150 µg onto the array slide, the 
protein load on the SIGMA spin columns increased from 150 µl to 300 µl. Second, the dye 
solubilisations were carried out using an organic solvent (e.g. dimethyl-sulphoxide; DMSO), 
under basic pH conditions, at room temperature instead of an aqueous based solution (AbMA 
extraction/labelling buffer; Buffer A). With the above modifications, a third optimisation 
experiment using a new sample pair #38 (CS) and #15B (CR) was carried out. This experiment 
was called experiment #2b. 
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       LABELLED Cy 3 #16B (CS) vs. Cy 5 #1B (CR) FLOW CHART 
 
Figure 27: The flowchart for the ‘Half-labelling Microarray Protocol’ is as shown above. 
Labelled Cy3#16B and Cy5#1B were use. A volume of 150 µl was loaded onto Sigma spin-
columns and a maximum 100 µg protein load was determined for each of the sample to load onto 
the array slide. 
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3.5 EXPERIMENT 2b: SAMPLE #38 (CS) vs. #15B (CR) 
Protocol Used: ‘Half-Labelling Microarray Protocol’ (With modifications) 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #071M4826 (2012 Stock Kit)  
3.5.1 Introduction: 
For this optimisation experiment, three modifications were carried out to the ‘Half labelling 
Microarray Protocol’ as listed below: 
1. A 50 µl of freshly prepared DMSO was used instead of Buffer A for the dye solubilisation 
2. A 300 µl of labelled samples were loaded on to the SIGMA spin columns instead of 150 µl 
3. A maximum protein load of 150 µg was added on to the array slide 
The sample details, response summary along with the final protein concentrations and Buffer A 
sample dilution volumes are provided in the Table 23 and 24 respectively. 
 
Table 63:       Summary of Samples Characteristics and Therapy Response 
 
 
 
Sample Receptor Status NACT Response 
 
#38(CS) 
 
 
ER + PR + HER2- 
 
EC X4; D X 4 
 
PR 
#15B(CR) ER + PR + HER2- EC X4; D X4 SD 
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Table 74:    Final Sample and Dilution Buffer Volumes (µl) for Sample #38 vs #15B 
 
 
Samples Final Bradford Conc. 
(mg/ml) 
Final Sample volumes 
in µl 
Final Buffer A 
volumes in µl 
 
#38 (CS) 
 
3.228 
 
154.8474 
 
345.1526 
#15B (CR) 1.825 273.50 226.50 
3.5.2 Protein labelling and Dye Solubilisation: 
In this experiment, cyanine dyes were diluted in a freshly prepared 50 µl of DMSO solution. The 
rest of the steps in the protocol were as described in sections 2.9.2 and 2.9.3.  A total of 300 µl of 
each of the labelled sample was loaded on to the SIGMA spin columns (Figure 28). A 2
nd
 
Bradford assay was carried out using 10 µl of each labelled sample in duplicates (Table 25). 
 
Table 85:  Results from 2nd Bradford Quantification using Labelled Samples 
 
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#38 Cy3; CS 0.215 0.82122905  
0.8195859 #38 Cy3; CS 0.214 0.81794282 
#15B Cy5; CR 0.235 0.886953664  
0.8836674 #15B Cy5; CR 0.233 0.880381203 
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EXPERIMENT 2b SAMPLE #38 vs #15B FLOWCHART 
 
Figure 28: The flowchart for the ‘Half-labelling Microarray Protocol’ with modifications is as 
shown above. Prior to sample labelling with the dyes, the dyes are diluted with 50 µl of DMSO 
instead of Buffer A solution. A 25 µl of the dye-DMSO solution is then added to each of the 
samples to reduce the volume of dye used for the low sample volume in this protocol. A volume 
of 300 µl is loaded onto spin-columns and a maximum protein load of 150 µg onto the array 
slide.  
155 
 
3.5.3 D/P Ratio, Slide Hybridisation & Quality Control: 
The D/P ratio for ty3 and Cy5 samples was determined as 4.32 and 4.09 respectively and a 
maximum protein load of 183.0 µg (150 µl) for Cy3 #38 and 169.7 µg (150 µl) for Cy5 #15B 
was added onto the array slide. The slide was incubated and scanned. For the above experiment, 
a substance match percentages of 91% on TH and 92% on VH analysis were obtained and the 
experiment was classed as ‘Pass Quality-Control. The data obtained from this experiment was 
then carried forward for the final analysis.  After optimising the protocol with success, the ‘Half-
labelling Microarray Protocol’ with modifications was used for two other experiments involving 
samples #12B (CS) vs #1 (CR) and the first sample pair of sample # 16B (CS) vs. 1B (CR) that 
failed the quality control in experiment#1 and #1b earlier. 
Whilst the above experiments were optimised, a single microarray experiment was carried out 
using the standard ‘Full-labelling Microarray Protocol’ with samples #38 (CS) and #15B (CR)   
to explore any quantification errors that may have caused previous two failures. As the standard 
protocol was previously used with the breast tumour samples in the VH pilot study, a pass 
quality control at sample protein concentration was considered to vindicate the possibility of 
such an error. This experiment was called experiment #2.  
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3.6 EXPERIMENT #2: SAMPLE #38 (CS) vs #15B (CR) 
Protocol Used: ‘Full-Labelling Microarray Protocol’ 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #089K4791 (2012 Stock Kit)  
 
This experiment was carried out using SIGMA’s standard Full-labelling Microarray Protocol’ 
prior to the optimization of the ‘Half-labelling Microarray Protocol’. The sample pair selected 
for this experiment was #38 (CS) and #1B (CR) used earlier in the ‘Half-labelling Microarray 
Protocol’ optimisation experiment # 2b. The above pair was selected as it had a higher volume 
of lysate to carry out two experiments with ease. Further, using the same sample pairs with two 
different protocols (half and full) data comparison across two experiments could be performed to 
confirm the robustness of the optimised new protocol.   
The volume of protein and Buffer A solution for this experiment was calculated using the 
formula as described in the section 2.8.1. The final sample and buffer volumes calculated for this 
experiment are shown in the Table 26.  
3.6.1 Protein Labelling for Samples:  
Following the protocol labelling as described in the section 2.8.1.1, the 1100 µl volume of 
sample lysate was directly mixed with cyanine dyes. A 150 µl volume of labelled protein was 
loaded on to the spin-columns and unbound dye removed. A 2
nd
 Bradford quantification was 
performed using 10 µl of each of the sample in duplicates (Table 27). 
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Table 96:  The Final Sample and Dilution Buffer A Volumes (µl) for Sample #38 vs #15B 
 
 
Samples Final Bradford Conc. 
(mg/ml) 
Final Sample volumes 
in µl 
Final Buffer A 
volumes in µl 
 
#38 (CS) 
 
3.386 
 
324.86 
 
775.14 
#15B (CR) 1.782 617.3 482.71 
 
 
 
Table 27:    Results from 2nd Bradford Quantification using Labelled Samples 
 
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#38 Cy3; CS 0.209 0.81294964  
0.795746 #38 Cy3; CS 0.198 0.778542383 
#15B Cy5; CR 0.257 0.963090397  
0.9583985 #15B Cy5; CR 0.254 0.9537066 
 
 
 
 
 
 
158 
 
3.6.2 D/P Ratio & Quality Control: 
The D/P ratios determined for Cy3 and Cy5 in this experiment were as follows: Cy3 #38 (CS): 
3.78 and Cy5 #15B (CR): 3.39.  Slide was incubated with a maximum protein load of 80 µg was 
and scanned for analysis (Figure 29). For the above experiment, substance match percentages of 
93% and 93% were obtained independently by TH and VH.  The data generated from this 
experiment carried forward for the final analysis.  
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     EXPERIMENT #2: SAMPLE #38 (CS) vs #15B (CR) FLOW CHART 
 
 
Figure 29:  The ‘Full-labelling Microarray Protocol’ for experiment #2 is shown above. An 
1100 µl of each of the sample volume was directly added to cyanine dyes and 150 µ of the 
labelled protein is the loaded into the spin-columns. A maximum protein of 80 µg was loaded 
onto the array slide. 
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3.7 EXPERIMENT 1c: SAMPLE 16B (CS) vs. 1B (CR) 
Protocol Used: ‘Modified-Half-Labelling Microarray Protocol’ 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #071M4826 (2012 Stock Kit)  
 
This experiment was carried out using the first pair of samples #16B and 1B that earlier failed 
the two optimisation experiments (#1 and #1b). The sample dilution for this experiment was 
carried out using fresh lysates. The details of the volume dilutions used in this experiment are 
highlighted in the Table 28 below: 
 
Table 28:     Final Sample and Dilution Buffer A Volumes (µl) for Sample #16B vs #1B 
 
Samples Final Bradford Conc. 
(mg/ml) 
Final Sample volumes 
in µl 
Final Buffer A 
volumes in µl 
 
#16B (CS) 
 
4.431977 
 
112.84 
 
387.15 
#1B (CR) 1.263599 395. 5 104.5 
 
3.7.1 Protein labelling and Dye Solubilisation: 
For this experiment, cyanine dyes were first diluted in a freshly prepared 50 µl of DMSO (Lot 
#RNBB8134) solution.  A total of 300 µl of each of the labelled sample is then loaded on to the 
SIGMA spin columns and unbound dye removed. A 2
nd
 Bradford assay was then carried out 
using 10 µl of each labelled sample in duplicates (Table 29). 
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Table 29:  Results from 2
nd
 Bradford Quantification using Labelled Samples 
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#16B Cy3; CS 0.202 1.054961089  
1.057393 #16B Cy3; CS 0.203 1.059824903 
 
#1B Cy5; CR 0.227 1.17655642  
1.09144 #1B Cy5; CR 0.192 1.006322957 
 
 
 
3.7.2 D/P Ratio and Quality Control: 
The D/P ratios determined for Cy 3 # 16B and Cy 5 #1B in this experiment were as follows: Cy3 
#16B (CS): 2.92 and Cy5 #1B (CR): 1.8. The D/P ratio for Cy5 #1B came out ≤ 2; however, we 
decided to go ahead with the experiment following SIGMA’s recommendation on a D/ P ratio ≤ 
2. A maximum protein load of 141.9 µg for Cy3 #16B and 137.4 µg for Cy5 #1B was 
determined and added onto the array slide. The slide was incubated and scanned. For the above 
experiment, a substance match percentage of 96% was obtained by TH and the data was taken 
forward for the final analysis. The workflow of the above experiment is illustrated in the Figure 
30 below. 
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EXPERIMENT 1c WITH SAMPLE #16B vs #38B AND MODIFIED-HALF 
LABELLING MICROARRAY PROTOCOL 
 
Figure 30: Repeat experiment 1c using sample #38B and #15B with the ‘Modified-Half-
labelling Microarray Protocol’ is shown above.  
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3.8 EXPERIMENT #3: SAMPLE #12B (CS) vs. #1 (CR) 
Protocol Used: ‘Modified-Half-Labelling Microarray Protocol’ 
Kit: SIGMA-Panorama XPRESS-725 Profiler Kit 
Catalogue #071M4826 (2012 Stock Kit)  
This experiment was carried out using the ‘Half-labelling Microarray Protocol’. The average 
Bradford quantification results for the samples are as highlighted in Table 30. 
 
Table 100:   Final Sample and Dilution Buffer A Volumes (µl) for Sample #12B vs #1 
 
 
Samples Final Bradford Conc. 
(mg/ml) 
Final Sample volumes 
in µl 
Final Buffer A 
volumes in µl 
 
#12B (CS) 
 
3.71145 
 
134.7 
 
365.3 
#1 (CR) 8.07335 61.9 438.1 
 
3.8.1 Protein labelling and Dye Solubilisation: 
In this experiment, cyanine dyes were diluted in a freshly prepared 50 µl of DMSO 
(LOT#RNBB8134) solution. A total of 300 µl of each of the labelled sample is then loaded on to 
the SIGMA spin-columns. A 2
nd
 Bradford assay was carried out using 10 µl of each labelled 
sample in duplicates (Table 31). 
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Table 31:      Results from 2
nd
 Bradford Quantification using Labelled Samples 
 
 
 
Sample Absorbance Protein 
Concentration 
(mg/ml) 
Average 
#12B Cy3; CS 0.174 0.7939352641  
0.752981 #12B Cy3; CS 0.182 0.766609881 
#1 Cy5; CR 0.295 1.151618399  
1.146508 #1 Cy5; CR 0.292 1.141396934 
 
3.8.2 D/P Ratio and Quality Control: 
The D: P ratios determined for Cy3 and Cy5 were as follows: Cy3 #38 (CS): 4.29 and Cy5 #15B 
(CR): 2.9. A maximum protein load of 199.46 µg was added for Cy3 #12B and 130.8 µg for Cy5 
#1 onto the array slide and the slide was scanned. For the above experiment, a substance match 
percentage of 91% was obtained by TH and the data generated from the experiment was carried 
forward for the final analysis. In the Table 32 a brief summary of all the experiments 
(optimisations and research) with sample pairs, slide analysis percentage match data and quality-
control data is provided.  
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  Table 32:  A   Summary of Optimisation and Research Experimental Protocols and  Quality-Control Data 
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3.9 MICROARRAY DATA ANALYSIS: 
 
The data from the experiment was analysed and protein fold changes were calculated to 
determine a significant fold-change cut-off value as described in the section 2.8.1.3. Using the 
equation y=log2 x and x=2
y
 where ‘x’ is the fold change and ‘y’ is the Log base 2 ratios of Cy3 
and Cy5 the protein fold changes were determined.  A fold change of >1.8 (log ratios above 
~0.85) was considered significant for differential expression and represented in bold (section 
2.8.1.3). Fold change values between 1.50 and 1.79 were recorded as supporting data and 
represented in italics. Fold change values <1.5 were not considered eligible for interpretation and 
recorded in the data set as ‘---’. Lastly, proteins that failed the quality control due to a substance 
match of ≥ 90% in the data set were represented as . 
In the Table 33 from the discovery phase of the study, the combined DEP data from all four 
antibody microarray experiments that passed the quality control is listed in the above described 
format. Table 34 lists the total number of discovered DEPs from all four antibody microarray 
experiments, with the total number of DEPs that had a significant (≥ 1.8) fold change values in 
atleast one experiment out four, 2/4 and 3/4 experiments respectively. 
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Table 33:                     Antibody Microarray  Data: Current Study ( 4 Experiments) 
Significant expression fold change (> 1.8) is indicated in bold. For proteins which show < 1.8-fold change in expression, supporting 
data from other experiments is shown upward of 1.5-fold. Values considered to be not significant (---) and antibody spots which did 
not pass the analysis criteria for experimental quality control () are also indicated. 
Protein ID Fold change 
    #1c Repeat 16B vs 1B #2 38 vs 15B #2b 38 vs 15B #3 12B vs 1 
14 3 3 T5942 3.15 1.54  5.28 
ARC A8344  ---  ---  --- 1.89 
aSynuclein S3062  ---  ---  ---  --- 
BclxL B9429 2.57 1.71  --- 1.99 
Calbindin D 28K C7354 5.27  ---  ---  
Casein  Kinase 2b C3617  ---  ---  ---  
Cathepsin D C0715 1.76  ---  ---  
CDK5 C6118 1.92  ---  ---  --- 
Csk C7863  ---  ---  --- 2.44 
CUGBP1 C5112 2.24   ---  --- 
Cytokeratin peptide 4 C5176 2.51  ---  ---  --- 
Dimethyl Histone H3 dimeLys 9 D5567  ---  ---  ---  --- 
DR3 D3563  ---  ---  ---  --- 
DR4 D3813  ---  --- 1.79 2.76 
Dystrophin D8043 1.88  ---  ---  --- 
E2F6 E1532 2.74  ---  1.96 
FAKpTyr577 F8926 1.98 2.05  ---  
FANCD2 F0305 1.95 1.86  --- 2.05 
G9a Methyl Transferase G6919  1.99  --- 2.3 
GRANZYME B G1044  --- 1.82  ---  --- 
HDAC2 H3159 1.79  ---  ---  --- 
HDAC6 H2287 1.88  ---  ---  --- 
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Histone H3 pSer 10 H6409  --- 1.5  ---  --- 
ILK I1907 2.06 2.05   --- 
LIM Kinase 1 L2290  --- 1.81  ---  --- 
MAP Kinase Activated Protein 
Kinase 2  M3550  ---  ---  ---  --- 
MAP Kinase ERK1 M7927  ---  ---  ---  --- 
MAP1 M4278  ---  ---  ---  --- 
MAP1 Light chain M6783     
MDMX M0445 1.8  ---  --- 1.51 
MeCP2 M9317  --- 1.86  ---  --- 
Mint2 M3319 4.03  ---  
MSK1 M5437  ---  ---  --- 3.42 
Myosin Light Chain Kinase M7905  ---  ---  ---  --- 
Neurofilament 68 N5139  ---  ---  ---  --- 
NFkB N8523 1.87  ---  
p19INK4d P4354 2.53 1.61  --- 2.14 
P38 MAP Kinase Non Activated M8432  ---  --- 1.61  --- 
Pan cytokeratin C2931 2.1 2.79 1.65 2.17 
Pinin P0084 1.76  ---  --- 2.26 
PKB pSer473 P4112 1.72  ---  ---  
PRMT2 P0748 3.56 2.91  ---  --- 
Protein Kinase Ba P1601  ---  ---  --- 1.69 
Protein Kinase C PKC P5704 ---   ---  --- 
Rab7 R8779 1.74   2.16 
RNaseL R3529  ---  ---  --- 2.25 
SHPTP2 S3056  ---  ---  ---  
SNX6 S6324  ---  ---  5.33 
SynCAM S4945 1.97   ---  
Tau pSer199 202 
 
T6819 1.98    
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Tranforming Growth factor beta 
pan T9429 3.2 1.59  ---  
TWEAK receptor T9700 2.76 1.66  ---  --- 
Tyrosine hydroxylase T2928  ---  ---  ---  --- 
Ubiquitin C terminal Hydroxylase  U5258   ---  ---  --- 
ZAP70 Z0627  ---  --- 1.87  --- 
Zyxin Z0377 2.15  ---  ---  --- 
 
Table 114:                 Total Number of DEPs Identified from the Discover Phase: Current Study 
 
 Number 
Total Number of DEPs from the Antibody Microarray Discovery Phase 55 
Total Number of DEPs from the Discovery  Data showing a Significant Fold Change of ≥ 1.8 36 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 1/4  experiments  25 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 2/4 experiments 9 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 3/4 experiments 2 
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3.9.1 Discussion: 
From the discovery stage of this project, a total of 55 DEPs were discovered across four antibody 
microarray experiments. Of these, a total of 36 DEPs showed a significant fold change of ≥1.8. A 
total of 25/36 DEPs were found in atleast one experiment (Table 35), 9/36 DEPs in atleast two 
experiments (Table 36) and 2/36 DEPs in atleast three experiments (Table 37). Comparing the 
data from the sample pair #38 (CS) vs #15B (CR) which was analysed using both full (expt. #2) 
and half (expt. #2b) labelling protocols, a total of 15 DEPs and 4 DEPs were discovered in each 
of experiment respectively. Of the 15 DEPs from experiment # 2 using the standard labelling 
protocol, only 9/15 DEPs were found to show significant (≥ 1.8) protein expressions. In contrast, 
only 2/4 identified DEPs in experiment #2b from the half labelling protocol showed a significant 
(≥ 1.8) fold change (Table 38).  
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Proteins Number of Experiments (n=4) Significant fold change (≥1.8) 
ARC 1/4 Yes 
Calbindin D 28K 1/4 Yes 
CDK5 1/4 Yes 
CSK 1/4 Yes 
CUGBP 1/4 Yes 
Cytokeratin Peptide 1/4 Yes 
Dystrophin  1/4 Yes 
GRANZYME B 1/4 Yes 
HDAC6 1/4 Yes 
Pinin 1/4 Yes 
Rab 2 1/4 Yes 
RNaSeL 1/4 Yes 
SNX 1/4 Yes 
SynCAM 1/4 Yes 
LIM Kinase 1/4 Yes 
MDMX 1/4 Yes 
MeCP2 1/4 Yes 
Mint2 1/4 Yes 
MSK1 1/4 Yes 
NFkB 1/4 Yes 
Tau pSer199202 1/4 Yes 
TGF β Pan 1/4 Yes 
TWEAK Receptor 1/4 Yes 
ZAP 70 1/4 Yes  
Zyxin 1/4 Yes 
 
 
Table 35:   List of Significantly Expressed DEPs : One out of Four Discovery Microarray Experiments 
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Table 37:  List of Significantly Expressed DEPs : Three out of Four Discovery Microarray Experiments 
 
Proteins (n=2) Number of Experiments (n=4) Significant fold change (≥1.8) 
FANCD2 3/4 Yes 
Pancytokeratin 3/4 Yes 
 
Table 36:    List of Significantly Expressed DEPs : Two out of Four Discovery Microarray Experiments 
 
Proteins (n=9) Number of Experiments (n=4) Significant fold change (≥1.8) 
14-3-3 2/4 Yes 
BcL-XL 2/4 Yes 
DR4 2/4 Yes 
E2F6 2/4 Yes 
FAKpTyr577 2/4 Yes 
G9a Methyl transferase 2/4 Yes 
ILK 2/4 Yes 
P19INK4d 2/4 Yes 
PRMT2 2/4 Yes 
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Table 38:                       List of Significantly Expressed DEPs : Full Labelling vs. Half Labelling Protocols  
                                                                   Sample #38B (CS) vs. #15B (CR) 
  
Proteins with Significant Fold Change (≥1.8) Sample pair Proteins with Significant Fold Change (≥1.8) 
Full-Labelling Protocol  
 
 
#38 (CS) vs. #15B (CR) 
Half-Labelling Protocol 
FAKpTyr577 DR4 
FANCD2 ZAP70 
G9a MethylTransferase  
GRANZYME B 
ILK 
Lim Kinase 1 
MeCP2 
Pancytokeratin 
PRMT2 
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3.9.2 Data Analysis : Combined Approach 
3.9.2.1 Combined Antibody Microarray Experiment Data: 
For the next stage of the project, the DEP data from the current study (4 x AbMA experiments) 
was combined with the antibody microarray data (5 x AbMA experiments) from the VH study 
(Table 39) and analysed using IPA software in the data mining phase.  
A total of 89 DEPs were discovered from the combined 9 experiments (Table 40). Of these, 8/89 
DEPs were found in two experiments, 5/89 in four experiments, 1/89 in  four experiments, 1/89 
in five experiments and 1/89 in six experiments (Table 41 and 42). In the VH study, all five 
antibody microarray experiments were carried out using fresh breast tumour samples (Table 9) 
and the ‘Standard/Full-labelling Microarray Protocol’. In the data mining phase (details to 
follow in next chapter) of the 89 DEPs identified using the combined analysis, only 72/89 DEPs 
were successfully matched onto IPA for the initial analysis.  
3.9.2.2  Combined 2D-PAGE/MS & Antibody Microarray Data: 
A further expansion of the list of DEPs identified at the discovery stage for IPA analysis was 
performed by combining the DEP data from the three 2D-PAGE/MS experiments (Table 43) of 
the VH study with the DEP data from the nine combined antibody microarray experiments 
(Table 44). The combined data from 12 discovery experiments was then re-analysed with IPA. 
The aim of this combined analysis was to match DEPs onto new molecular pathways involved in 
breast chemotherapy resistance and/or to increase the number of DEP matches onto the 
previously identified molecular pathways from the VH study. 
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Table 39:                              Antibody Microarray DEP Data: VH Study ( 5 Experiments) 
 
Significant expression fold change (> 1.8) is indicated in bold. For proteins which show < 1.8-fold change in expression, 
supporting data from other experiments is shown upward of 1.5-fold. Values considered to be not significant (---) and antibody 
spots which did not pass the analysis criteria for experimental quality control () are also indicated. 
 
IPA SYMBOL ID 
1 11 vs 19 
Fold Changes 
2 15 vs 9 
Fold Changes 
3 15 vs 19 
Fold Changes 
4 12 vs 25 
Fold Changes 
5 18 vs 25 
Fold Changes 
ZYX Z0377 -7.797 -2.01 -2.21 -2.02 -2.63 
MAPK12 S0315 -1.04 -3.76  1.07 -1.46 
TPM1 T2780 -1.02 -2.67 -1.08  -1.09 
YWHAQ T5942 -1.54 -1.9 -2.29 -2.55 -1.52 
CASP13 C8854 -1.28 -1.19 -2.69 -1.47 -1.08 
MYD88 M9934 -1.28 -1.17 -2.08 -2.18 -1.09 
TNFSF10 T9191 -1.17 -1.05 -1.83 -1.62 1.11 
H3F3A H9286 -1.09 -1.07 -1.27 -2.21 -1.03 
EGF E2520 1.01 -1.06 -1.39 -2.13 -1.17 
UNC13A M6194 -1.23 -1.14 -1.11 -2.08 -1.09 
TBP T1827 -1.45 -1.39 -1.19 -2.08 -1.37 
ANXA5 A8604 -1.03 -1.27 -1.21 -2.02 -1.09 
LIMS1 P9371 -1.35 -1.26 -1.51 -1.9 -1.38 
PNN P0084  2.54 2.39 1.53 1.48 
RALA R8529 1.37 CNM 3.7  1.18 
PRKCB P3203 3.256 1.16 1.29 1.7 1.24 
BCL2L1 B9429 1.09 2.26 1.49 1.57 2.62 
STK17A D1314 1.03 2.18 1.05 1.22 1.37 
BID B3183 -1.05 2.16 1.55 1.97 1.96 
H3F3A D5567 2.135 -1.1 1.03 -1.11 1.03 
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AKT1 P1601 2.099 -1.01 -1.3 -1.1 -1.07 
RIPK1 R8274 2.071 1.34 1.2 2.56 1.45 
MAPT T5530 1.63  2.04  1.17 
ACAN C8035 1.56 1.19 2 1.3 1.12 
DSC1 D1286 1.07 1.06 1.92 1.45 -1.11 
RELN R4904 1.95  1.19  1.43 
MKI67 P6834 1.921 1.22 1.26 1.41 1.01 
RPS6KB1 S4047 1.08 1.25 1.22 2.44 1.1 
RPS6KA1 R5145 1.04 1.21 1.15 2.33 1.07 
PTK2 F8926 1.06  1.01 2.2 -1.08 
MYC C3956 1.32 1.23 1.15 2.17 1.02 
MECP2 M9317 1.38 1.22 1.1 2.17 1.15 
SIRT1 S5313 1.39 1.32 1.12 2.08 1.44 
PRKCB P3078 1.23 1.22 1.2 2.06 1.47 
CHUK I6139 1.61 1.31 1.15 2.03 1.4 
SMARCB1 H9912 1.38 1.42 1.1 2.03 1.33 
CETN1 C7736 1.51 1.47 1.17 1.9 1.44 
TNPO1 T0825 1.13 1.28 1.16 1.84 1.26 
SP1 S9809 1.39 1.35 1.08 1.82 1.08 
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Table 120:      Combined Antibody Microarray DEP Data : Current Study + VH Study ( 9 Experiments) 
 
Significant expression fold change (> 1.8) is indicated in bold. For proteins which show < 1.8-fold change in expression, supporting data 
from other experiments is shown upward of 1.5-fold. Values considered to be not significant (---) and antibody spots which did not pass 
the analysis criteria for experimental quality control () are also indicated.  
 
Protein Name Gene Name 
#1 
(11vs19) 
 
#2 
(15vs9) 
 
#3 
(15vs19) 
 
#4 
(12vs25) 
 
#5 
(18vs25) 
 
#6 
(16Bvs1B) 
#7 
(38vs15B) 
#8 
(38vs15B) 
#9 
(12Bvs1) 
14-3-3 YWHAQ -1.54 -1.90 -2.29 -2.55 -1.52 -3.15 -1.54  -5.28 
Acetyl Histone H3 AcLys9 H3F3A  ---   ---   ---  -2.21  ---   ---  ---  ---  --- 
Annexin V ANXA5  ---   ---    ---  -2.02  ---   ---   ---  --- 
ARC NOL3 ---  ---   ---  --- ---   ---  ---  --- 1.89 
aSynuclein SNCA ---   --- ---  ---  ---   ---  ---  ---  --- 
BclxL BCL2L1  ---  2.26  ---  1.57 2.62 2.57 1.71  --- 1.99 
BID BID  ---  2.16 1.55 1.97 1.96  ---  --- 1.69  --- 
Calbindin D 28K CALB1  ---  ---  --- ---  ---  -5.27  ---  --- 
Casein  Kinase 2b CASP13  ---  --- ---  ---  ---   ---  ---  --- 
Caspase 13 CASP13  ---   ---  -2.69  ---   ---   ---  ---  ---  --- 
Cathepsin D CTSD  ---  ---  ---  --- ---  -1.76  ---  --- 
CDK5 CDK5  ---  ---  --- ---   --- -1.92  ---  ---  --- 
Centrin CETN1 1.51  ---   ---  1.90  ---   ---  ---  ---  --- 
Chondroitin sulfate ACAN 1.56  ---  2.00  ---   ---   ---  ---  ---  --- 
cMyc MYC  ---   ---   ---  2.17  ---   ---  ---  ---  --- 
Csk CSK ---  ---  ---   ---  ---  ---  ---  --- 2.44 
CUGBP1 CUGBP1 ---  ---  ---  ---  ---  -2.24   ---  --- 
Cytokeratin peptide 4 KRT4 ---   --- ---   ---  --- -2.51  ---  ---  --- 
Desmosomal protein DSC1  ---   ---  1.92  ---   ---   ---  ---  ---  --- 
Dimethyl Histone H3 H3F3A 2.14  ---   ---   ---   ---   ---  ---  ---  --- 
DR3 TNFRSF25 ---   ---  ---      ---  ---  ---  --- 
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DR4 TNFRSF10A ---  ---  ---  ---   ---  ---  --- 1.79 2.76 
DRAK1 STK17A  ---  2.18  ---   ---   ---   ---  ---  ---  --- 
Dystrophin DMD  --- ---   ---  --- ---  1.88  ---  ---  --- 
E2F6 E2F6 ---   ---  ---  --- ---  -2.74  ---  -1.96 
Epidermal Growth Factor EGF  ---   ---   ---  -2.13  ---   ---  ---  --- 
FAK pTyr577 PTK2  ---   ---  1.51  ---  -1.95  ---  ---  --- 
FAKpTyr397 PTK2  ---    ---  2.20  ---  -1.98 -2.05  --- 
FANCD2 FANCD2  ---  ---  --- ---   --- 1.95 1.86  --- 2.05 
G9a Methyl Transferase EHMT2    --- ---  ---   -1.99  --- -2.3 
GRANZYME B GZMB  ---  --- ---  ---  ---   --- 1.82  ---  --- 
HDAC2 HDAC2 ---   --- ---  ---  ---  1.79  ---  ---  --- 
HDAC4 HDAC4  ---   ---    ---   ---  -1.89  ---  ---  ---  --- 
HDAC6 HDAC6  ---  ---  --- ---  ---  1.88  ---  ---  --- 
Histone H3 pSer 10 H3F3A  ---  ---  --- ---   ---  --- 1.5  ---  --- 
hSNF5 INI1 SMARCB1  ---   ---   ---  2.03  ---   ---  ---   --- 
IKKa CHUK 1.61  ---   ---  2.03  ---   ---  ---   --- 
ILK ILK           2.06 2.05   --- 
Ki-67 MKI67 1.92  ---   ---   ---   ---   ---  ---  ---  --- 
LIM Kinase 1 LIMK1            --- -1.81  ---  --- 
MAP Kinase Activated Protein 
Kinase 2  MAPKAPK2 --- ---  ---   --- ---   ---  ---  ---  --- 
MAP Kinase ERK1 No Human  ---  --- ---  ---   ---  ---  ---  ---  --- 
MAP1 No Human ---  ---  ---   ---  ---  ---  ---  ---  --- 
MAP1 Light chain No Human ---  ---  ---  ---   ---    
MDMX MDM4 ---  ---  ---  ---   --- 1.8  ---  --- 1.51 
MeCP2 MECP2  ---   ---   ---  2.17  ---   --- 1.86  ---  --- 
Mint2 APBA2 ---  ---  ---   ---  --- -4.03  --- 
MSK1 RPSK6KA5 ---  ---   --- ---  ---   ---  ---  --- 3.42 
MyD88 MYD88  ---   ---  -2.08 -2.18  ---   --- -1.52  --- -1.64 
Munc13 1 UNC13A  ---   ---   ---  -2.08  ---   ---  ---  ---  --- 
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Mysoin Light Chain Kinase MYLK  ---  ---  --- ---   ---  ---  ---  ---  --- 
Neurofilament 68 NEFL  --- ---  ---  ---  ---   ---  ---  ---  --- 
NFkB NFKB1 ---  ---   --- ---  ---  -1.87  --- 
p19INK4d CDKN2D  ---  --- ---  ---  ---  2.53 -1.61  --- -2.14 
P38 MAP Kinase Non Activated MAPK14 ---   --- ---  ---  ---   ---  --- 1.61  --- 
Pan cytokeratin No gene name ---  ---        2.1 2.79 1.65 2.17 
PINCH 1 LIMS1  ---   ---  -1.51 -1.90  ---   ---  ---  ---   
Pinin PNN  2.54 2.39 1.53  ---  1.76  ---  --- 2.26 
PKB pSer473 AKT1  ---  ---  ---  --- ---  -1.72  ---  --- 
PRMT2 PRMT2  ---  --- ---   --- ---  -3.56 -2.91  ---  --- 
Protein Kinase Ba AKT1 2.10  ---   ---   ---   ---  ---  ---  --- 1.69 
Protein Kinase C PKC PRKCB  ---  --- ---  ---  ---  ---   ---  --- 
Protein Kinase Cb1 PRKCB  ---   ---   ---  2.06  ---   ---   ---  --- 
Protein Kinase Cb2 PRKCB 3.20  ---   ---  1.70  ---   1.53  --- 
Rab7 RAB7A ---  ---   ---  ---   -1.74   -2.16 
RALAR RALA  ---   3.70   ---   ---  ---  --- 
Reelin RELN 1.95   ---    ---   --- 1.76  ---  --- 
RIP RIPK1 2.07  ---   ---  2.56  ---   --- 1.65  --- 1.54 
RNaseL RNASEL ---   ---  ---  --- ---   ---  ---  --- -2.25 
ROCK1 ROCK1 ---   ---  ---  --- ---   ---  --- 1.96  --- 
Rsk1 RPS6A1  ---   ---   ---  2.33  ---   ---  ---  ---  --- 
S6 Kinase RPS6KB1  ---   ---   ---  2.44  ---   ---  ---  ---  --- 
SAPK3 MAPK12  ---  ---  ---  ---  ---    --- 
SHPTP2 PTPN11  ---  -3.76   ---   ---   ---  ---  --- 
Sir2 SIRT1  ---   ---   ---  2.08  ---   --- 1.71  ---  --- 
SNX6 SNX6  ---   ---   --- ---   ---  ---  5.33 
Sp1 SP1  ---   ---   ---  1.82  ---   ---  ---  ---  --- 
SynCAM no human  ---  ---  ---   ---  -1.97   --- 
Tau MAPT 1.63  2.04   ---    
Tau pSer199 202 MAPT  ---  ---  ---  --- ---  -1.98   
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TBP TBP  ---   ---   ---  -2.08  ---   ---  ---   --- 
TRAIL TNFSF10  ---   ---  -1.83 -1.62  ---   ---  ---   --- 
Tranforming Growth factor beta 
pan TGFB1 ---  ---   ---  ---  --- -3.2 -1.59  --- 
Transportin 1 TNPO1  ---   ---   ---  1.84  ---   ---  ---  ---  --- 
Tropomyosin TPM1  ---  -2.67  ---    ---   ---  ---  ---  --- 
TWEAK receptor TNFRSF12A  ---     ---  ---  -2.76 -1.66  ---  --- 
Tyrosine hydroxylase TH ---    ---   ---  ---  ---  ---  ---  --- 
Ubiquitin C terminal Hydroxylase 
L1 UCHL1 ---  --- ---   ---  ---   ---  ---  --- 
ZAP70 ZAP70            ---  --- -1.87  --- 
Zyxin ZYX -7.80 -2.01 -2.21 -2.02 -2.63 -2.15  ---  ---  --- 
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Table 41:      Total Number of DEPs Identified from Combined TH +VH Microarray Analysis 
 
 
 
 
 
 
 
 
 Number 
Total Number of Combined DEPs from the Discovery Phase (TH and VH AbmA) 89 
Total Number of DEPs from the Discovery  Data showing a Significant Fold Change of ≥ 1.8 74 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 2/9  experiments  8 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 3/9 experiments 5 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 4/9 experiments 1 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 5/9 experiments 1 
Total Number of DEPs with ≥ 1.8 Fold Change in atleast 6/9 experiments 1 
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Table 4132:    DEPs Identified in ≥ 2 Experiments from the Combined Microarray Data: TH & VH Studies 
 
 
DEPs in 2 or more 
experiments 
(n=16) 
 
 
DEPs identified in 
experiments 
(2/9) 
DEPs identified in 
experiments 
(3/9) 
DEPs identified in 
experiments 
(4/9) 
DEPs indentified in 
experiments 
(5/9) 
DEPs identified in  
experiments 
(6/9) 
Bcl-XL      
BID      
DR4      
E2F6      
FAKpTyR577      
FANCD2      
ILK      
MeCP2      
MyD88      
P1911INK4d      
PRMT2      
Pancytokeratin      
Pinin      
RIP      
14-3-3      
Zyxin      
Total 8 5 1 1 1 
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Table 43:               The DEP Data from 2D-PAGE/MS Experiments (n=3) : VH Study 
 
A total of three comparative 2D-PAGE MALDI-TOF/TOF experiments were performed by VH to identify differentially expressed 
proteins (DEPs) associated with chemotherapy resistance. The table lists (alphabetically by gene symbol, from the IPI database) those 
DEPs identified in at least two experiments (n=57), showing ≥ 2-fold change in expression, along with the direction of change (↓↑). 
Protein identifications with 1 peptide match are indicated (1). Where a protein is not identified as a DEP, --- is shown, to represent status 
unknown. 
 
Protein  
 
Gene Symbol  #15CS v #19CR  #15CS v #1CR  #18CS v #1CR  
Activator of 90 kDa heat shock protein ATPase 
homolog 1  
AHSA1  ↑1  ↑  ---  
Annexin A3  ANXA3  ---  ↑  ↑  
Serum amyloid P-component  APCS  ↓  ↓  ↓1  
Apolipoprotein A1 APOA1  ↓  ↓  ↓1  
Adenine phosphoribosyltransferase  APRT  ↑1  ---  ↑1  
Rho GDP-dissociation inhibitor 1 ARHGDIA  ---  ↑  ↑  
Rho GDP-dissociation inhibitor 2  ARHGDIB  ↑  ↑  ↑1  
ATP synthase subunit beta, mitochondrial ATP5B  ↑  ---  ↑1  
Barrier-to-autointegration factor  BANF1  ---  ↑  ↑1  
Macrophage-capping protein  CAPG  ---  ↑  ↑  
Isoform 2 of F-actin-capping protein subunit beta CAPZB  ↑  ↑  ↑1  
T-complex protein 1 subunit beta  CCT2  ↓1  ↑  ---  
Creatine kinase B-type  CKB  ↓  ↓  ↓  
Chloride intracellular channel protein 1  CLIC1  ↑  ↑  ↑1  
Coactosin-like protein  COTL1  ---  ↑1  ↑  
Cellular retinoic acid-binding protein 2  CRABP2  ↑1  ↑  ↑  
Isoform 1 of Eukaryotic translation initiation factor 
5A-1  
EIF5A  ---  ↑  ↑  
Ferritin light chain  FTL  ↓  ↓1  ↑  
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Glycerol-3-phosphate dehydrogenase [NAD+] 
cytoplasmic  
GPD1  ↓  ↓  ---  
Glutathione S-transferase  
omega-1  
GSTO1  ---  ↑  ↑  
Glutathione S-transferase P  GSTP1  ↓  ↑  ↑  
HEBP2 protein (fragment)  HEBP2  ---  ↑  ↑  
highly similar to Heat-shock protein beta-6  HSPB6  ↓  ↓  ---  
Keratin, type I cytoskeletal 19  KRT19  ↑  ↑/↓  ↑1  
Keratin, type II cytoskeletal 8*  KRT8  ↑  ↓  ---  
Isoform 1 of Acyl-protein thioesterase 1  LYPLA1  ↑1  ↑1  ---  
Microtubule-associated protein RP/EB family 
member 1  
MAPRE1  ---  ↑  ↑  
Microfibril-associated glycoprotein 4  MFAP4  ↓  ↓1  ---  
Myosin regulatory light chain 12B  MYL12B  ↑  ↑  ↑  
Isoform 1 of Nucleoside diphosphate kinase A  NME1  ↑  ↑  ↑  
Protein disulfide-isomerase  P4HB  ↑  ---  ↑  
Platelet-activating factor acetylhydrolase IB 
subunit beta  
PAFAH1B2  ---  ↑1  ↑  
Prohibitin  PHB  ---  ↑  ↑1  
Inorganic pyrophosphatase  PPA1  ---  ↑  ↑  
Peroxiredoxin 3 isoform b  PRDX3  ↑  ↑  ↑  
Proteasome subunit alpha type-1(isoform long)  PSMA1  ---  ↑  ↑1  
Proteasome subunit beta type-3  PSMB3  ---  ↑  ↑  
Proteasome activator complex subunit 1  PSME1  ↑  ↑  ↑  
Proteasome activator subunit 2  PSME2  ---  ↑  ↑  
Histone-binding protein RBBP4  RBBP4  ---  ↑  ↑  
Ribonuclease inhibitor  RNH1  ↑  ↑  ↑  
RPSA 40S ribosomal protein SA  RPSAP15  ↑  ↑  ↑  
Protein SEC13 homolog  SEC13  ↑1  ↑  ↑  
Isoform 3 of Alpha-1-antitrypsin SERPINA1  ↓  ↓1  ---  
Stathmin  STMN1  ↑  ↑1  ↑  
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Tubulin-specific chaperone A  TBCA  ↑1  ↑1  ↑1  
Isoform 2 of Tropomyosin alpha-1 chain  TPM1  ↓  ↑  ↑  
Isoform 2 of Tropomyosin alpha-3 chain  TPM3  ↑  ↑  ↑  
Isoform 2 of Tropomyosin alpha-4 chain  TPM4  ---  ↑  ↑  
Tumor protein, translationally-controlled 1  TPT1  ↑  ↑1  ↑  
Transthyretin TTR  ---  ↓  ↓1  
Vimentin VIM  ↓  ↓  ↑  
14-3-3 protein beta/alpha  YWHAB  ---  ↑  ↑  
14-3-3 protein epsilon  YWHAE  ↑  ↑  ↑1  
14-3-3 protein gamma  YWHAG  ---  ↑  ↑  
14-3-3 protein theta/tau  YWHAQ  ↑  ↑  ↑  
14-3-3 protein zeta/delta  YWHAZ  ↑  ↑  ↑  
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Table 144:   Combined DEP Data from 2D-PAGE/MS + Microarray Experiments for IPA Analysis  
 
A total of 3 x 2D-PAGE/MS and 9 x Combined Microarray experiments were performed using breast tumour samples in two 
proteomic studies (VH and TH). The combined DEP data shown below was used for IPA analysis. A total of 122 DEPs were 
identified from the combined approach (57 from 2D-PAGE/MS and 65 from AbMA experiments). 
 
Protein Name Gene Name 
14-3- 3 YWHAQ 
14-3-3 protein epsilon YWHAE 
14-3-3 protein gamma YWHAG 
14-3-3 protein theta YWHAQ 
14-3-3 protein zeta/delta YWHAZ 
Activator of 90 kDa heat shock protein ATPase homolog 1 AHSA1 
Adenine phosphoribosyltransferase APRT 
Annexin A3 ANXA3 
Annexin V ANXA5 
Apolipoprotein A1 APOA1 
ARC NOL3 
ATP synthase subunit beta, mitochondrial ATP5B 
Barrier-to-autointegration factor BANF1 
BclxL BCL2L1 
BID BID 
Calbindin D 28K CALB1 
CDK5 CDK5 
Cellular retinoic acid-binding protein 2 CRABP2 
Centrin CETN1 
Chloride intracellular channel protein 1 CLIC1 
Chondroitin sulfate ACAN 
cMyc MYC 
Coactosin-like protein COTL1 
Creatine kinase B-type CKB 
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Csk CSK 
CUGBP1 CUGBP1 
Cytokeratin peptide 4 KRT4 
Desmosomal protein DSC1 
Dimethyl Histone H3/Acetyl Histone H3 AcLys9 H3F3A 
DR4 TNFRSF10A 
DRAK1 STK17A 
Dystrophin DMD 
E2F6 E2F6 
Epidermal Growth Factor EGF 
FAKpTyr577 PTK2 
FANCD2 FANCD2 
Ferritin light chain FTL 
G9a Methyl Transferase EHMT2 
Glutathione S-transferase omega-1 GSTO1 
Glutathione S-transferase P GSTP1 
Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic GPD1 
GRANZYME B GZMB 
HDAC4 HDAC4 
HDAC6 HDAC6 
HEBP2 protein (fragment) HEBP2 
highly similar to Heat-shock protein beta-6 HSPB6 
Histone-binding protein RBBP4 RBBP4 
hSNF5 INI1 SMARCB1 
IKKa CHUK 
ILK ILK 
Inorganic pyrophosphatase PPA1 
Isoform 1 of Acyl-protein thioesterase 1 LYPLA1 
Isoform 1 of Alpha-1-antitrypsin SERPINA1 
Isoform 1 of Eukaryotic translation initiation factor 5A-1 EIF5A 
Isoform 1 of Nucleoside diphosphate kinase A NME1 
Isoform 2 of F-actin-capping protein subunit beta CAPZB 
Isoform 2 of Tropomyosin alpha-3 chain TPM3 
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Isoform 2 of Tropomyosin alpha-4 chain TPM4 
Isoform 3 of Tropomyosin alpha-1 chain TPM1 
Isoform Long of 14-3-3 protein beta/alpha YWHAB 
Isoform Long of Proteasome subunit alpha type-1 PSMA1 
Keratin, type I cytoskeletal 19 KRT19 
Keratin, type II cytoskeletal 8 KRT8 
Ki-67 MKI67 
LIM Kinase 1 LIMK1 
Macrophage-capping protein CAPG 
MDMX MDM4 
MeCP2 MECP2 
Microfibril-associated glycoprotein 4 MFAP4 
Microtubule-associated protein RP/EB family member 1 MAPRE1 
Mint2 APBA2 
MSK1 RPS6KA5 
Munc13 1 UNC13A 
MyD88 MYD88 
Myosin regulatory light chain 12B MYL12B 
NFkB NFKB1 
p19INK4d CDKN2D 
peroxiredoxin 3 isoform b PRDX3 
PINCH 1 LIMS1 
Pinin PNN 
Platelet-activating factor acetylhydrolase IB subunit beta PAFAH1B2 
PRMT2 PRMT2 
Prohibitin PHB 
Proteasome activator complex subunit 1 PSME1 
Proteasome activator subunit 2 PSME2 
Proteasome subunit beta type-3 PSMB3 
Protein disulfide-isomerase P4HB 
Protein Kinase Ba AKT1 
Protein Kinase Cb2/Protein Kinase Cb1 PRKCB 
Protein SEC13 homolog SEC13 
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Rab7 RAB7A 
RALAR RALA 
Reelin RELN 
Rho GDP-dissociation inhibitor 1 ARHGDIA 
Rho GDP-dissociation inhibitor 2 ARHGDIB 
Ribonuclease inhibitor RNH1 
RIP RIPK1 
RNaseL RNASEL 
ROCK1 ROCK1 
RPSA 40S ribosomal protein SA RPSAP15 
Rsk1 RPS6KA1 
S6 Kinase RPS6KB1 
SAPK3 MAPK12 
Serum amyloid P-component APCS 
Sir2 SIRT1 
SNX6 SNX6 
Sp1 SP1 
Stathmin STMN1 
Tau pSer199 202 MAPT 
TBP TBP 
T-complex protein 1 subunit beta CCT2 
TRAIL TNFSF10 
Tranforming Growth factor beta pan TGFB1 
Transportin 1 TNPO1 
Transthyretin TTR 
Tropomyosin TPM1 
Tubulin-specific chaperone A TBCA 
Tumor protein, translationally-controlled 1 TPT1 
TWEAK receptor TNFRSF12A 
Vimentin VIM 
ZAP70 ZAP70 
Zyxin ZYX 
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3.10 PILOT OPTIMISATION EXPERIMENTS USING SMALL TUMOUR 
SAMPLES: 
3.10.1 Introduction: 
Keeping with the secondary aims of the current study, smaller breast tissue samples that were 
excluded from the study were used in pilot experiments to optimise protein extraction and 
quantification methods. The aim of this exercise was to optimise a protocol that will facilitate 
using smaller size breast core biopsy samples for future proteomic experiments. 
3.10.2 Experiment Protocol: 
For this pilot experiment, breast tumour samples were cut into small tissue sizes and the samples 
were weighed (Table 48) before suspending them into 4 w/v antibody microarray 
extraction/labelling buffer. All samples were then mechanically homogenised using a water 
sonicator bath as described in the section 2.5.1 and left on the end-over-end rotator overnight at 
4
o
C. Protein quantification was carried out using Bradford assay at 1:2 and 1:5 dilutions. Results 
from the quantification for each sample are displayed below in the Table 46. 
 
Table 45:  Pilot Series Samples: Recorded Tissue Weights and Dilution Volumes 
 
Sample # Weight in grams Dilution Volume in µl 
(4w/v) 
1 0.0779 311.6 
2 0.0605 242 
3 0.0644 257.6 
4 0.0311 124.4 
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Table 46:                    Bradford Quantification Results: AbMA Extraction Buffer & Water Sonicator Method           
sample Absorbance 
Protein 
concentration 
(x) 
Correct for 
dilution 
Average 
Final 
concentrations               
(mg/ml) 
Weight of 
Sample 
(g) 
Conc. in mg/ml at 1ml 
dilution 
1(neat) 0.802 2.93 2.927360775 
2.932549291 
5.01 0.0779 1.67 
1(neat) 0.805 2.937737807 2.937737807 
1(1:2) 0.573 2.135247319 4.270494639 
4.457281218 1(1:2) 0.627 2.322033898 4.644067797 
1(1:5) 0.263 1.062953995 5.314769976 
5.565548253 1(1:5) 0.292 1.163265306 5.816326531 
2(neat) 0.761 2.785541335 2.785541335 
2.73884469 
4.65167762 0.0605 1.163 
2(neat) 0.734 2.692148046 2.692148046 
2(1:2) 0.542 2.028017987 4.056035974 
4.101003113 2(1:2) 0.555 2.072985126 4.145970253 
2(1:5) 0.25 1.017986856 5.089934279 
5.202352127 2(1:5) 0.263 1.062953995 5.314769976 
3(neat) 0.719 2.640262885 2.640262885 
2.557246627 
4.270321688 0.0644 1.06 
3(neat) 0.671 2.47423037 2.47423037 
3(1:2) 0.553 2.066067105 4.13213421 
4.090626081 3(1:2) 0.541 2.024558976 4.049117952 
3(1:5) 0.203 0.855413352 4.277066759 
4.450017295 3(1:5) 0.223 0.924593566 4.622967831 
4(neat) 0.737 2.702525078 2.702525078 
2.683500519 
3.332670356 0.0311 0.41 
4(neat) 0.726 2.66447596 2.66447596 
4(1:2) 0.452 1.716707022 3.433414044 
2.604462124 4(1:2) 0.469 1.775510204 1.775510204 
4(1:5) 0.197 0.834659287 4.173296437 
4.060878589 4(1:5) 0.184 0.789692148 3.94846074 
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3.10.3   Discussion: 
In the above experiment, the feasibility of protein extraction using smaller size tissue samples 
and protein quantification to 1mg/ml concentration was explored. The protein concentrations of 
different size breast tissue samples were recorded and analysed to a 1ml of sample volume. 
Results from the Bradford assay (Table 49) showed that protein concentrations varied according 
to the sample size. The protein yields for samples #1 to #3 (weight range: 0.0779 -0.0644) were 
found to be ≥ 1mg/ml. Sample #4 (weight 0.0311g) yielded a protein concentration of ≤ 1mg/ml. 
Therefore, from the above study findings, it was hypothesised that it may be feasible to extract 
proteins using the antibody extraction/labelling buffer with sample weight ≥ 0.05 g using the 
water sonicator method for microarray analysis.  
If the above results can be replicated, the next step would involve determining the number of 
core biopsies (14 gauge hand-held biopsy gun) that can be safely obtained from patients to yield 
the required protein concentration (1mg/ml) for microarray analysis. In a recent two-phase 
randomised controlled study, using different size biopsy guns, breast cores obtained from 
cadaver breast tissues and parenchymal models showed the mean specimen volume of breast 
tissue obtained using a 14 gauge biopsy gun can be about 14.9 mm
3
 (Krebs, Berg et al. 1996). 
Another study investigating the quantity and quality of tissue harvested from breast biopsy using 
14, 16 and 18-gauge concluded, that both the quantity and quality of breast biopsy specimens 
was maximum with only 14-gauge biopsy needles with atleast six passes in each lesion  (14-
gauge, 13.14 mm
2
; 16-gauge, 9.6 mm
2
; 18-gauge, 6.41 mm
2
; p < .05) (Helbich, Rudas et al. 
1998). However, in both these studies, tissue volume and surface areas and not the tissue weights 
were taken as the reference points to report the study findings.  
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Therefore, hypothesising from the above experiment (protein concentrations matches to tissue 
weights), if the weight to surface area and/or volume correlations are to be performed, an 
approximate assumption is that 3 to 4 breast cores may be needed to yield the required protein 
concentration of 1mg/ml to run a microarray experiment. However, researchers should be 
mindful that the recommended biopsy numbers have to be reasonable for patients’ compliance 
and safety, and should also be agreeable to ethics committee for approval prior to the moving 
towards core biopsy sample collection from patients. 
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CHAPTER IV 
DATA MINING 
Aim: 
The aim of this chapter is to discuss the data mining process using the combined antibody 
microarray and 2D-PAGE/MS experimental data with Ingenuity Software Analysis.  
 
 
Hussain T; Scaife L; Hodgkinson V; Agarwal V; Mahapatra T; Kneeshaw P; McManus P; Lind 
M; Cawkwell L. A Comparative Proteomic Approach to identify putative biomarkers of 
chemotherapy resistance in breast cancer. Abstract, 2013 ASCO Annual Meeting, Chicago, IL. 
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Chapter 4.   
4.1 INTRODUCTION: 
In the last decade, the use of proteomic approaches in cancer research for the identification of 
novel biomarkers of disease diagnosis, prognosis and therapy resistance has gained popularity. 
Although proteomics has great potential in providing deeper understanding of the role of 
individual proteins and protein networks in disease and in unveiling the underlying disease 
mechanisms, challenges arise in transforming the large-scale experimental data into biomedical 
knowledge for clinical practice. Therefore, in order to understand how proteins relate to, or 
interact with each other in a biological context, enhanced interpretation of the generated data 
through the use of data mining tools is essential. The overall goal is to extract useful information 
that leads to the identification of protein biomarker candidates. However, data mining have 
limitations in that the pathways and/or protein families may not be able to find all identified 
proteins at the discovery stage.  
4.1.1 Data Mining Approaches: 
There are several widely-used bioinformatics software systems available to perform 
bioinformatics analysis and interpret the analysis result. Examples of some of the commonly 
used software programmes include R/Bioconductor, GALAXY, DAVID, KEGG, Panther, Gene 
Set Enrichment Analysis, PPI spider, Reactome and Ingenuity Pathway Analysis (IPA) (Satoh 
2012). IPA contains a library of approximately 3,000,000 biological and chemical interactions 
and functional annotations in Ingenuity knowledge base). Each molecular pathway in knowledge 
base is manually curated by expert biologists and has definite scientific evidence. By uploading 
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the list of Gene IDs and expression values into the Core Analysis tool, the network-generation 
algorithm identifies focused genes integrated in a global molecular network which can then be 
selected for further investigation. IPA also calculates the score p-value that reflects the statistical 
significance of association between the genes and the networks by the Fisher’s exact test. 
4.1.2 DEP selections for IPA Analysis: 
As described in the section 4.2, a combined approach was used to analyse the DEP data. 
Differentially expressed proteins of breast chemotherapy resistance previously identified by our 
research group (Hodgkinson et al, 2012) were combined with the DEP data from the current 
study (4 x AbMA experiments) for IPA analysis. Identified DEPs with ≥ 1.8 fold-changes in 
expression from the combined 9 antibody microarray experiments and ≥ 2 fold-changes in 
expression from the 2D-PAGE/MS studies were considered for IPA analysis. A total of 65 DEPs 
from the combined nine antibody microarray experiments and 57 DEPs from 2D-PAGE/MS 
experiments (n=122 DEPs) were found eligible for IPA analysis. Further, a literature review for 
proteins associated with breast chemotherapy resistance, showed 57 proteins to be involved with 
resistance to various cytotoxic agents (e.g. Doxorubicin, Paclitaxel, Etoposide and Mitoxantrone) 
in MCF-7 cell lines (Hodgkinson et al, 2010). Of the 57 implicated proteins, 14-3-3 epsilon, 
cytokeratin-19, HSP27, Sorcin and Stathmin were reported to be involved with anthracycline-
taxane (Doxorubicin and/or Paclitaxel) resistance and confirmed on immunoblotting 
(Chuthapisith et al. 2007). Of these 5 proteins, 2 proteins (14-3-3 epsilon and Stathmin) were 
also found in the 2D-PAGE/MS pilot studies (Hodgkinson et al 2012). Therefore, a total of 
additional three proteins leaving the two duplicates found in 2D-PAGE/MS data were selected 
and added 122 DEPs and a total of 125 DEPs were loaded onto IPA for analysis (Table 47; 
Figure 31 and 32).  
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4.1.2.1  Combined Antibody Microarray IPA Analysis: 
The IPA analysis was carried out in two stages; at first 72 DEPs identified from the combined 
antibody microarray data was analysed with their gene names. This analysis was called ‘Analysis 
#1’. In this analysis, a total of 65 DEPs from the original 72 loaded were mapped onto Ingenuity 
Knowledge Base Pathway Network. The final results from this analysis are presented in the next 
section of this thesis. 
4.1.2.2 Combined 22-PAGE/MS & Antibody Microarray IPA Analysis: 
A further second analysis (Analysis #2), involving DEPs from the combined nine antibody 
microarray, three 2D-PAGE/MS experiments and three literature proteins was carried out by 
loading a total of 125 DEPs onto IPA as highlighted in the Figure 34. Of these, only 124 DEPs 
were successfully mapped onto Ingenuity Knowledge Base Pathway Network. The final results 
from this analysis are also presented in the following next sections of this thesis. 
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Table 47:     Ingenuity Pathway Analysis: Data Selection & Proteomic Method 
Samples Method DEPs 
Breast Tumour Samples(TH) 
 
 
AbMA 
 
Appendix 3 
#16B
CS
 vs #1B
CR
; Half Protocol 
 
#38
CS
 vs #15B
CR
; Full & Half 
Protocols 
AbMA Appendix 4 
#12B
CS
 vs #1
CR
; Half Protocol AbMA Appendix 5 
Breast Tumour Samples(VH) 
 
 
AbMA 
Table 43 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 4, 2012) #11
CS
 vs #19
CR
; Full Protocol 
#15
CS
 vs # 9
CR
 ; Full Protocol  AbMA 
Table 43 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 4, 2012) 
#15
CS
 vs #19
CR
; Full Protocol AbMA 
Table 43 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 4, 2012) 
#12
CS
 vs #25
CR
; Full Protocol AbMA 
Table 43 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 4, 2012) 
#18
CS
 vs #25
CR
; Full Protocol AbMA 
Table 43 
 ( Hodgkinson et al.; Journal of Proteomics, Vol 
75, Issue 4, 2012) 
Breast Tumour Samples(VH) 
 2DMS 
Table 47 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 9, 2012) #15
 CS
 vs #19
CR
 
#15
 CS
 vs # 1
CR
 2DMS 
Table 47 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 9, 2012) 
#18
 CS
 vs # 1
CR
 2DMS 
Table 47 
( Hodgkinson et al.; Journal of Proteomics, Vol 75, 
Issue 9, 2012) 
Literature (2D-PAGE/MS 
Duplicates*) 
 
2DMS 
 
*14-3-3 epsilon Chuthapisith et al.; Intl. J Oncol, 30(2007) 
Sorcin 2DMS Chuthapisith et al.; Intl. J Oncol, 30(2007) 
HSP27 2DMS Z. Fu, C. Fenselau;  J.Proteome Res 4(2005) 
*Stathmin  2DMS Chuthapisith et al.; Intl. J Oncol, 30(2007) 
Cytokeratin 19 2DMS Chuthapisith et al.; Intl. J Oncol, 30(2007) 
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       FLOWCHART SHOWING DEP NUMBERS ELIGIBLE FOR A COMBINED IPA ANALYSIS 
 
Figure 31: Flowchart showing number of DEPs that were eligible for combined IPA analysis. A total of 89 DEPs were discovered 
from combined 9 AbMA experiments; of these only 72 DEPs were eligible for IPA analysis after exclusions and 65/72 DEPs were 
matched onto IPA for analysis. From the combined 2D-PAGE/MS data, a total of 122 DEPs were found eligible for IPA loading; 3 
literature proteins (* protein duplicates from 2D-PAGE/MS) were added onto this list a total of 125 DEPs were loaded onto IPA. 
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       FLOWCHART SHOWING SOURCE OF DEP DATA FOR COMBINED IPA ANALYSIS 
 
 
Figure 32: Flowchart showing the source of DEPs for combined IPA analysis is shown. DEPs from the current study and the VH 
pilot work along with the 5 literature proteins from the Mcf-7 cell line work were analysed with IPA. A total of 125 DEPs (65 from 
combined AbMA 9 experiments + 57 from 2D-PAGE/MS + 3 additional literature proteins) were loaded onto IPA of which 124 were 
successfully mapped onto IPA for final analysis. * Protein duplicates from 2D-PAGE/MS data 
201 
 
4.2 RESULTS: 
4.2.1 Combined Antibody Microarray (9 experiments) Data Mining Results: 
As described in the section 4.1.2 and Figures 34 and 35, a total of 89 DEPs were discovered from 
combined nine antibody microarray experiments. Of these only 72/89 DEPs were eligible for 
IPA analysis and 17/89 DEPs were excluded if found only once in each of the nine experiments 
and/or had missing gene names.  A total of 72 DEPs with their gene names were loaded onto IPA 
(Appendix 6) and the protein genes were matched onto the pathway network of Ingenuity 
Knowledge Base (Analysis #1, section 4.1.2.1). A total of 65/72 molecules in the dataset were 
matched and a list of 269 canonical pathways was generated. The top three canonical networks 
identified from the data were ‘Cell Death and Survival’, ‘Renal Necrosis/Cell Death’ and ‘Cell-
To-Cell Signalling and Interaction’ pathways. In total the three pathways between them 
contained 56 focus molecules with a network score of 115. Further, IPA also identifies top five 
canonical pathways from the protein matches and included ‘CML signalling’ with 11 DEPs, ‘IL-
8 signalling’ with 11 DEPs , ‘ERK5 with  6 DEPs, ‘Molecular Mechanisms of Cancer’ with 13 
DEPs and ‘Pancreatic signalling’ pathways with 6 DEPs respectively. Other 5 canonical 
pathways were selected if they included atleast 4 proteins from the combined analysis #1 data set 
and included 14-3-3 mediated signalling (6 DEPs), apoptosis signalling (6 DEPs), death receptor 
signalling (6 DEPs), PI3K/AKT signalling (8 DEPs) and PTEN signalling (8 DEPs). A list of top 
five canonical pathways and five other selected pathways with the number of matched DEPs is 
highlighted in the Table 48. 
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Table 48:   Canonical Pathways and Protein Matches Identified on IPA with Combined Analysis # 1 Data 
 
The table shows the top 5 and 5 other most relevant canonical pathways identified by IPA (n=10). The 5 pathways were selected if they had 
atleast 4 molecules from the data. The molecules (gene identifiers) associated with each of the canonical pathways are listed in a decreasing 
order, along with the number of canonical pathways (-) each of them appeared in. For each canonical pathway, the number of matched 
molecules from the data is also shown at the end. 
 
Gene 
Identifier  IPA Identified Canonical Pathways 
  
CML 
signalling 
ERK5 
Signalling 
IL8 
Signalling 
Molecular 
Mechanisms 
of Cancer 
Pancreatic 
Signalling 
14-3-3 
mediated 
PIP3/ AKT PTEN 
Apoptosis 
Signalling 
Death Receptor 
Signalling  
NFKB1
(9) 

          
AKT1
(8)          

  
BCL2L1
(7)                
CHUK(5)       

         
MAPK12(4) 
  
 
  
  
 RPS6KB1(4) 

          

  
BID
(3) 

    

          
EGF
(3)                  
E2F6
(3)
  
 
 
     
MYC
(3)                    
PTK2
(3) 

                  
RPS6KA1
(3)
                    
CDKN2D 
(2)             
 
    
ILK
(2)     

              
PRKCB
(2)
             

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RALA
(2)
     

 

        
ROCK
(2)
           

        
TGFB1
(2)
 

               
TNFSF10
(2)
 
    

  

YWHAQ
(2)
 

  
  

   FANCD2(1)     

             
HDAC4
(1)
     
 
      

    
HDAC6
(1)       
 
    

    
LIMK1
(1)
                   
LIMS1(1)     

          

  
MAPT
(1)
   

           

  
RIPK1
(1)
 
        
 
RPS6KA5
(1)                    
TNFRSF10A
(1)   
 
      
 
    
# Molecules 11 6 11 13 6 6 8 8 6 6 
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4.2.2 Combined Antibody Microarray & 2D-PAGE/MS Data Mining Results: 
A total of 125 proteins with their gene names (65 from combined AbMA experiments + 57 from 
2D-PAGE/MS experiments + 3 literature proteins; (Figure 35) (Appendix 7) were loaded onto 
IPA in this analysis (Analysis #2, section 4.1.2.2). Of these, a total of 124 DEPs were mapped on 
to the Ingenuity Knowledge Base and a list of 286 canonical pathways was generated. Some of 
the pathways identified in this combined analysis (analysis #2) overlapped with the pathways 
identified in the analysis #1. Looking at the enormity of the generated data output (286 
pathways) from this analysis, only 9 pathways out of 286 were selected for analysing 
chemoresistance. Of these, 5 pathways were the top 5 canonical pathways given by IPA and the 
other four were manually selected. The criteria to pathway selection were defined and included, 
pathways which had 4 or more DEPs mapped onto them from the data set and/or had a highest 
number of DEP matches onto a single discrete pathways and/or if a pathway(s) had been 
previously reported with chemotherapy resistance in cancers and/or if pathway dysregulation can 
be associated with chemoresistance. The 9 selected pathways with the matched DEPs are 
highlighted in the Table 49. Further, Table 50 highlights the 6 most relevant pathways selected 
from the original 9 pathways with their DEPs matches. These 6 pathways included PIP3/AKT 
signalling pathway with 13 DEPs matches, 14-3-3 mediated pathway with 11 DEPs, 
ERK/MAPK signalling pathway with 10 DEPs, P70S6K pathway with 12 DEPs, Cell Cycle: 
G2/M DNA Damage Checkpoint Regulation pathway with 6 DEPs and Death receptor signalling 
pathway with 6 DEPs respectively. Each pathway with DEPs from across the combined data 
(analysis #2, section 4.2.2) is illustrated in Figures 33 to 38.  
 
 
205 
 
Gene Identifier IPA Identified Canonical Pathways 
  
PIP3/AKT 
Signalling 
ERK 5 
Signalling 
14-3-3 
Mediated 
Signalling 
Acute 
Phase 
Response 
Signalling 
Myc 
Apoptosis 
Signalling 
Death 
Receptor 
Signalling 
P70S6K 
Signalling 
Cell Cycle: 
G2/M DNA 
Damage 
Checkpoint 
Regulation 
ERK/MAPK 
Signalling 
*
YWHAZ
(7)
           
*
YWHAQ
(7)
           
*
YWHAG
(7)
           
*
YWHAB
(7)
             
*
YWHAE
(7)
          
AKT1(6)     
 

 RPS6KA1(4) 

 
   



CHUK
(3)
 
 
 

 
  PRKCB(3) 
 

   



NFKB1
(3)
 
 
 

 
  MYC(3) 


  

  

MAPK12
(3)
 
 
  
   RPS6KB1(3)  
    

 RIPK1(2) 
  
 

 
 
 
Table 49:     IPA Identified Canonical Pathways and Protein Matches with Combined Analysis # 2 Data 
 
The table shows the top 5 and 4 other most relevant canonical pathways identified by IPA (n=9), that contain at least 4 molecules from the data. 
The molecules (gene identifiers) associated with each of the canonical pathways are listed, along with the number of canonical pathways (-) 
each of them appeared in decreasing order. For each canonical pathway, the number of matched molecules from the data is also shown at the 
end.  
*YWHAZ (14-3-3 zeta/delta); *YWHAQ (14-3-3 theta/tau);*YWHAG (14-3-3 gamma);*YWHAB(14-3-3 epsilon);*YWHAE(14-3-3 epsilon) 
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VIM
(3)
 
 
  
  

 BID(2) 
    
  
  H3F3A/H3F3B(2) 
      

RPS6KA5
(2)
 


     

MAPT
(2)
 
 

   

 TTR(1)                   
TNFSF10
(1)
                  
TNFRSF10A
(1)
                  
SERPINA1
(1)
                  
PTK2
(1)
       

  
 
  
MYD88
(1)
                  
MDM4
(1)
                  
LIMS1
(1)
                  
ILK
(1)
                  
FTL
(1)
                  
EGF
(1)
   

             
CRABP2
(1)
                  
BCL2L1
(1)
                  
APOA1
(1)
                  
APCS
(1)
                  
 
#Molecules 13 10 11 13 10 6 12 6 10 
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Table 50:  Relevant Pathways Selected from the Combined Analysis # 2 Data 
 
4.2.3 Confirmed DEPs from the Combined  Data: VH Study 
Previously, our research group confirmed a total of three DEPs on immunoblotting from the 
combined AbMA + 2D-PAGE/MS data in the VH study. Details of the three confirmed DEPs 
with their used antibody dilutions and antibody details are listed in the Table 51 below.  
Table 151:             Previously Confirmed DEPs on Immunoblotting: 
 
Protein Antibody Dilution Antibody Cat # 
14-3-3 
( beta, eta, tau and sigma) 
1:1000 ab9063 (AbCAM) 
 
BID 
 
1:200 
 
ab32060 (AbCAM) 
BcL-XL 1:400 ab23270(AbCAM) 
 
Canonical Pathway Number of Mapped DEPs 
PIP3/AKT Signalling 13 
14-3-3 Mediated 11 
P70S6K Signalling 12 
ERK/MAPK Signalling 10 
Cell Cycle: G2/M DNA Damage Check point 
Regulation 
6 
Death Receptor Signalling 6 
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Figure 33: A total of 13 DEPs were mapped onto the PI3K AKT signalling pathway. Of these 
13, 8 proteins were identified more than once. As seen in the figure above, the total number of 
DEPs highlighted in the pathway are different to the total numbers actually mapped onto the 
pathway (bar chart); this variability is because each pathway is created manually after searching 
literature listing the proteins and their isoforms either under a single gene name or omitting 
inclusion of some proteins or their isoforms due to paucity of evidence in defining their roles in 
the pathway development. 
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Figure 34: A total of 10 DEPs were mapped onto the ERK MAPK Signalling pathway as 
indicated above. Of these 10, 6 proteins were identified more than once. 
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Figure 35: A total of 6 DEPs were mapped onto the Death Receptor Signalling pathway as 
indicated above. Of these 6, 3 proteins were identified more than once. 
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Figure 36: A total of 9 DEPs were mapped onto the P70S6K Signalling pathway as 
indicated above. Of these 9, 7 proteins were identified more than once. 
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Figure 37: A total of 7 DEPs were mapped onto the Cell Cycle: G2M DNA Damage 
Checkpoint Regulation pathway as indicated above. Of these 7, 5 proteins were identified more 
than once. 
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Figure 38: A total of 11 DEPs were mapped onto the 14-3-3 mediated signalling pathway as 
indicated above. Of these 11, 8 proteins were identified more than once. 
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4.3 DISCUSSION: 
As discussed in the section 4.1.2 our research group had previously identified 14-3-3 theta/tau, 
BcL-XL and BID as putative biomarkers of breast chemotherapy resistance using fresh tumour 
samples in a pilot study (Hodgkinson et al. 2012). All three proteins, 14-3-3 theta/tau (YWHAQ), 
BcL-XL (BCL2L1) and BID (BID) were successfully confirmed on immunoblotting (refer Table 
55 for details) and 14-3-3 theta/tau and truncated form of BID were successfully validated using 
the MRI-iFEC series. 
From this project, leading from our previous work, a further three additional proteins, AkT1 
(PKCB), Vimentin (VIM) and Focal Adhesion Kinase (FAKY397) (PTK2) were selected from 
the combined IPA analysis #2 data. Of the three selected proteins, vimentin was identified from 
all three 2D-PAGE/MS experiments from the VH study (Table 43) and was mapped onto 14-3-3 
mediated signalling pathway from the selected 6/9 pathways (Figure 40) and overall onto 3/9 
analysed pathways, AkT1 was identified from 1/9 combined microarray data (Table 40) and 
mapped onto PIP3/AKT signalling (Figure 33) and p70S6K signalling (Figure 36) and 14-3-3 
mediated signalling (Figure 40) pathways from the selected 6 pathways but overall onto 6/9  
pathways analysed. The FAKY397 protein was identified from 3/9 combined microarray data 
(Table 40) and was mapped only onto ERK/MAPK signalling pathway (Figure 36) from the 
overall 9 pathways analysed.   
Also, from the combined analysis #2, previously identified and confirmed proteins (14-3-3 pan, 
BID and BcL-XL) and the five isoforms of 14-3-3 family namely, 14-3-3 theta/tau (YWHAQ), 
14-3-3 zeta/delta (YWHAZ), 14-3-3 gamma (YWHAG), 14-3-3 epsilon (YWHAE) and 14-3-3 
beta/alpha (YWHAB) were also analysed. Of the five 14-3-3 protein isoforms, theta/tau 
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(YWHAQ) was found in 3/3 2D-PAGE/MS (Table 43) and 3/9 combined antibody microarray 
experiments (Table 40) and mapped onto seven IPA pathways (Table 49), 14-3-3 zeta/delta 
(YWHAZ) in 3/3 2D-PAGE/MS experiments (Table 46) and mapped onto seven IPA pathways 
(Table 49), 14-3-3 gamma (YWHAG) in 2/3 2D-PAGE/MS experiments (Table 47) and mapped 
onto seven IPA pathways (Table 52), 14-3-3 epsilon (YWHAE) in 3/3 2D-PAGE/MS 
experiments and mapped onto six IPA pathways (Table 49) and 14-3-3 beta/alpha (YWHAB) in 
2/3 2D-PAGE/MS experiments (Table 43) and mapped onto seven IPA pathways (Table 52). 
Similarly, BcL-XL (BCL2L1) was identified in 4/9 combined antibody microarray data (Table 
46) and mapped onto only PIP3/AKT signalling pathway (Figure 35), BID (BID) was identified 
in 3/9 combined antibody microarray data (Table 43) and mapped only onto Death Receptor 
Signalling pathway (Figure 35) from the selected 6/9 pathways and overall onto two pathways 
from the nine analysed. 
4.4  DEPs For Confirmations and Validations: Current Study 
From the combined data mining stage in this current study, majority of molecular pathways that 
were identified were keeping in line with the expected pathways of chemotherapy resistance 
(sections 1.9.4.1, 1.9.4.2 and 1.9.3.1). However, despite using a combined approach, not all 
molecular pathways involved in chemoresistance may have been identified. This mainly due to 
the limitations of discovery techniques (section 1.13.1.2 and 1.13.1.3) and the data mining 
approaches (section 4.1.14.1.1). Therefore, working within the above limitations, so far, three 
proteins (AkT1, FAK, and Vimentin) have passed through the discovery pipeline, where their 
differential expression was first recognised during discovery-phase experiments. The above three 
proteins will now be taken to the next stages of confirmations and clinical validations.  
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Further, three other isoforms of the 14-3-3 protein (epsilon, beta/alpha, zeta/delta) previously 
identified but not validated will be clinically validated. The 14-3-3 theta/tau isoform previously 
validated using the MRI-iFEC series (section 2.3.3.1) will now undergo further validations using 
the  EC-D series (section 2.3.3.2) in a combined approach. The aim of this combined analysis 
(MRI-iFEC + EC-D) was to validate 14-3-3 theta/tau in a large patient cohort for a more 
extensive downstream analysis. 
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CHAPTER V 
 
CONFIRMATION AND CLINICAL VALIDATION 
 
Aim: 
To carry forward prioritised DEPs from the data mining phase for confirmation and clinical 
validation 
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Chapter 5.   
5.1 INTRODUCTION: 
As discussed in the section 4.4, three protein candidates (AKT1 phosphoser473, FAK 
phosphoY397 and Vimentin) from this current study were selected for confirmation using 
western blotting. Pilot validations of the selected three proteins and 4 isoforms of 14-3-3 protein 
(theta/tau, beta/alpha, zeta/delta, and epsilon) previously identified by our research group was 
carried out using immunohistochemistry. Western blotting was performed using the technique as 
described in section 2.11.1. The details of primary antibodies optimised for the western 
experiments are listed in Table 52 below.  
 
Table 52:    Details of the primary antibodies used for Western Blotting 
 Antibody Concentration Blocking agent Incubation 
period 
Antibody details 
 
Vimentin 
 
1:15,000 
 
5% non-fat milk 
      
   2hrs 
 
Rabbit polyclonal 
(#ab92547, Abcam) 
 
 
AKT1 phospho 
Ser473 
 
Not fully optimised 5% BSA      - Rabbit polyclonal 
(#ab66138, Abcam) 
Rabbit Monoclonal 
(#3787S, Cell 
Signaling 
Technology) 
 
FAK 
phosphoY397 
 
Not fully optimised 1% and 5% BSA     - Rabbit polyclonal 
(#ab4803, Abcam) 
 
219 
 
5.1.1 Optimisations of Primary Phospho-Antibodies: 
Primary antibody optimisation experiments for phospho-antibodies: AKT1 phosphoSer473 and 
FAK phosphoY397 for immunoblotting were unsuccessful. A total of 6 optimisation experiments 
were carried out for AKT1 phosphoSer473 antibody using MCF-7 and Daudi cell lines after 
blocking non-specific membrane sites with 5% milk and 5% bovine serum albumin (BSA) and 
using i-blot (semi-dry) membrane transfer technique. The AKT1 phosphoSer473 antibody used 
for the optimisation experiments was purchased from Cell Signaling Technology (Lot#3787S) 
and AbCAM (Lot#66138) and was rabbit monoclonal (Cell Signaling Technology) and rabbit 
polyclonal (AbCAM) respectively. The details of the AKT1 phosphoSer473 antibody, 
optimisation dilutions, incubations times and membrane blocks are listed in the Table 53 below. 
For FAK phosphoY397 antibody, a total of 4 optimisation experiments were carried out using 
MCF-7 and Daudi cell lines after blocking non-specific membrane sites with 5% milk and 1% 
bovine serum albumin (BSA) using i-blot (semi-dry) membrane transfer technique. The FAK 
phosphoY397 antibody used for the optimisation experiments was purchased from AbCAM 
(Lot#4803) and was rabbit polyclonal. The details of the FAK phosphoY397 antibody, 
optimisation dilutions, incubations times and membrane blocks are listed in the Table 54 below. 
The secondary antibody (Santa Cruz Lot #D0312) used in all optimisation experiments (both 
AkT1 and FAK) was raised in the same animal (rabbit) as the primary. The duration of TBS-
Tween washes was increased from two 3 x 5 min (a total 30 min) before and after secondary 
incubations from the standard protocol as described in the section 2.11.62.11.6 to a total of two 3 
x10 min ( a total 60 min) washes to avoid excessive background staining from non-specific 
binding.  
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Table 53:         AkT1 phosphoSer473 Primary Antibody Immunoblotting Optimisation Experiments  
 
 
 
Table 54:         FAK phosphoY397 Primary Antibody Immunoblotting Optimisation Experiments 
 
Antibody 
 
Supplier 
 
Dilutions 
 
Primary Incubation Time 
 
Block 
 
TBS-Tween Washes 
 
AkT1 
phosphoSer473 
(Molecular Wt. 56 kDa) 
 
Cell Signaling Technology 
(Lot#3787S) 
 
 
1:1000 ( Expt #1 & 2) 
 
 
       2 hrs Overnight at  
4
o
C 
 
 
 
 
5% Milk 
1hr 
 
3 x 5 min  twice before and 
after secondary 
 
( Total of 30 min) 
 
 
 
 
 
1:500 (Expt #3 & 4) 
 
 
 
 
 
 
 
AbCAM 
(Lot#66138) 
 
 
 
 
1:5000 ( Expt #5 & #6) 
 
 
 
x 
 
5% Milk 
1hr 
3 x 10 min  twice before and 
after secondary 
 
( Total of 60 min)  x 5% BSA 
1hr 
 
Antibody 
 
Supplier 
 
Dilutions 
 
Primary Incubation Time 
 
Block 
 
TBS-Tween Washes 
 
FAKphosphoY397 
(Molecular Wt. 125 kDa) 
 
AbCAM 
(Lot#4803) 
 
 
 
1:1000 ( Expt #1 & 2) 
              2 hrs Overnight at 
4
o
C 
 
 
5% Milk 
1hr 
 
3 x 10 min  twice before 
and after secondary 
 
( Total of 60 min) 
 
 
 
 
 
1:1000 (Expt #3 & 4) 
 
 
 
 
 
 
1% BSA 
2hr 
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5.1.2  Reasons for Failed Optimisations: 
The possible reasons for the optimisations failure can be broadly studied under two main categories:  
 Absence of band detection  
 High background staining 
5.1.2.1 Reasons for No Band Detection: 
Table 5165:              
 
The primary antibody and the secondary antibody are not compatible 
Not enough primary or secondary antibody is bound to the protein of interest 
Cross-reaction between blocking agent and primary or secondary antibody. 
The primary antibody does not recognize the protein in the species being tested. 
The protein of interest is not abundantly present in the tissue 
Poor transfer of protein to membrane. 
Excessive washing of the membrane 
Too much blocking does not allow the visualization of protein of interest 
Over-use of the primary antibody 
5.1.2.2 Reasons for High Background Staining: 
Table 56:                      
 
Blocking of non-specific binding might be absent or insufficient 
The primary antibody concentration may be too high. 
Incubation temperature may be too high. 
The secondary antibody may be binding non-specifically or reacting with the blocking reagent 
Washing of unbound antibodies may be insufficient. 
Membrane choice may give high background 
The membrane has dried out. 
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5.1.2.3 Trouble shooting with Optimisation Experiments: 
With both the phospho-antibodies from the ten optimisation experiments (6 x AkT1; 4 x FAK), a 
high background staining and absence of protein specific bands was noted (Figure 39 and 40). 
For the above reasons the antibody optimisations failed. Exact reasons for the failures were not 
fully determined, however, they were assumed to be related to the protein transfer technique as 
described in the section 2.11.4 and/or combination of any of the above factors listed in sections 
5.1.2.1 and 5.1.2.2. The above two issues were discussed with AbCAM and experiments #5 and 
#6 for AkT1 and #3 and #4 for FAK were repeated with a few modifications to the standard 
protocol (e.g. longer TBS-Tween washes, using different BSA concentrations, and longer 
periods of non-specific blocking). However, non-specific staining was still visibly persistent with 
no detection of protein specific bands. A further attempt at optimisations was given up due to 
time limitation. Learning from the experience, the author suggests that any future western 
experiments involving phospho-antibodies should have protein extractions done in a western 
specific buffer, protein separation done using 8% gels (instead of 12 % used) and protein transfer 
performed using wet-transfer technique. 
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SCANNED WESTERN BLOT IMAGE OF AkT1 phosphoSer473 ANTIBODY 
                                           A 
 
 
                                                B 
 
Figure 39:  The scanned western blot images of AkT1 Phosphoser473 antibody. Figure A represents membrane image at 1:5000 
dilution (Cell signaling #3787S) with 2 hr primary incubation using 5% milk block. Figure B represents membrane with 5% BSA 
block at 1:5000 dilution with 60 min washes. In both images, protein bands were not detected with excessive background staining 
noted. 
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                     SCANNED WESTERN BLOT IMAGE OF FAK phosphoY397 ANTIBODY 
                                         A 
 
 
                                              B 
                              
    
 
Figure 40:  The scanned western blot images of FAK PhosphoY397 antibody. Figure A represents membrane image at 
1:5000 dilution (abcam#4803) with 2 hr primary incubation using 5% milk block and 60 min washes. Figure B represents 
membrane with 1% BSA block at 1:5000 dilution and 60 min washes. In both images, protein bands were not detected with 
excessive background staining noted. 
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5.2 RESULTS: 
Vimentin (VIM) was selected for downstream analysis and taken forward to the next stages of 
confirmation and validations in the biomarker discovery pipeline. The optimised antibody 
dilution used for this protein for immunoblotting is listed in the Table 55. Western blot for this 
protein was performed using breast tumour lysates; protein extractions from the tumour samples 
was performed using protein extraction technique as described in the section 2.5 using antibody 
microarray extraction labelling buffer. Immunoblotting for the experiment was performed using 
the technique as described in the section 2.11.1. Vimentin expressions were confirmed on 
immunoblotting in both chemosensitive and chemoresistant tumour lysates. However, protein 
expressions in only 1/3 chemoresistant samples (#38B and #15B) was found to show a ≥ 1.8 fold 
change (Figure 41).  
           
 CONFIRMATION OF VIMENTIN EXPRESSION ON WESTERN BLOT 
 
  
 #16B (CS)    #1B (CR)                  #38B (CS)      #15B (CR)                   #12B (CS)      #1(CR)                                                                                     
-------------------------          -------------------------           ------------------- 
        1.1 fold                             10.5 fold                            0.9 fold  
Figure 41: Western blot showing vimentin expression using breast tumour lysates. In 1/3 
(#38B and #15B) CR lysates, vimentin expression was ≥ 1.8 fold as shown above. Beta-actin 
was used as a loading control to allow densitometric analysis of fold changes. Bands were 
observed at expected sizes of 53 and 42 k Da for vimentin and B-actin respectively.  
 
 
Beta-actin (42kDa) 
Vimentin (53kDa) 
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5.3 IMMUNOHISTOCHEMISTRY: 
5.3.1 Introduction: 
As described in the section 4.4 of the thesis, three proteins from the current study and four 
isoforms of 14-3-3 protein from the VH study will be taken forward for clinical validations .A 
total 7 proteins will be validated using two different archival series described in the section 2.3.3. 
Immunohistochemistry technique used for the experiments will be as described in the section 
2.122.12 of the thesis. The details of primary antibodies and the detection methods for each 
antibody are given in the Table 57 below. 
 
Table 57:    Primary Antibodies used for Immunohistochemical Staining 
Antibody Archival Series Dilution Antibody Details Detection Method 
14-3-3 theta/tau ECD series 1:100 #ab64991, Abcam Streptavidin-avidin-
biotin method 
14-3-3 beta/alpha i-FEC series 1:50 #ab32560, Abcam Streptavidin-avidin-
biotin method 
14-3-3 zeta i-FEC series 1:25 #ab51129, Abcam Streptavidin-avidin-
biotin method 
 
14-3-3 epsilon i-FEC series 1:100 #ab43057, Abcam Streptavidin-avidin-
biotin method 
 
AkT1 phospho Ser 
473 
ECD series 1:50 #ab66138, Abcam Streptavidin-avidin-
biotin method 
Vimentin ECD series 1:50 #ab92547, Abcam Streptavidin-avidin-
biotin method 
 
FAK phosphoY397 ECD series 1:50 #ab4803, Abcam Streptavidin-avidin-
biotin method 
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5.4 CLINICAL VALIDATION OF VIMENTIN PROTEIN: 
Clinical studies have shown vimentin has a role in breast chemotherapy resistance on 
immunoblotting. Therefore, in order to confirm the expression of vimentin in clinical samples 
and validate protein expressions with chemoresistance, a pilot immunohistochemical study using 
21 chemosensitive and 8 chemoresistant FFPE samples from patients treated with 4 cycles of 
epirubicin-cyclophosphamide and 4 cycles of docetaxel (EC-D series; section 2.3.3.2) was 
performed. Slide staining was assessed and scored independently by 2 assessors (TH and 
Veronica M O’Donnell) with any discrepancies adjudicated by a consultant breast pathologist 
(Dr.Ann Campbell). Following observation of all the slides, two slides were selected as reference 
controls that showed strong and weak antibody staining for the experiment. The staining 
assessments for the rest of the slides were adjudicated against the reference controls and the 
above routine was followed across all the seven immunohistochemical studies.  
 
After slide assessments, it was observed that when present, strong positive staining was 
predominantly nuclear, with occasional cytoplasm and cell membrane staining observed (Figure 
42). Intensity of nuclear staining was called positive (strong staining) if staining was noted in 
≥20% of clusters of tumour cells and negative (weak/no staining) if staining was weak or absent 
in ≤20% of clusters of tumour cells. In total 7/21 (33.3%) chemosensitive samples demonstrated 
an increase expression of vimentin in the invasive carcinoma compared to 3/8 (37.5%) from the 
chemoresistant group. However, the decrease expression of vimentin was not significantly 
associated in the chemoresistant group (p=1.00; Fishers exact test) (Table 58). 
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                   IHC Analysis of Vimetin Expression Using the EC-D series 
 
                           A 
 
 
                               B 
 
 
 
Figure 42: Immunohistochemical analysis of vimentin expression in invasive breast carcinoma 
cells. The Figure A shows the slide that was assessed as positive for nuclear staining with 
moderate cytoplasm positivity in at least 20% of invasive carcinoma cells. The Figure B shows 
weak nuclear and cytoplasm staining which was recorded as negative (reference control). 
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ECD series; Vimentin (ab92547, Abcam) at 1:50 dilution 
 
Table 58: IHC scoring assessment results for vimentin staining using the EC-D series. Brown 
staining was predominantly nuclear with occasional cytoplasm and cell membrane staining 
observed. However, decreased expression of vimentin in the nucleus and cytoplasm was not 
significantly associated in the chemoresistant group (p=1.00; Fishers exact test).  
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5.5 CLINICAL VALIDATION OF AKT1 PhosphoSer473 PROTEIN: 
The role of AkT1 in chemotherapy resistance in general and breast chemotherapy resistance in 
specific has been already discussed in the section 1.9.4.1 of the thesis. For clinical validation of 
this protein, a serine phosphorylated form of AkT1 was selected because of its previously 
reported association with anthrayclines (e.g. Doxorubicin) chemotherapy resistance (Li, Lu et al. 
2005). Further, the serine473 phosphorylated form in the same study was also found to be 
associated with chemoresistance to other drugs such as paclitaxel, 5-flurouracil and gemcitabine. 
Therefore, in order to explore the role of AkT1 phosphoser473 in mediating resistance to 
anthracycline-taxane chemotherapy, using the EC-D series, 19 chemosensitive and 12 
chemoresistant FFPE samples from 30 patients were analysed in a small pilot 
immunohistochemical study. 
 
Following the assessments of slides, it was observed that when present, strong positive staining 
was predominantly cytoplasmic and nuclear, with occasional cell membrane staining observed 
(Figure 43). Intensity of cytoplasmic staining was called as positive (strong/moderate staining) if 
staining was noted in ≥50% of clusters of tumour cells and negative (weak/weak-moderate 
staining) if staining was weak or weak-moderate in ≥50% of clusters of tumour cells. In total 
8/12 (66.6%) chemoresistant samples demonstrated an increase expression of AkT1 Phospho 
Ser473 in the invasive carcinoma compared to 5/19 (26.3%) from the chemosensitive group. The 
increase expression of AkT1 PhosphoSer473 was significantly associated in the chemoresistant 
group (p=0.05; Fishers exact test). Intensity of nuclear staining was called as positive (strong 
staining) if staining was noted in ≥20% of clusters of tumour cells and negative (weak staining) 
if staining was weak in ≤20% of clusters of tumour cells. In total 6/12 (50%) chemoresistant 
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samples demonstrated an increase expression of AkT1 PhosphoSer473 in the invasive carcinoma 
compared to 0/21 (0%) from the chemosensitive group. The increase expression of AkT1 
phosphoSer473 was significantly associated in the chemoresistant group (p=0.0001; Fishers 
exact test) (Table 59).  
 
 
   IHC Analysis of AkT1 PhosphoSer473 Expression Using the EC-D series 
                                 A 
 
                             B 
 
 
Figure 43: Immunohistochemical analysis of AkT1 PhosphoSer473 expression in invasive 
breast carcinoma cells Figure A shows, positive nuclear staining of AkT1 PhosphoSer473 with 
moderate cytoplasm positivity in at least 20% of invasive carcinoma cells. Figure B shows weak 
staining for the protein recorded as negative (reference control). 
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ECD series; AkT1 PhosphoSer473 (ab66138, Abcam) at 1:50 dilution 
 
Table 59: IHC scoring for AkT1 PhosphoSer473 using the ECD series. Brown staining was 
predominantly cytoplasmic & nuclear with occasional cell membrane staining observed. An 
increased expression of AkT1 PhosphoSer473 in nuclear membrane and cytoplasm was 
significantly associated in the chemoresistant group (p=0.05 and 0.0001; Fishers exact test).  
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5.6 CLINICAL VALIDATION OF FAK PosphoY397 PROTEIN: 
As discussed in the section 1.9.4.2, Focal Adhesion Kinase (FAK) is an integrin involved in 
integrin-mediated cell signalling and overexpressed in a variety of solid tumours. In breast 
cancer, expression of FAK protein compared to normal breast tissue has been shown to be 
specifically unregulated (Watermann, Gabriel et al. 2005). The role of integrins in breast cancer 
chemotherapy resistance specific to taxanes was first reported by Aoudjit F and Vuori K using 
breast cell lines (Aoudjit and Vuori 2001). Since then, integrins have also been linked with 
chemoresistance to 5FU in breast and colonic cancers (Chen, Wang et al. 2009). It has been 
reported, knock down of FAK using antisense oligonucleotides increases the sensitivity of breast 
cancer cells to chemotherapeutic agents (Satoh, Surmacz et al. 2003). This finding supports the 
pivotal role FAK plays in neoplastic signal transduction thereby showing potential to be a 
biomarker for malignant transformation and chemoresistance. Therefore, in order to assess the 
differential expression of FAK phosphoY397 in the clinical context of breast chemoresistance, a 
small pilot immunohistochemical study using 20 chemosensitive and 9 chemoresistant samples 
from the EC-D series was undertaken.   
Following the assessments of slides, it was observed that when present, strong positive staining 
was predominantly cytoplasmic and nuclear, with occasional cell membrane staining observed 
(Figure 44). Intensity of cytoplasmic staining was called positive (strong/moderate staining) if 
staining was noted in ≥50% of clusters of tumour cells and negative (weak/weak-moderate 
staining) if staining was weak or weak-moderate in ≥50% of clusters of tumour cells. In total 6/9 
(66.6%) chemoresistant samples demonstrated an increase expression of FAK phosphoY397 in 
the invasive carcinoma compared to 5/20 (25%) from the chemosensitive group. The increase 
expression of FAK phosphoY397 was significantly associated in chemoresistant group (p=0.04; 
234 
 
Fishers exact test). In total 2/9 (22.2%) chemoresistant samples demonstrated an increase nuclear 
expression of FAK phosphoY397 in the invasive carcinoma compared to 9/20 (45%) from the 
chemosensitive group. The increase expression of FAK phosphoY397 was not significantly 
associated in the chemoresistant group (p=0.41; Fishers exact test) (Table 60).  
 
 
  IHC Analysis of FAK PhosphoY397 Expression Using the EC-D series 
                             A 
               
                               B    
   
 
Figure 44: Immunohistochemical analysis of FAK phosphoY397 expression in invasive breast 
carcinoma cells. Figure A shows positive cytoplasmic staining recorded when seen in at least 
≥50% of invasive carcinoma cells. Figure B shows weak staining recorded as negative (reference 
control). 
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5.7 CLINICAL VALIDATION OF 14-3-3 theta/tau ISOFORM: 
As described in the section 4.2.3 of this thesis, previously pilot immuno validations were carried 
out for the 14-3-3 theta/tau isoform using a small pilot series of pre-treatment archival samples 
(MRI-iFEC series; section 2.3.3.1) (Hodgkinson et al. 2012). From that study, (Hodgkinson, D et 
al. 2012) following assessment of slides, a positive staining of 14-3-3 theta/tau was recorded 
when strong nuclear membrane positivity was seen in at least 20% of invasive carcinoma cells 
(Figure 47 (A: 1)). Positive staining was seen in 8/9 (88%) chemotherapy resistant (CR) samples, 
 
ECD series; FAK Phospho Y397(ab4803, Abcam) at 1:50 dilution 
 
Table 6170: IHC scoring for FAK phosphoY397 using the ECD series. Brown staining was 
predominantly cytoplasmic & nuclear with occasional cell membrane staining observed. An 
increased expression of FAK phosphoY397 in the cytoplasm was significantly associated in the 
chemoresistant group (p=0.04; Fishers exact test).  
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compared with 9/22 (40%) of chemotherapy-sensitive (CS) samples (p=0.020, Fisher’s exact 
test).  
In order to fully assess the role of 14-3-3 theta/tau in chemoresistance, clinical validations in a 
larger sample cohort was required. Therefore, this protein isoform was included for further 
clinical validations using the EC-D series. A combined data analysis from both the studies (VH + 
current study) was then carried out to assess the expression of this protein isoform with 
chemoresistance.  
Following assessments of slides in this study, strong cytoplasm and nuclear membrane positivity 
(Figure 45 (A: 2)) was seen in 3/6 (50%) of the chemoresistant group compared to 13/17(76.4%) 
from the chemosensitive group (p=0.315; Fishers exact test) (Table 61). On the combined 
analysis (MRI-iFEC + EC-D series), an overall cytoplasm and nuclear membrane positivity was 
seen in 11/15 (73.3%) of the chemoresistant group compared to 22/39 (56.4%) from the 
chemosensitive group (p=0.35; Fishers exact test) (Table 62).  
In conclusion, no significant association with chemoresistance was found with this protein 
isoform from the combined analysis. 
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IHC Analysis of 14-3-3 theta/tau Expressions: MRI-iFEC and EC-D series 
                           A:1 
 
                                        
                               B:1 
                        
                            A:2 
 
 
 
B:2 
 
 
 
Figure 45: Immunohistochemical analysis of 14-3-3 theta/tau expression in invasive breast 
carcinoma cells Figure A1 and A2 shows positive cytoplasmic staining in > 50% of cells and 
strong nuclear membrane positivity in at least 20% of invasive carcinoma cells. Figure B1 and 
B2 show weak staining which was recorded as negative (reference control). 
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MRI-iFEC + ECD series; 14-3-3 theta/tau (ab64991, Abcam) at 1:100 dilution
 
Table 62: IHC scoring for 14-3-3 theta/tau from the combined analysis. Brown staining was 
predominantly nuclear with occasional cytoplasm and cell membrane staining observed. 
However, an increased expression of 14-3-3 theta/tau in the nucleus and cytoplasm was not 
significantly associated in chemoresistant group (p=0.35; Fishers exact test).  
 
ECD series; 14-3-3 theta/tau (ab64991, Abcam) at 1:100 dilution
 
Table 61: IHC scoring for 14-3-3 theta/tau using the ECD series. Brown staining was 
predominantly nuclear with occasional cytoplasm and cell membrane staining observed. 
However, an increased expression of 14-3-3 theta/tau in the nucleus and cytoplasm was not 
significantly associated in the chemoresistant group (p=0.31; Fishers exact test).   
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5.8 CLINICAL VALIDATION OF 14-3-3 epsilon ISOFORM: 
The above protein isoform was found in all three 2D-PAGE/MS experiments in the VH study 
(Table 46). The up-regulations of four 14-3-3 isoforms (14-3-3 eta, 14-3-3 beta/alpha, 14-3-3 
theta/tau, and 14-3-3 sigma) were confirmed using an antibody which recognised all four 14-3-3 
isoforms previously by our research group (Hodgkinson et al. 2012). The 14-3-3 epsilon isoform 
was independently confirmed using epsilon specific antibody on the western blot in the same 
study. Therefore, this isoform was now selected for clinical validation using archival 8 
chemoresistant and 18 chemosensitive FFPE samples from the MRI-iFEC series. Following 
assessments of slides, a strong cytoplasm and cell membrane positivity was seen in 3/8 (37.5%) 
of the chemoresistant group compared to 7/18 (38.8%) from the chemosensitive group (p=1.00; 
Fishers exact test) (Table 63). 
 
MRI-iFEC series; 14-3-3 epsilon (ab43057, Abcam) at 1:100 dilution 
   
Table 63: IHC scoring for 14-3-3 epsilon using the MRI-iFEC series. Brown staining was 
predominantly in cytoplasm with occasional cell membrane staining observed. However, an 
increased expression of 14-3-3 epsilon in cytoplasm was not significantly associated in the 
chemoresistant group (p=0.31; Fishers exact test).   
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5.9 CLINICAL VALIDATION OF 14-3-3 beta/alpha ISOFORM: 
The above protein isoform was found in three 2D-PAGE/MS experiments in the VH study 
(Table 46) and confirmed on the western blot using a pan 14-3-3 antibody (Hodgkinson et al. 
2012). This isoform was now selected for clinical validation using archival 8 chemoresistant and 
18 chemosensitive FFPE samples from the MRI-iFEC series. Following slide assessments, a 
strong cell membrane and cytoplasm positivity was seen in 8/9 (88.8%) of the chemoresistant group 
compared to 10/18 (55.5%) from the chemosensitive group (p=0.19; Fishers exact test) (Table 64). 
 
MRI-iFEC series; 14-3-3 beta/alpha (ab32560, Abcam) at 1:50 dilution 
 
Table 64: IHC scoring for 14-3-3 alpha/beta using MRI-iFEC series. Brown staining was 
predominantly in cell membrane with occasional cytoplasmic staining observed. However, an 
increased expression of 14-3-3 beta/alpha in cytoplasmic membrane was not significantly 
associated in the chemoresistant group (p=0.19; Fishers exact test).  
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5.10 CLINICAL VALIDATION OF 14-3-3 zeta/delta ISOFORM: 
The above protein isoform was found in two 2D-PAGE/MS experiments in the VH study (Table 
46) but was not confirmed on western blotting. Therefore, this isoform was now selected for 
clinical validation using archival 8 chemoresistant and 18 chemosensitive FFPE samples from 
the MRI-iFEC series. Following slide assessments, a strong cytoplasmic and membrane positivity 
was seen in 4/9 (44.4%) of the chemoresistant group compared to 15/21 (71.4%) from the 
chemosensitive group (p=0.22; Fishers exact test) (Table 65). 
 
 
 
MRI-iFEC series; 14-3-3 zeta/delta (ab51129, Abcam) at 1:25 dilution 
 
Table 185: IHC scoring for 14-3-3 zeta isoform using the MRI-iFEC series. Brown staining 
was predominantly in cytoplasm with occasional cell membrane staining observed. However, an 
increased expression of 14-3-3 zeta in cytoplasm was not significantly associated in the 
chemoresistant group (p=0.22; Fishers exact test). 
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5.11 DISCUSSION: 
5.11.1 Role of 14-3-3 in Breast Chemoresistance: 
Our research group identified five isoforms (epsilon, theta/tau, beta/alpha, zeta/delta and gamma) 
of 14-3-3 protein from three 2D-PAGE/MS experiments using fresh breast tumour samples. Of 
these, only the 14-3-3 theta/tau (YWHAQ) isoform was taken through all stages of biomarker 
discovery pipeline and successfully validated (Hodgkinson, D et al. 2012). The 
immunohistochemical analysis of 14-3-3 theta/tau from our previous study showed a statistically 
significant association between high expression of 14-3-3 theta/tau within the nuclear membrane 
and chemoresistance (p=0.02). Therefore in this project, this protein isoform was selected for a 
more extensive downstream analysis using the EC-D series. The aim of the analysis was to 
combine the IHC data from both the MRI-iFEC and the EC-D series in order to assess the 
protein expression in a larger patient cohort. However, IHC result from the combined 
immunohistochemical analysis of 54 patients’ combined series (MRI-iFEC + EC-D) did not 
reach a statistical significance for the protein expression with chemoresistant samples.  
Analysing the above findings for the possible reasons of failure to achieve a clinical significance 
indicate a multifactorial trail. Some of these include, study under-power, higher number of 
responders than non-responders in the combined analysis, slide ambiguities from low and/or 
absent tissue staining, inter-observer variability in slide assessments and scoring and the use of 
two different chemotherapy regimens (FEC vs EC-D). Furthermore, the IHC assessments for the 
other isoforms (epsilon, beta/alpha, and zeta/delta) also failed to achieve any statistical 
significance which could well be again secondary to the combination of any of the above listed 
factors. Therefore, in order to fully assess the significance this protein expression in breast 
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chemotherapy resistance, future screening should involve a larger patient cohort in a well 
designed study with equal numbers for responders and non-responders and patients with similar 
chemotherapy regimens.  
The 14-3-3 protein has seven mammalian isoforms which are all reported to associate with 
proteins involved in critical processes including cell cycle regulation, intracellular signalling and 
apoptosis (Tzivion, Gupta et al. 2006). Overall, studies have shown that 14-3-3 proteins promote 
cell survival by inhibition of apoptosis (Masters, Subramanian et al. 2002) and have been widely 
associated with cancer and response to therapeutic agents (section 1.9.4.3). The association 
between doxorubicin and paclitaxel chemotherapy resistance in breast cancer and expression of 
14-3-3 proteins has been shown previously using MCF-7 breast cancer cell lines (Liu, Liu et al. 
2006; Chuthapisith 2007). Furthermore, 14-3-3 theta/tau (YWHAQ) has been also found involved 
with tamoxifen resistance via inhibition of tamoxifen-induced apoptosis in breast cancer cells 
(Wang, Liu et al. 2010). Also, the 14-3-3 theta/tau (YWHAQ) isoform is shown to be associated 
with response to chemotherapeutic agents, where single nucleotide polymorphisms affect the 
gene encoding of YWHAQ (Vazquez, Grochola et al. 2010). Therefore, aberrations within the 14-
3-3 proteins may present an array of mechanisms by which resistance to chemotherapeutic 
agents may arise, warranting a wider research into their role as the putative biomarkers of breast 
chemotherapy resistance. 
5.11.2 Role of Vimentin in Breast Chemoresistance: 
The above protein was found in three 2D-PAGE/MS experiments, mapped onto 3/9 molecular 
pathways on analysis #2 (section 4.1.2.2) and therefore selected for downstream analysis in this 
project. Vimentin is a member of the intermediate filament family. Along with microtubules and 
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actin microfilaments, vimentin is an integral component of the cell cytoskeleton. In cancer, 
altered vimentin level is associated with a dedifferentiated phenotype, increased motility, 
invasiveness, and poor clinical prognosis (Kokkinos, Wafai et al. 2007). 
The protein expression was confirmed on western blotting with a ≥ 1.8 fold change noted in only 
1/3 analysed chemoresistant samples (section 5.2). On IHC, vimentin expressions were largely 
nuclear with some moderate cytoplasmic staining. However, these expressions failed to achieve a 
statistical significance in the chemoresistant tumours. Vimentin (VIM) expression has recently 
been documented in tumour cells of infiltrating human breast carcinomas ((He, Whelan et al. 
2011). The development of breast chemotherapy resistance and cancer invasiveness by losing the 
expression of epithelial marker and acquisition of vimentin expression was first shown by 
Sommers et al.; using Adriamycin and Vinblastine-resistant human breast cell lines (Sommers, 
Heckford et al. 1992). The mechanism of chemoresistance with vimentin however, remains 
poorly understood; although two different biological theories: direct histogenetic derivation from 
myoepithelial cells and epithelial–mesenchymal transition (EMT) reflecting the end-stage of 
breast cancer dedifferentiation have been postulated to explain a potential link between the 
development of chemoresistant phenotype and vimentin expression by immunohistochemical 
analysis (Korsching, Packeisen et al. 2005). Using a Molecular Evolution Assay, increased 
expression of the epithelial marker E-cadherin and the mesenchymal marker vimentin have been 
found associated with in-vitro resistance to doxorubicin in breast cancer cells (Kopp, Oak et al. 
2012). Further, in-vitro studies involving breast cell lines (MCF-7) transfected with 
transcription-inhibitor Sna1 gene (Snail gene), showed an increased correlation of vimentin 
expression with EMT and multidrug resistance via Breast Cancer Resistant Protein (BCRP) 
(Chen, Wang et al. 2010). In another recent study, a higher level of vimentin expression 
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alongside an increased alteration in expression levels of genes (e.g. slug) related to epithelial-
mesenchymal transition (EMT) has been shown to cause chemoresistance to paclitaxel, 
docetaxel, and doxorubicin (Iseri, Kars et al. 2011). Acquired resistance to breast chemotherapy 
in relation to vimentin can also be explained by the alteration to death receptor signaling 
pathway that promote epithelial-to-mesenchymal transition (Antoon, Lai et al. 2012). Therefore, 
from the above evidence, the role of vimentin in the EMT transition and development of 
multidrug resistance becomes clear. Targeting EMT transcription factors and studying the 
downstream molecular targets of vimentin therefore may serve as novel strategies to curb both 
metastasis and the associated drug resistance. From this study, down-regulation of vimentin was 
observed with chemoresistance on IHC, however, without achieving a statistical significance. 
Based on the above finding, a further exploration of loss of vimentin expression with 
chemoresistance in ER+ breast tumours need to be explored. 
 
Although vimentin is an aggressive marker for breast cancer growth, up-regulation of the protein 
has been reported to be associated with favourable responses to Taxotere/Carboplatin/Herceptin 
neoadjuvant chemotherapy in triple negatives and HER2+ breast cancer subtypes (He, Whelan et 
al. 2011). The above evidence, suggest down-regulation of the Vimentin protein may therefore 
be associated with chemoresistance. In the ER+ breast tumours, association of vimentin down-
regulation with chemoresistance has been recently reported following Taxotere, Epirubicin and 
Cyclophosphamide neoadjuvant chemotherapy (Yi, Peng et al. 2013). However, this trend was 
not demonstrated for vimentin in 2/3 chemoresistant ER+ breast tumours on immunoblotting 
from the current study, although previously, vimentin was found down-regulated in all three 2D-
PAGE/MS experiments by our research group (Hodgkinson et al. 2012).  
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However, selection of vimentin as biomarker of chemotherapy resistance requires a careful 
consideration as this protein is included in the “Top15” human repeatedly identified 
differentially expressed proteins (RIDEPs) list (Petrak, Ivanek et al. 2008). The RIDEP 
phenomenon in proteomics experiments has been recently reported (Mariman 2009) and is 
hypothesised to occur involving proteins that may be involved in the cellular stress response. 
Therefore, these proteins if selected would require careful validation for further downstream 
analysis.  
5.11.3 Role of AkT1 in Breast Chemoresistance: 
AkT protein (PKB) was found in one experiment from the combined antibody microarray 
analysis, and mapped onto 8/10 molecular pathways on IPA analysis #1 (Table 51) and onto 6/9 
in analysis #2 (Table 52). In this study, expression of AkT1 phosphoser473 in breast cancer cells 
was confirmed on IHC and a significant correlation was noted between higher nuclear 
expressions in the chemoresistant tumours (Figure 43). The role of PIP3/AkT pathway in 
chemoresistance has been discussed in the section 1.9.4.1 of this thesis. Many studies in the past 
have revealed a prognostic and/or predictive role of Akt phosphorylation not just in breast 
cancers but also other cancers such as prostate and non-small cell lung cancer (Lin, Hsieh et al. 
2005; Al-Bazz, Brown et al. 2009). Lin et al; using breast cancer cells (MDA-MB-468 and 
MCF-7) and Kinexus phosphorylated protein screening assays showed a greater than 70% 
correlation between invasive breast carcinomas (p<0.05) and phosphorylated forms of PDK-1, 
AKT, p70S6K, and EGFR (Lin, Hsieh et al. 2005). In sharp contrast, phosphorylation of the 
same proteins was nearly undetectable or was at low levels in normal mammary tissues in the 
same assay. The above findings clarify the role of phosphorylated Akt in the breast malignant 
phenotype. The activation of phospho-Akt in breast cancer was further demonstrated by Al-Bazz 
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et al. using western blot analysis of the breast tumour lysates with phospho-Ser473 antibody. 
Findings from the study showed phospho-Akt was expressed in 88% of primary breast tumours 
with the highest frequency in invasive ductal carcinoma (NOS) (Al-Bazz, Brown et al. 2009). In 
the same study, expression of activated (phosphorylated) form of Akt (Ser473) was also found to 
be significantly related to oestrogen receptor status (p=0.014) but showed a poor correlation to 
the disease recurrence and patient survival. Furthermore, phosphorylation of AkT1 at Ser473 and 
not Thr 308 results in cell survival, proliferation and tumour progression has been shown by a 
transfection study of MDA-MB 468 breast cell line with the human kinome siRNA library. 
Findings from the study showed, choline-kinase can significantly up-regulate the AkT1 activity. 
A reduction in Ser473 phosphorylation of AkT1 with choline-kinase inhibitors was noted to 
cause tumour regressions in rat xenograft models (Chua, Gallego-Ortega et al. 2009). Using 
tissue microarrays, examination of FOXO3a and phosphorylated-Akt (P-Akt) expression in 
breast cancer tissue showed chemotherapy resistance and tumour progression in invasive ductal 
breast carcinoma linked to an uncoupling of the Akt-FOXO3a signaling axis (Chen, Gomes et al. 
2010). In these breast cancers activated Akt fails to inactivate and re-localize FOXO3a to the 
cytoplasm, and nuclear-targeted FOXO3a does not induce cell death or cell cycle arrest. Also, 
phosphorylated AkT1 has been also shown to cause chemoresistance to cisplatin in breast cancer 
cells from the activation of it downstream mediators, (e.g., glycogen synthase kinase-3 beta 
(GSK-3β) and forkhead in human rhabdomyosarcoma (FKHR) via the CCR9-CCL25 signaling 
axis (Johnson-Holiday, Singh et al. 2011). 
However, before considering taking forward AkT1 for clinical assays as the biomarker of breast 
chemoresistance, further confirmations of the protein up-regulation in chemoresistant tumours 
with a complimentary technique may be required. In conclusion, AkT1 phosphoSer473 should 
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now undergo rigorous confirmations with complimentary techniques alongside extensive clinical 
validations using a larger cohort of pre-treatment archival sample series. 
5.11.4 Role of FAK in Breast Chemoresistance: 
The above protein was found in three combined antibody microarray experiments and mapped 
onto 1/9 in combined IPA analysis #2 (Table 52). The role of integrins in general and FAK in 
specific with regards to breast chemotherapy resistance have been discussed earlier in the section 
1.9.4.2 of the thesis. Focal adhesion kinase (FAK) is a protein of 125 kDa that localizes to focal 
adhesions and activates tyrosine phosphorylation in response to integrin clustering. Tyrosine 397 
is an autophosphorylation site of FAK, which is a critical component in downstream signaling 
and important for the anti-apoptotic activity of FAK and activation of Akt pathways (Lorch, 
Thomas et al. 2007). Activation of FAK leads to stimulation of the MAP kinase cascade and of 
PKB/Akt/NF-κB cell signalling cascade and induce PI3K/Akt dependent anti-apoptosis 
(Yamamoto, Sonoda et al. 2003). The role of FAK phospho Y397 protein in tumour survival and 
the effects of its inhibition and reversal of anti-apoptosis have been further clarified in a recent 
in-vitro study using a small molecule inhibitor called ‘Y11’ (Golubovskaya, Figel et al. 2012). In 
this study, ‘Y11’ molecule was found to significantly and specifically decrease FAK 
autophosphorylation at Y397 site thereby effecting the viability and clonogenicity of breast 
BT474 cancer cells and increased detachment and apoptosis in-vitro. Further, constitutive 
activation of FAK and/or Laminin induced phosphorylation of FAK protein has been reported to 
cause intrinsic chemoresistance to gemcitabine (Huanwen, Zhiyong et al. 2009). Studies aimed at 
identifying the cause of chemo-resistance from activation of FAK protein revealed; 
constitutively FAK remains active in both the chemo-sensitive and chemo-resistant cell lines. 
However, inhibition of phosphorylation of Y397 by chemotherapeutic agents (e.g. cisplatin) is 
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found to confer the benefits of chemo-sensitivity by reversing its affects of anti-apoptosis 
(Villedieu, Deslandes et al. 2006).  
The effects of FAK inhibition on chemo-resistance has also been studied in- vitro and in-vivo 
using the FAK inhibitor TAE226, alone and in combination with docetaxel, in taxane-sensitive  
(SKOV3ip1 and HeyA8) and taxane-resistant (HeyA8-MDR) ovarian cancer cell lines (Halder, 
Lin et al. 2007).  In-vitro, TAE226 was found to inhibit the phosphorylation of FAK at both 
Y397 and Y861 sites thus inhibiting cell growth in a time- and dose-dependent manner, and 
enhancing docetaxel-mediated growth inhibition by 10 and 20-fold in the taxane-sensitive and 
taxane-resistant cell lines, respectively. In-vivo, FAK inhibition by TAE226 significantly 
reduced tumour burden in the HeyA8, SKOV3ip1, and HeyA8-MDR models (46-64%) with the 
greatest efficacy observed with concomitant administration of TAE226 and docetaxel in all three 
models. Alternatively, FAK activity can also be modified by transient, constitutive or conditional 
expression of inhibitory splice variants of FAK, FAK-related non-kinase (FRNK), or the Focal 
Adhesion Targeting (FAT) domain (Jones, Machado et al. 2001; van Nimwegen, Verkoeijen et 
al. 2005). Overexpression of these mutant variants is shown to either induce tumour cell killing 
by itself, or enhance the susceptibility to cell death to various anticancer drugs (e.g. 
Doxorubicin) in-vitro (Heidkamp, Bayer et al. 2002; Tsutsumi, Kasaoka et al. 2008). 
In our study, FAK phosphoY397 expressions were confirmed on IHC only and a significant 
correlation was noted between higher cytoplasmic expressions in the chemoresistant tumours 
(Figure 46). However, limitations to protein assessments on IHC exists and include absence of a 
widely accepted single scoring system, site of staining, embedding medium (HistoGel™ or 
agarose), density of cells and thickness of cut sections (Atkins, Reiffen et al. 2004). All these 
factors alone or in combination can potentially influence the statistical correlations of protein 
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expressions determined using the technique. Therefore, due to above reasons, before concluding 
on the role of this protein in chemoresistance, rigorous confirmations are required.  
5.11.5 Study Limitations: 
This thesis has involved the analysis of novel biomarkers of anthracyline-taxane neoadjuvant 
breast chemotherapy using fresh tumour samples. So far, in the current study, two proteins 
(AkT1 and FAK) have come through the discovery and validation phases of the proteomic 
discovery pipeline, where their differential expression first recognised during discovery-phase 
experiments, and their expressions validated in clinical samples in small pilot series (AkT1 vs 
FAK; nuclear vs cytoplasm; p=0.05 vs p=0.04). These proteins are in addition to the two 
proteins (14-3-3 theta/tau, tBID) discovered and validated previously by our research group 
(Hodgkinson et al. 2012). However, 14-3-3 theta/tau protein previously validated using a pilot 
archival series (iFEC) in the VH study failed to show a significant association with 
chemoresistance in the combined (iFEC and EC-D series) IHC analysis. The possible reason to 
this, as elucidated in the section 5.11.1 include having a smaller patient series for the immuno 
validations (under-power study) AND/OR having a higher ratio of responders to non-responders 
in the combined analysis AND/OR potential bias introduced from the inter-observer variability 
as the slides were assessed by two different researchers at two different time points AND/OR 
using archival series from patients treated with two different chemotherapy regimens (iFEC vs 
EC-D). Further, the immuno validations of 14-3-3 beta/alpha, zeta/delta and epsilon protein 
isoforms also failed to attain statistical significance with chemoresistance for the above same 
reasons and also because researchers (TH and VH) undertaking the pathological assessments  
were not fully blinded to the treatment outcomes. Thus, future immuno work with these proteins 
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should involve a larger archival patient series treated with similar chemotherapy regimens with 
assessors fully blinded to treatment outcomes. 
Using a comparative approach (AbMA + 2D-PAGE/MS) and a combined data analysis (9 x 
AbMA + 3 x 2D-PAGE/MS experiments) in two studies, a total of only 8 proteins (14-3-3 
theta/tau, epsilon, beta/alpha, gamma, zeta/delta vimentin, AkT1 and FAK) have been identified 
as putative markers of chemoresistance. The reasons to such a low number of identified DEPs 
include technical limitations of proteomic methods, tumour heterogeneity and paucity of 
complete information on the molecular pathways on IPA. In both the studies (TH and VH), the 
two proteomic methods (2D-PAGE/MS and antibody microarray) that were used to analyse 
breast tumour samples are known to have limitation at providing a full proteome coverage on 
their own in a single experiment. With the conventional gel-based methods, gel variability, 
limitations at detecting low-abundant, membrane bound proteins and background variations with 
structural proteins all preclude a thorough proteome interrogation. With the antibody microarray, 
only 725 pre-coated antibodies cannot provide whole proteome coverage. Therefore, possibilities 
exist that a few other proteins of clinical relevance to therapy resistance may have been missed 
despite adopting a complimentary approach.  
Both the cancer studies (TH & VH projects) used fresh tumour samples for proteomic analysis. 
Clinical tissues by nature are complex and heterogeneous. Utilising them for biomarker 
discovery studies can be a potential confounder. The reasons to this include difficulties of 
recapitulating the in-vivo molecular interactions and analysation of sub-populations of cells from 
the heterogeneous microecology. Laser Capture Micro-Dissection (LCM) is one technique that 
isolates histologically pure cancer cells using laser-assisted micro-dissection from complex 
heterogeneous tissues and micro-environments. However, the most critical limitation of 
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performing LCM, on any sample type, prior to proteomic analysis is sample loss, and the ability to 
retain sufficient sample for downstream applications (Craven, Totty et al. 2002). 
As discussed in the section 2.10.2 of the thesis, molecular information stored in the Ingenuity 
Knowledge Base is manually curetted and up-dated in a timely fashion from the published 
literature, pilot experimental data involving human cancer research studies and archival 
databases. Possibilities exist that a particular pathway(s) identified but not reported previously 
may therefore have been missed. This pathway(s) may be relevant to chemoresistance and has a 
potential to be overlooked. The above limitation has to be always kept in mind when using IPA 
for data mining purposes. Analysing data using a combination of different analytic methods may 
help overcome the above limitation. However, for this research, as only IPA was used for 
analysing the DEP data, author acknowledges this being one of the limitations of the study. 
The clinical response data for the tumour samples used in the study was reported using the 
RECIST criteria (section 2.3.1). Tumours showing a ≥30% reduction in tumour size post-
treatment (at final histology) and/or complete disappearance at the final histology were called 
responders. However, a more robust method of representing therapy responses involves plotting 
a water fall plot assessing therapy response at different time points. A waterfall plot is an ordered 
chart where each tumour is symbolized by a vertical bar, which represents the maximum change 
with respect to a reference evaluation obtained during a specific period. For this study research 
samples, plotting a waterfall graph required assessing variations in the sum of the longest 
diameters of tumours on imaging (MR or US scan) whilst on therapy (e.g. 0, 3 and 6 months). 
However, assessing therapy responses by the above method for the study samples was difficult. 
This because imaging technique used in the therapy monitoring lacked uniformity in application 
coupled with missed patient attendances at times. Further, it was also discovered that there was 
253 
 
paucity of some important radiological information (e.g. tumour size not mentioned) from the 3 
month scan reports which made difficult assessing therapy responses across different time points. 
A combination of all the above factors made assessments of therapy responses via waterfall 
graph method restrictive and challenging. Therefore, author acknowledges this as one other 
limitation of the study. 
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Chapter 6.      
The main aim of this project was to identify and expand the list of putative biomarkers of 
neoadjuvant breast chemotherapy using fresh tumour samples in an antibody microarray 
proteomic approach. Our research group have already demonstrated the feasibility of transition 
of proteomics based research from the cancer cell lines to clinical tissue samples. In this project, 
for the first time, the feasibility of working with low sample volumes (≤ 1ml) was explored with 
an aim to advance the antibody microarray based proteomic research to much smaller tissues  
(e.g breast cores). Also, pilot immunohistochemistry experiments were carried out for the 
previously identified but not validated 14-3-3 protein isoforms (epsilon, beta/alpha and 
zeta/delta) to confirm their clinical relevance. Lastly, using a few excluded breast tumour 
samples, pilot optimisation experiments were carried out for protein extractions to explore the 
feasibility of obtaining a required protein yield (1mg/ml) for proteomic studies using smaller 
clinical tissues. 
6.1 SUMMARY  FROM MICROARRAY ANALYSIS: 
A combined analysis of four antibody microarray experiments from this project and five 
experiments from the previous project generated a list of 89 differentially expressed proteins 
(DEPs). Of these 72/89 proteins were eligible for loading onto IPA and 65/72 were mapped onto 
molecular networks. From the combined microarray (9 experiments) and 2D-PAGE/MS (3 
experiments) analysis a total of 122 DEPs were generated and analysed using IPA. The top, most 
significant, canonical pathways identified was the ERK/MAPK cell signalling, PIP3/AkT cell 
signalling and 14-3-3 mediated cell signalling pathway. Additionally, ERK5 signalling, P70S6K 
signalling and Cell Cycle: G2/M DNA Damage Check point Regulation pathways previously 
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identified as top, most significant pathways were also identified in the combined data re-analysis 
in this project. The PIP3/AkT pathway from the combined analysis emerged as the most 
significant pathway with 13 DEPs mapped onto it. Following a thorough data analysis of the 
combined DEPs and the molecular pathways, three protein candidates were selected and taken 
forward to the confirmation and clinical validation stages of the biomarker discovery pipeline. 
These proteins included Vimentin (VIM), AkT1 phospho Ser473 (PKB1) and FAK phosphoY397 
(PTK2). Of the three proteins, the differential expression (down regulation) of only vimentin was 
confirmed in 1/3 samples by western blotting. Previously our research group have confirmed the 
differential expression of apoptosis-related proteins tBID and Bcl-xL, and 14-3-3 on western 
blotting. These proteins were identified from five antibody microarray experiments. The 
differential expression of 14-3-3 theta/tau and tBID was also clinically validated using 
immunohistochemistry in a small pilot study (MRI-iFEC). The increased expression of 14-3-3 
theta/tau, which is an anti-apoptotic protein, was found to be significantly associated with breast 
chemoresistance. Further, decreased expression of tBID was observed, showing reduced 
cleavage of BID into its active form (tBID) for apoptosis. The above evidence support increased 
survival of the cancer cell, by evasion of apoptosis, which is essential for the chemotherapy-
resistant phenotype. Therefore, leading from the previous work, 14-3-3 proteins isoforms needed 
to be validated using a larger archival series for a more extensive downstream analysis.  
From the current study, AkT1 phosphoser473 and FAK phosphoY397 proteins were identified 
and successfully validated in the chemoresistant ER+ (luminal A) subtype. Both these proteins 
directly or via ERK/MAPK pathway activate the PIP3/AkT pathway resulting in cell 
proliferation, cell cycle progression and cell survival via inhibition of apoptosis; the above 
cellular mechanisms mainly responsible for the chemoresistance with these proteins.  
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6.2 FUTURE CONFIRMATIONS AND VALIDATIONS:  
There are several other DEPs highlighted by IPA that warrant future research. These protein 
candidates include P70S6K, DR4/5, RIP and PKC proteins. Of these, P70S6K was mapped onto 
4/6 selected pathways from analysi#2 data, and the other three proteins were found in atleast 2 
experiments from the combined data analysis. Cancer studies have found P70S6K protein 
associations with paclitaxel and carboplatin chemotherapy response in advanced ovarian cancers 
(Carden, Stewart et al. 2012) and with cisplatin-induced cell death in MCF-7 breast cancer cell 
lines (Dhar, Persaud et al. 2009). Increased levels of P70S6K protein was reported to be 
associated with drug resistance in both these studies.  
6.3 SUMMARY FROM THE NEW MICROARRAY PROTOCOL: 
One of the aims of this current study was to advance the antibody microarray proteomic research 
platform to extend its application to smaller sample volumes. The study was successful in 
optimising ‘Half-Labelling Microarray Protocol’ using 0.5 ml of sample volume. Of the 4 
antibody microarray experiments performed in this study, a total of 3/4 experiments were 
successfully performed using the new protocol. As a result of this advancement, scientists can 
now use this high-throughput technique with smaller tissue sizes and low lysate volumes for the 
biomarker discovery process. 
6.4 SUMMARY FROM POTEIN EXTRACTION EXPERIMENTS: 
One of the secondary aims of the project was to assess the feasibility for protein extraction and 
quantification using small sample volumes for microarray analysis. The aim was to optimise 
protein extraction technique using small breast tissue samples such as breast cores. The results 
from the pilot work have shown the feasibility to obtain the required 1mg/ml protein 
258 
 
concentration needed for the microarray analysis from a sample size ≤ 0.1 g. Our research group 
aims to present this research finding to support an ethic application for the breast core biopsy 
project.  
6.5 PROTEOMICS-FUTURE PERSPECTIVE: 
6.5.1  Monitoring for Chemoresistance: Intrinsic vs. Acquired 
The ability to predict tumour response at the time of diagnosis would benefit both the patient and 
clinician, allowing the individualisation of treatment and the administration of chemotherapy to 
only those who are mostly likely to benefit, thus maximising treatment efficacy. In order to 
achieve this, clinical samples (core biopsy pre-treatment and resection samples post-treatment) 
had to be collected alongside corresponding relevant clinical information. Comparative 
proteomic analysis performed on these clinical samples would allow the identification of putative 
biomarkers associated with both the ‘intrinsic’, (where cancer cells are innately resistant to 
chemotherapy), and ‘acquired’ (where cancer cells develop resistance during treatment) 
mechanisms of chemotherapy resistance. If predictive biomarkers of chemotherapy resistance 
were transferred to the clinic, screening would be performed at the time of diagnosis, to allow 
subsequent treatment to be tailored accordingly. This may involve the routine screening of 
formalin-fixed paraffin-embedded (FFPE) core biopsy samples, with an established panel of 
predictive biomarkers. This is a clinically accepted approach, currently used for routine ER PR 
and HER2 screening, therefore if a panel of predictive biomarkers was identified it would be 
relatively simple to incorporate this into an existing routine protocol, without requiring extra patient 
samples. Also, monitoring for acquired resistance will identify molecular targets that can help 
understand the mechanism of chemoresistance and aid in developing targeted molecular therapies in 
future. 
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6.5.2 Developing  Pre-Clinical Models: 
To mimic a clinical setting, in-vitro breast cancer cell lines models of anthracyline-taxanes 
chemotherapy resistance should be developed and the identified putative biomarkers of breast 
chemoresistance analysed using specific protein inhibitors. From the data from our research 
work, ERK/MAPK and PIP3/AkT pathway protein candidates (e.g. AkT1, 14-3-3, FAK, and 
P70S6K) appear interesting targets for further explorations. If chemoresistance can be 
successfully overcome by inhibition of these proteins, an important breakthrough will be 
achieved in developing novel targeted treatments for the ER+ (luminal A) breast cancer subtype. 
6.5.3 Concluding Remarks: 
From this study and our previous pilot work, protein extraction, labelling and quantification 
methods using clinical tissue samples with antibody microarray and 2D-PAGE/MS proteomic 
techniques have been optimised and successfully used to discover biomarker of breast 
chemotherapy resistance. Pilot optimisation work for protein extraction & quantification using 
smaller size tissue samples for using core biopsies in future proteomic experiments has been 
performed. The current study has been complimentary to the previous work done by our research 
group and identified two more novel proteins (AkT1 and FAK).  Future work utilising core biopsy 
samples for the discovery of predictive biomarkers of breast intrinsic chemoresistance is currently in 
the pipeline. Planning for a proof-of-principle study and ethics application has now been completed.  
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4 
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(based on 
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responder 
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80mm all 
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4 
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ded 
partiall
y 
 -   
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reduction 
responder 
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ar 
Grade 2 
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 -  24mm EC x4 
Docetaxel 
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to measure 
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made of small foci 
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reduction 
responder 
Ductal Grade 3 
(poor) 
ER- PR- 
HER2+ 
 -  30mm  neoTANG
O. EC x 6 
only 
 -  29mm  97mm Stable 
disease 
non-
responder 
Ductal Grade 2 
(mod) 
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O  
ECx4 and 
Paclitaxel 
x4 
17mm 2 patches with  
overall area 30mm 
27mm 3.8% 
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Non-
responder 
Appendix 1: The full clinico-pathological, and therapy response details of the breast tumour samples collected for the research 
project between January 2008 to June 2011 from the Hull and East Yorkshire Hospitals NHS Trust breast unit. A total of n=50 fresh 
tumour samples were collected and the clinical information details including the tumour grade, IHC determined receptor status, pre 
and post treatment MRI/US tumour sizes, chemotherapy administered, final histopathological size and therapy response as 
determined using the RECIST criteria are outlined in the table below (refer sections 2.3 and 2.3.1) 
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Lobul
ar 
Grade 2 
(mod) 
ER+ PR+ 
HER2- 
66mm  -  EC x 4 
Docetaxel x 
4 
Decrea
sed in  
volume 
by 65% 
after 
EC. No 
further 
red. 
After D 
 50mm 
 -  Multifocal. Largest 
focus 7mm. Extensive 
LCIS.  
Involves all 4 
quadrants 
24.2% 
reduction 
non-
responder. 
Stable 
disease 
Ductal Grade 3 
(poor) 
ER- PR- 
HER2+ 
 -  28mm EC x 4 
Docetaxel x 
4 
40mm 
 ('lack 
of 
uptake'
) 
 -  no residual disease 
0mm 
100% 
reduction 
responder 
Ductal Grade 3 
(poor) 
ER+ PR+ 
HER2+ 
Only have 
Pre-
treatment  
CT scan. 
29mm  
T1 14mm 
T2 12mm 
total 26mm 
had 
surgery & 
chemo 
previously 
on other 
breast. 
ECx2 
(already 
received.Do
c x 4 (side 
effects so 
last 2 doses 
reduced by 
25%  
T1 
16mm 
T2 
19mm 
take 
total = 
35mm 
After EC: 11.5 and 
7 (total 18.5) After 
D: 13mm and 
6mm (total 19) 
3 lesions 
T1 10mm 
T2 10mm 
T3 6mm 
+ 20mm DCIS. 
Multifocal 
26.9 % 
reduction. 
Stable 
disease 
Ductal Grade 2 
(mod) 
ER+ PR+ 
HER2- 
extensive' 
(no size) 
clinically 
40mm 
mammogra
m 
20mm + 
no size (u5) EC x 4, 
Docetaxel x 
4 but at  
25% ¯ dose 
Consid
erable 
tumour 
present. 
Area 
50mm 
but 
mid docetaxel: 
T1 10mm 
T2 15mm  
Mastectomy. High 
grade DCIS. 
Size of tumour + 
DCIS = 40mm 
T1 30mm (max). T2 
10mm (max) 
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20mm fragme
nted 
Tubul
ar 
(core 
was 
ductal
) 
Grade 2 
(mod) 
ER+ PR+ 
HER2- 
extensive 
malignancy 
78mm 
2 x foci of 
diffuse 
change. 
Whole area 
27mm 
EC x 4 
Docetaxel x 
4 
 
Fragme
nted. 
24mm 
for 
largest 
 -  Grade 1 Tubular. 
20mm 
74.4% 
reduction 
responder 
Ductal Grade 2 
(mod) 
ER+ PR+ 
HER2+  
luminal B 
80mm  
diffuse 
thickening 
extensive 
malignancy 
multifocal 
lesion 
largest 
33mm 
EC x 4. 
Docetaxel x 
2 at full 
dose & 
docetaxel x 
2 at 20% 
¯ dose 
57mm  -  Partial response to  
chemotherapy'. 33 
mm tumour  
58.8% 
reduction 
Responder 
Ductal Grade 3 
(poor) 
ER+ PR- 
HER2-.  
Luminal 
max 47mm 
+ another 
 of 8mm. + 
suspicious  
lesion in 
other 
 breast 
Multifocal. 
43mm 
EC x 4, 
docetaxel X 
1 at full  
dose. 
Docetaxel ¯ 
by 20%  
(severe 
reaction) 
for 2,3&4 
good 
respons
e' 
21mm 
 -  5mm residual cancer  89.4% 
reduction 
Responder 
Ductal Grade 2 
(mod) 
ER+ PR+ 
(core) 
HER2+  
(PR in 
resection 
was 
negative) 
43mm 
multifocal 
40mm 
possibly  
another 
focus 
EC x 4 
Docetaxel x 
4 
max 
diamet
er 
of 
30mm 
 -  15mm. ER+ PR-  65.1% 
reduction 
Responder 
Ductal Grade 3 
(poor) 
ER+ PR+ 
HER2+ 
30mm  25mm ECx4. Dx2. 
3rd cycle 
reduced 
20mm  -  no residual cancer 
0mm. Complete  
regression 
100% 
reduction 
responder 
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by 20% 
(toxicities).
no cycle 4 
Lobul
ar  
Grade 2 
(mod) 
ER+ PR+ 
HER2- 
60mm max  
diameter 
 -  EC x 6  
(had bone 
metastasis 
at start - 
palliative 
chemo) 
No 
signific
ant  
alterati
on’ at 
least 
54mm 
 -  47mm minimum.  21.7% 
reduction 
Non-
responder 
Lobul
ar 
Grade 2 
(mod) 
ER+ PR+ 
HER2- 
max 56mm  
fragmented  
diffuse area 
max 34mm 
EC x 4 
Docetaxel x 
4 
20mm  -  partial regression & 
response to chemo'. 3 
ops; 1 (wide local) 
26mm ; 2 (surgery to 
remove more tumour) 
22mm; 3 
(mastectomy).total of 
48mm 
14.3% 
reduction 
non-
responder  
Lobul
ar 
Grade 2 
(mod) 
ER+ PR+ 
HER2- 
2 lesions. 
T1 23mm  
& T2 
24mm.  
47mm total 
2 lesions; 
23mm 
 and 16mm. 
Area 
of 50mm 
total 
EC x 4 
Docetaxel x 
4 
 -   -  max 32 mm 31.9% 
reduction 
Responder 
Ductal Grade 3 
(poor) 
ER - PR - 
HER2-  
E-
cadherin + 
extensive 
disease' 
47mm 
'diffuse'' EC x 5 (#6 
abandoned 
- no  
response) 
 -  After 2/3 cycles 
40mm. After 4th 
'no change' 
Mastectomy. Large 
foci 24mm.  
Extensive overall 
40mm malignancy 
14.9% 
reduction 
non-
responder  
Ductal Grade 3 
(poor) 
ER- PR- 
HER2-  
CK5/6/14
+ 
max 82mm 2 separate 
lesions. 
Largest 
42mm 
ECx4. 
Docetaxel x 
1  
(tumour 
progressed 
and  
Overall 
volume 
unchan
ged. 
''not 
respon
'no change'' (bilateral 
mastectomy) 
RHS: 2 lesions. 
Largest 47mm 
overall area 115mm 
40.2% 
increase 
non-
responder 
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developed 
new 
tumour in  
other 
breast) 
ded'' 
Ductal Grade 1 
(well) 
ER+ PR+ 
HER2- 
40mm 6mm EC x 4 
Docetaxel x 
1 then  
Docetaxel 
2-4 at 20%  
reduced 
dose 
good 
respons
e' 
2 
lesions 
of 
10mm 
each, 
but 
overall 
30mm 
 -  15mm 62.5% 
reduction 
responder 
Ductal  Grade 2 ER+ PR- 
HER2- 
> 40mm 34mm 4 x EC, 2 x 
Docetaxel 
(no  
evidence of 
good 
response) 
54mm 
(report
ed  
progres
sion) 
- overall 57mm progressiv
e disease 
Lobul
ar 
Grade 2 ER+ PR+ 
HER2- 
28mm - EC x 4, D x 
4 
(complete) 
little 
change 
in 
volume
, 
fragme
nted 
25mm 
- 28mm invasive, plus 
LCIS 
stable 
disease 
Ductal Grade 3 ER+ PR+ 
HER2+ 
(not done) 30mm EC x 4, D x 
4 
(complete)  
lesion 
13mm 
plus 27 
mm 
DCIS 
(mid treatment  
18.6.10: 50mm, 
13.8.10: 40mm) 
Largest residual 
focus 10mm.  
Overall extent of 
malignancy 38mm 
progressiv
e disease 
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Ductal  ER+ PR+ 
HER2- 
53mm 30mm EC x 4, D x 
4 
46mm (mid 15mm) 36mm Partial 
Responder 
Ductal Grade 1 
(well) 
ER+ PR+ 
HER2- 
28mm 40mm EC x 4 
Docetaxel x 
4 
 -  36mm 26mm 7.1% 
reduction 
Non-
responder 
Ductal Grade 2 
(mod) 
ER+ PR+ 
HER2- 
93mm 43mm EC x 4 
Docetaxel x 
4 
fragme
nted 
disease 
over 
max 
area of 
87mm 
 -  60mm 35.5% 
reduction 
responder 
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ANTIBODY SIGMA 
No. 
P/M 
  Reactivity   
  Human Mouse Rat 
1 14-3-3  T5942 M y y y 
2 Acetylated Protein A5463 P y n/d n/d 
3 Actin A5060 P y y y 
4 Actin A3853 M y y y 
5 Actin, α-Smooth Muscle A5228 M y y y 
6 β-Actin  A1978 M y y y 
7 β-Actin  A2228 M y y y 
8 β-Actinin  A5044 M y y n/d 
9 Actopaxin A1226 P y n/d n/d 
10 AP2 A7107 M y n/d n/d 
11 β1 and β2-Adaptins  A4450 M y n/d y 
12 I-Afadin A0349 P y y y 
13 AFX A8975 P y n/d n/d 
14 AFX (FOXO4) A5854 M y n/d n/d 
15 AKR1C3 A6229 M y n/d n/d 
16 Aly A9979 M y n/d n/d 
17 β-Amyloid  A8354 M y n/d n/d 
18 Amyloid Precursor Protein, C-Terminal  A8717 P y y y 
19 Amyloid Precursor Protein, N-Terminal  A8967 P y y y 
20 Amyloid Precursor Protein, KPI Domain  A8842 P y y y 
21 Androgen Receptor  A9853 P y n/d y 
22 Annexin V  A8604 M y n/d n/d 
23 Annexin VII  A4475 M y y y 
24 Anti Cy3+Cy5 C0992 M NA NA NA 
25 AOP1  A7674 M y y y 
26 AP-1 A5968 P y n/d n/d 
27 AP-2 A0844 P y n/d n/d 
28 AP Endonuclease A2105 M y y y 
29 Apaf1, N-Terminal  A8469 P y y n/d 
30 Apoptosis Inducing Factor (AIF) A7549 P y y n/d 
31 APRIL, Extracellular Domain A1726 P y n/d n/d 
32 APRIL, Extracellular Domain 2 A1851 P y n/d n/d 
33 ARC, C-Terminal  A8344 P y n/d n/d 
34 ARNO (Cytohesin-2)  A4721 M y n/d y 
35 Arp1/Centractin  A5601 P y y y 
36 ARP2 A6104 M y y y 
37 ARP3 A5979 M y y y 
38 ARTS A3720 P y n/d n/d 
39 ARTS     A4471 M y n/d n/d 
40 ASAP1/Centaurin β4  A4227 P y y y 
41 ASC-2 A5355 M y n/d n/d 
42 ASPP1 A4355 M y y n/d 
43 ASPP2 A4480 M y y n/d 
Appendix 2: The list of 725 Antibodies (Panorama Antibody Microarray XPRESS Profiler). All 725 
have human, mouse and rat reactivity and coated in duplicates on the nitrocellulose slide; section 2.7.1). 
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44 ATF-1 A7833 P y n/d n/d 
45 ATF2 A4086 P y n/d n/d 
46 phospho-ATF-2 (pThr
69,71
)  A4095 M y y y 
47 ATM A6093 M y n/d n/d 
48 Anti Cy3+Cy5 C0992 M NA NA NA 
49 ATM A6218 M y n/d n/d 
50 Aurora-B A5102 P y y y 
51 BACE-1 B0806 P y n/d n/d 
52 BACH1 B1310 P y y y 
53 BAD B0559 M y n/d n/d 
54 BAF57 B0436 P y y n/d 
55 BAK B5897 P y n/d n/d 
56 BAP1 B9303 M y n/d n/d 
57 Bax B3428 P y n/d n/d 
58 Bax B8429 M y y y 
59 Bax B8554 M y n/d n/d 
60 Bax B9054 M n/d y n/d 
61 Bcl-10 B7806 M y n/d n/d 
62 Prion protein P0110 M y y y 
63 Bcl-10 B0431 P y y y 
64 Seladin S4697 M y n/d n/d 
65 Bcl-2 B9804 P n/d y y 
66 Bcl-2 B3170 M y n/d n/d 
67 Bcl-x B9304 P y n/d n/d 
68 Bcl-xL  B9429 M y y y 
69 BID B4305 P y n/d n/d 
70 BID B3183 P n/d y n/d 
71 Bim B7929 P y y y 
72 Anti Cy3+Cy5 C0992 M NA NA NA 
73 CDK5 C6118 M y y n/d 
74 Bmf, N-Terminal  B1684 P y y n/d 
75 Bmf, C-Terminal  B1559 P y y n/d 
76 BNIP3 B7931 M y n/d n/d 
77 BOB.1/OBF.1 B7810 M y y n/d 
78 Brg1/hSNF2β  B8184 P y n/d n/d 
79 BTK, C-Terminal  B0811 P y n/d n/d 
80 BTK, N-Terminal B0686 P y n/d n/d 
81 BUB1 B0561 M y n/d n/d 
82 BUBR1 B9310 M y n/d n/d 
83 c-Abl  A5844 M y y y 
84 c-Cbl   C9603 P y n/d n/d 
85 c-erbB-2 E2777 M y n/d n/d 
86 c-erbB-3 E8767 M y n/d n/d 
87 c-erbB-4 E5900 M y n/d n/d 
88 phospho-c-Jun (pSer
63
) J2128 P y y n/d 
89 phospho-c-Jun (pSer
73
)  J2253 P y y n/d 
90 c-Myc M4439 M n/d n/d n/d 
91 c-Myc C3956 P n/d n/d n/d 
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92 Uvomorulin/E-Cadherin  U3254 M y y n/d 
93 N-Cadherin  C2542 M y y y 
94 N-Cadherin  C2667 M n/d n/d n/d 
95 Pan Cadherin C1821 M y y y 
96 Anti Cy3+Cy5 C0992 M NA NA NA 
97 Calbindin-D-28K  C7354 P y n/d y 
98 -Subunit) C1956 M y n/d y 
99 Caldesmon C6542 M y n/d n/d 
100 Calmodulin C7055 M n/d n/d y 
101 Calnexin C4731 P y y y 
102 Calponin    C2687 M y y y 
103 Calreticulin C4606 P y n/d n/d 
104 Calretinin C7479 P y n/d y 
105 Claspin C7867 P y n/d n/d 
106 CaM Kinase IV (CaMKIV)  C2851 P y y y 
107 CaM Kinase Kinase  C7099 P n/d n/d y 
108 CaM Kinase IIα (CaMKIIα) C6974 P y y y 
109 CaM Kinase IV (CaMKIV) C9973 P y n/d n/d 
110 CASK/LIN2  C4856 P y n/d n/d 
111 Casein Kinase 2β  C3617 M y y y 
112 Caspase 2 C7349 P y n/d n/d 
113 Caspase 3 C9598 P y n/d n/d 
114 Caspase 3, Active C8487 P y y y 
115 Caspase 4 C4481 P y n/d n/d 
116 Caspase 4     C3392 M y n/d n/d 
117 Caspase 5     C6979 M y n/d n/d 
118 Caspase 6 C7599 P y n/d n/d 
119 Caspase 7 C7724 P y n/d n/d 
120 Anti Cy3+Cy5 C0992 M NA NA NA 
121 Caspase 7 C1104 M y n/d n/d 
122 Caspase 8 C3101 P y n/d n/d 
123 Caspase 8  C2976 P y n/d n/d 
124 Caspase 8      C4106 M y n/d n/d 
125 Pro-Caspase 8 C7849 P y n/d n/d 
126 Caspase 9 C7729 P y n/d y 
127 Caspase 9       C4356 M y n/d n/d 
128 Caspase 10 C8351 P y n/d n/d 
129 Caspase 10     C1229 M y n/d n/d 
130 Caspase 11 C1354 M n/d y n/d 
131 Caspase 12     C7611 M y y n/d 
132 Caspase 13 (ERICE) C8854 P y y y 
133 Catalase C0979 M y y y 
134 α-E-Catenin  C8114 P y n/d y 
135 N-Catenin C8239 P n/d y n/d 
136 Catenin C2081 P n/d n/d n/d 
137 β-Catenin  C7207 M y n/d n/d 
138 β-Catenin  C7082 M y n/d n/d 
139 phospho-β-Catenin (pThr41) C8616 M y n/d n/d 
284 
 
140 phospho-β-Catenin (pSer33/pSer37)  C4231 M y y y 
141 phospho-β-Catenin (pSer45) C5615 M y y y 
142 phospho-β-Catenin (pSer33) C2363 M y n/d n/d 
143 δ-Catenin/NPRAP  C4864 P n/d y y 
144 Anti Cy3+Cy5 C0992 M NA NA NA 
145 Cathepsin D    C0715 M y n/d n/d 
146 Cathepsin L C2970 M y y y 
147 Caveolin-1 C3237 P y y y 
148 CD40 C5987 M y n/d n/d 
149 Cdc14A  C2238 M y n/d n/d 
150 Cdc25c         C0349 M y n/d n/d 
151 Cdc25A  C9479 M y n/d n/d 
152 Cdc27         C7104 M y y y 
153 Cdc6          C0224 M y n/d n/d 
154 Cdc7 Kinase C6613 M y n/d n/d 
155 Cdh1          C7855 M y n/d n/d 
156 Cdk1
p34cdc2
 C4973 P y y n/d 
157 Negative Control NA M NA NA NA 
158 Cdk4    C8218 M y y y 
159 Cdk6    C8343 M y y y 
160 Cdk-7/cak   C7089 M y n/d n/d 
161 TBP T1827 M y n/d n/d 
162 CENP-E C7488 P y n/d n/d 
163 Centrin C7736 P y n/d n/d 
164 Chk1    C9358 P y n/d n/d 
165 Chk2 C9108 M y n/d n/d 
166 Chk2     C9233 M y n/d n/d 
167 Chondroitin Sulfate  C8035 M y y y 
168 Anti Cy3+Cy5 C0992 M NA NA NA 
169 Ciliated Cell Marker  C5867 M y n/d n/d 
170 CIN85 C8116 P y y y 
171 Casein Kinase 2α  C5367 M y y y 
172 Clathrin Light Chain C1985 M y y y 
173 Clathrin Heavy Chain C1860 M y y y 
174 CNPase C5922 M y y y 
175 Cofilin C8736 P y y y 
176 Coilin C1862 M y n/d n/d 
177 Collagen, Type IV C1926 M y n/d n/d 
178 Connexin 32 C3470 P y y y 
179 Negative Control NA         
180 Connexin- 32  C6344 M y y y 
181 Connexin- 43 C8093 M y y y 
182 Connexin- 43 C6219 P y y y 
183 β-COP    G6160 M y n/d y 
184 Cortactin  C6987 P y y y 
185 Corticotropin Releasing Factor  C5348 P y y y 
186 COX II C9354 M y n/d n/d 
187 Crk-L C0978 P y y n/d 
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188 Crk II C0853 P y y n/d 
189 Csk  C7863 P y n/d y 
190 CtBP1, N-Terminal  C9491 P y y n/d 
191 CtBP1, C-Terminal  C8741 P y y n/d 
192 Anti Cy3+Cy5 C0992 M NA NA NA 
193 CUG-BP1 C5112 M y y y 
194 Cyclin A C4710 M y y n/d 
195 Cyclin B1 C8831 P y y n/d 
196 Cyclin D1  C5588 P y n/d y 
197 Cyclin D1  C7464 M y y n/d 
198 Cyclin D2  C7339 M y y n/d 
199 Cyclin D3  C7214 M y y y 
200 Cyclin H C5351 P y n/d n/d 
201 Cystatin A       C3095 M y n/d n/d 
202 Cytohesin-1  C8979 M y n/d n/d 
203 Cytokeratin peptide 4 C5176 M y n/d n/d 
204 Cytokeratin CK5  C7785 M y n/d n/d 
205 Cytokeratin peptide 7 C6417 M y n/d n/d 
206 Cytokeratin 8.12 C7034 M y n/d n/d 
207 Cytokeratin 8.13 C6909 M y n/d n/d 
208 Cytokeratin peptide 13 C0791 M y n/d n/d 
209 Cytokeratin Peptide 17  C9179 M y n/d y 
210 Cytokeratin peptide 18 C1399 M y n/d n/d 
211 Cytokeratin peptide 19 C6930 M y n/d n/d 
212 Pan Cytokeratin C2931 M y y y 
213 DAPK           D2178 M y n/d n/d 
214 phospho-DAPK  (pSer
308
) D4941 M y n/d n/d 
215 DAP Kinase 2 D3191 P y y y 
216 Anti Cy3+Cy5 C0992 M NA NA NA 
217 Daxx D7810 P y n/d n/d 
218 DcR1 D3566 P y y y 
219 DcR2 D3188 P y n/d n/d 
220 DcR3 D1814 P y y y 
221 DEDAF D3316 P y y y 
222 Desmin D1033 M n/d y y 
223 Desmosomal Protein D1286 M y n/d n/d 
224 Destrin/ADF  D8940 P y y y 
225 Dnase I D0188 P n/d n/d n/d 
226 Dnase II D1689 P y n/d n/d 
227 DNMT1 D4567 P y y y 
228 DNMT1 D4692 P y y n/d 
229 DOPA Decarboxylase D0180 M y n/d y 
230 DP2 D7438 M y n/d n/d 
231 DR3 D3563 P y n/d n/d 
232 Negative Control NA         
233 DR4 D3813 P y n/d n/d 
234 DR5 D3938 P y n/d n/d 
235 DR6 D1564 P y n/d n/d 
286 
 
236 DRAK1 D1314 P y y y 
237 Dystrophin D8168 M y y y 
238 Dystrophin  D8043 M y y y 
239 E2F1 E9026 P y n/d n/d 
240 Anti Cy3+Cy5 C0992 M NA NA NA 
241 E2F1 E8901 M y y y 
242 E2F2 E8776 M y n/d n/d 
243 E2F3 E8651 M y n/d n/d 
244 E2F4 E8526 M y n/d n/d 
245 E6AP E8655 M y y y 
246 EGF receptor   E3138 M y n/d n/d 
247 ERK5 (Big MAPK-BMK1) E1523 P y y n/d 
248 Elastin E4013 M y n/d n/d 
249 ELKS E4531 M y y y 
250 Endothelial Cell Protein C Receptor  E6280 M y n/d n/d 
251 Endothelial Cells  E9653 M y n/d n/d 
252 Endothelin E0771 M y n/d y 
253 Epidermal Growth Factor  E2520 M y n/d n/d 
254 Episialin (EMA) E0143 M y n/d n/d 
255 ERP57 E5031 M y y n/d 
256 Estrogen Receptor  E0521 P y n/d n/d 
257 Estrogen Receptor  E1396 P y n/d n/d 
258 Exportin T E1531 M y y y 
259 Ezrin E8897 M y y y 
260 F1A F3428 P y y y 
261 FADD F8053 M y n/d n/d 
262 Focal Adhesion Kinase (pp125
FAK
)  F2918 P y y y 
263 FAK Phospho (pSer
772
) F9051 P y y y 
264 Anti Cy3+Cy5 C0992 M NA NA NA 
265 phospho-FAK Phospho (pSer
910
) F9301 P y y y 
266 phospho-FAK (pTyr
397
) F7926 P y y y 
267 phospho-FAK (pTyr
577
) F8926 P y y n/d 
268 Falkor/PHD1  F5303 M n/d y n/d 
269 Fas (CD95/Apo-1) F4424 M y n/d n/d 
270 Fas Ligand F2051 M y n/d n/d 
271 Fas Ligand F1926 M y n/d n/d 
272 FBI-1/PAKEMON F9429 P y y y 
273 Fibroblast Growth Factor-9 F1672 M y y n/d 
274 Fibronectin F0791 M y n/d n/d 
275 Fibronectin F3648 P y n/d n/d 
276 Fibronectin    F7387 M y y n/d 
277 Filamin F1888 M n/d n/d n/d 
278 Filensin F1043 M y y n/d 
279 FKHR (FOXO1a) F6928 M y n/d n/d 
280 FKHRL1 (FOXO3a) F2178 P y y n/d 
281 FKHRL1 (FOXO3a) F1304 M y n/d n/d 
282 FLIPγ/δ, C-Terminal  F9925 P y y n/d 
283 FOXC2 F1054 P y y n/d 
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284 FOXP2 F6304 P y y y 
285 FANCD2 F0305 P y y y 
286 FXR2 F1554 M y n/d n/d 
287 FRS2 (SNT-1)  F9052 P y y y 
288 Anti Cy3+Cy5 C0992 M NA NA NA 
289 G9a Methyltransferase G6919 P y n/d n/d 
290 Glutamic Acid Decarboxylase 65 (GAD 65)  G4913 P y y y 
291 Glutamic Acid Decarboxylase 65 (GAD 65)  G5038 P y y y 
292 Glutamic Acid Decarboxylase (GAD65/67) G5163 P y y y 
293 GADD 153 (CHOP-10) G6916 P y y n/d 
294 GAP1
IP4BP
 G6666 M y n/d n/d 
295 GAPDH G8795 M y y y 
296 GATA-1 G0290 P y n/d n/d 
297 Gelsolin G4896 M y n/d n/d 
298 Gemin 2 G6669 M y y y 
299 Gemin 3 G6544 M y n/d n/d 
300 GFAP (Glial Fibrillary Acidic Protein)  G9269 P y n/d y 
301 GFAP (Glial Fibrillary Acidic Protein)  G3893 M y n/d y 
302 Growth Factor Independence-1 (GFI) G6670 M y y y 
303 Glutamate receptor NMDAR 2a G9038 P y y y 
304 Glutamine Syntethase G2781 P n/d n/d y 
305 Glycogen Synthase Kinase-3β (GSK-3β)  G7914 P y n/d y 
306 Glycogen Synthase Kinase-3 (GSK-3) G4414 M y y y 
307 Glycogen Synthase Kinase-3 (GSK-3) G6414 M y y y 
308 Granzyme B G1044 M y n/d n/d 
309 Grb-2 G2791 M y y y 
310 GRK 2 G7670 M n/d n/d y 
311 GRP1 G6541 M y n/d y 
312 Anti Cy3+Cy5 C0992 M NA NA NA 
313 GRP 75 G4170 P y y y 
314 GRP78/BiP  G8918 P y y n/d 
315 GRP94 G4420 P y y n/d 
316 hABH1 A8103 M y n/d n/d 
317 hABH2 A8228 M y n/d n/d 
318 hABH3 A8353 M y y y 
319 hBRM/hSNF2α  H9787 P y n/d n/d 
320 HAT1 ( Histone acetyltransferase 1) H7161 P y y n/d 
321 HDAC-1  H3284 P y y y 
322 HDAC-1  H6287 M y y n/d 
323 HDAC-2 H3159 P y y y 
324 HDAC-2 H2663 M y y y 
325 HDAC-3 H6537 M y y n/d 
326 HDAC-3 H3034 P y y y 
327 HDAC-4 H9411 P y y y 
328 HDAC-4  H9536 P y y y 
329 Negative Control NA         
330 HDAC-5 H4538 M y y y 
331 HDAC-5 H8163 P y y y 
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332 HDAC-6 H2287 P y y n/d 
333 HDAC-7 H2537 P y y y 
334 HDAC-7 H6663 M y y n/d 
335 HDAC-8 H6412 M y n/d n/d 
336 Anti Cy3+Cy5 C0992 M NA NA NA 
337 HDAC-10 H3413 P y y y 
338 HDAC-11 H2913 M y n/d n/d 
339 HDRP/MITR H9163 P y y n/d 
340 Heat Shock Factor 1  H4163 P y y y 
341 Heat Shock Factor 2  H6788 P y n/d y 
342 Heat Shock Protein 25  H0148 M y y y 
343 Heat Shock Protein 27  P1498 P y n/d n/d 
344 Heat Shock Protein 27/25  H2289 P y y y 
345 Heat Shock Protein 70     H5147 M y n/d y 
346 Heat Shock Protein 90   H1775 M y y y 
347 Heat Shock Protein 110  H7412 P y y y 
348 Heat Shock Protein 110  H7287 P n/d y y 
349 Acetyl Histone H3 (Ac-Lys
9
) H9286 P y y n/d 
350 Acetyl Histone H3 (Ac-Lys
9
) H0913 M y y n/d 
351 
Acetyl- & phospho-Histone H3 (Ac-Lys
9
, 
Ser
10
) H9161 P y y n/d 
352 
Acetyl- & phospho-Histone H3 (Ac-Lys
9
, 
Ser
10
) H0788 M y n/d n/d 
353 Dimethyl Histone H3 (diMe-Lys
4
) D5692 P y y n/d 
354 Dimethyl Histone H3 (diMe-Lys
9
) D5567 P y n/d n/d 
355 methyl-Histone H3 (Me-Lys
9
) H7162 P y n/d n/d 
356 phospho-Histone H2AX (pSer
139
)  H5912 P y y n/d 
357 phospho-Histone H3 (pSer
10
)  H6409 M y n/d n/d 
358 phospho-Histone H3 (pSer
28
)  H9908 M y y n/d 
359 phospho-Histone H3 (pSer
10
)  H0412 P y n/d n/d 
360 Anti Cy3+Cy5 C0992 M NA NA NA 
361 SUV39H1 Histone Methyl Transferase S8316 M y y n/d 
362 HMG-1 H9537 M y y y 
363 hMps1 M5818 M y n/d n/d 
364 hnRNP-A1  R4528 M y y y 
365 hnRNP-A1  R9778 M y n/d n/d 
366 hnRNP-A2/B1  R4653 M y y y 
367 hnRNP-C1/C2  R5028 M y n/d n/d 
368 hnRNP-K/J  R8903 M y n/d n/d 
369 hnRNP-L R4903 M y y n/d 
370 hnRNP-Q  R5653 M y y y 
371 hnRNP-U R6278 M y n/d n/d 
372 hnRNP M3-M4         R3777 M y y y 
373 hPlk1  P5998 M y y y 
374 hPlk1  P6123 M y y y 
375 hSNF5/INI1 H9912 P y n/d n/d 
376 iASPP A4605 M y y n/d 
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377 IFI-16  I1659 M y n/d n/d 
378 IB I0505 P y y y 
379 IKK I6139 P y n/d n/d 
380 ILK I0783 M y y y 
381 ILK I1907 P y y y 
382 ILP2 I4782 P y y y 
383 Negative Control NA         
384 Anti Cy3+Cy5 C0992 M NA NA NA 
385 Importin-1  I9658 M y y n/d 
386 Importin-3  I9783 M y y y 
387 Importin-5/7 I9908 M y y n/d 
388 INCENP I5283 P y y y 
389 ING1 I3659 M y n/d n/d 
390 β-Internexin  I0282 M y n/d y 
391 JAB 1 J3395 P y y y 
392 JAB 1 J3020 P y y y 
393 JAK 1 J3774 M y n/d n/d 
394 c-Jun N-Terminal Kinase  J4500 P y y y 
395 JNK, Activated (Diphosphorylated JNK) J4750 M y y y 
396 KCNK9 (TASK-3) K0514 M y n/d n/d 
397 Kaiso K4263 M y y y 
398 KIF17 K3638 P n/d y y 
399 KIF3A K3513 P y y y 
400 KSR      K4261 M n/d y n/d 
401 Ku Antigen  K2882 M y n/d n/d 
402 L1CAM L4543 M y n/d n/d 
403 l/s-Afadin  A0224 P y y y 
404 Laminin L9393 P y n/d n/d 
405 Laminin- -2 Chain) L0663 M y y n/d 
406 LAP2 (TMPO) L3414 M y n/d n/d 
407 Leptin L3410 P y y n/d 
408 Anti Cy3+Cy5 C0992 M NA NA NA 
409 LIM Kinase 1 L2290 P y y y 
410 LIN-7 L1538 P n/d n/d y 
411 LIS1 L7391 M y y y 
412 LKB1 L7917 P y y y 
413 LDS1 L4793 P y y y 
414 Mad1 M8069 M y n/d n/d 
415 Mad2 M8694 M y n/d n/d 
416 MADD M5683 P y y n/d 
417 MAFF M8194 P y n/d n/d 
418 MAGI-1 M5691 P n/d n/d y 
419 MAGI-2 M2441 P n/d n/d y 
420 
MAP Kinase, Activated/Monophosphorylated 
(Phosphothreonine ERK-1&2) M7802 M y n/d y 
421 MAP Kinase, Monophosphorylated Tyrosine  M3682 M y n/d y 
422 
MAP Kinase, Activated (Diphosphorylated 
ERK-1&2)  M9692 M y y y 
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423 MAP Kinase, Monophosphorylated Threonine  M3557 M y y y 
424 MAP Kinase (ERK-1)  M7927 P y y y 
425 MAP Kinase (ERK1+ERK2) M5670 P y y y 
426 
MAP Kinase Activated Protein Kinase-2 
(MAPKAPK-2)  M3550 P y y n/d 
427 MAP Kinase Phosphatase-1 (MKP-1) M3787 P y n/d n/d 
428 MAPK non phosphorylated ERK M3807 M y n/d y 
429 MAP Kinase 2 (ERK-2)  M7431 M y y y 
430 MAP Kinase Kinase (MEK, MAPKK)  M5795 P y y y 
431 MAP2 (2a+2b) M2320 M n/d n/d y 
432 Anti Cy3+Cy5 C0992 M NA NA NA 
433 MAP1 M4278 M n/d y y 
434 MAP1 (Light Chain) M6783 M n/d n/d y 
435 MAP1b M4528 M y y y 
436 MAP2 M9942 M y y y 
437 MBD1 M6569 P y n/d n/d 
438 MBD2a M7568 P y y n/d 
439 MBD2a,b M7318 P y y n/d 
440 MBD4 M9817 P n/d y n/d 
441 MBDin/XAB1  M1944 P y n/d n/d 
442 MBNL 1 M3320 M y y n/d 
443 MCH M8440 P y n/d n/d 
444 Mcl-1 M8434 P y n/d n/d 
445 MDC1 M2444 M y n/d n/d 
446 MDM2 M8558 M n/d y n/d 
447 MDM2 M4308 M y y y 
448 MDM2   M7815 M y y n/d 
449 MDMX M0445 M y n/d n/d 
450 MeCP2 M9317 P y n/d n/d 
451 MeCP2 M7443 M y y y 
452 MeCP2 M6818 M y y y 
453 MEKK4 M7194 M y y y 
454 Melanocortin-3 Receptor  M4937 P n/d n/d y 
455 MGMT M3068 M y n/d n/d 
456 Anti Cy3+Cy5 C0992 M NA NA NA 
457 Mint2 M3319 P n/d n/d y 
458 LRRK2 (PARK8) L3044 M y y n/d 
459 MRP1 M9192 M y n/d n/d 
460 MRP2 M3692 M y n/d n/d 
461 MSH  M0939 P y n/d n/d 
462 MSH6 M2445 P  y y y 
463 MSH6 M2820 P y y n/d 
464 MSK-1 M5437 P y n/d y 
465 MTA 2 M7569 M y y y 
466 MTA1 M1320 M y y y 
467 MTA1 M7693 P y n/d n/d 
468 MTA2/MTA1L M7818 P y n/d n/d 
469 MTA3L M0819 P y n/d n/d 
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470 MTBP M3566 P y n/d n/d 
471 mTOR T2949 P y y y 
472 Munc-18-1 M2694 P n/d y y 
473 Munc-13/1 M6194 M n/d y y 
474 MyD88 M9934 P y y n/d 
475 Myosin M1570 M y y y 
476 Myosin Iβ (Nuclear)  M3567 P y y y 
477 Myosin IIA M8064 P y n/d y 
478 Myosin IX/Myr5  M5566 P n/d n/d y 
479 Negative Control NA         
480 Anti Cy3+Cy5 C0992 M NA NA NA 
481 Myosin Light Chain Kinase M7905 M y y Y 
482 Myosin Va M4812 P n/d n/d y 
483 Myosin Va  M5062 P n/d n/d y 
484 Myosin VI  M0691 M y y y 
485 Myosin VI  M5187 P n/d n/d y 
486 NBS1 (Nibrin) N9287 M y n/d n/d 
487 NBS1 (Nibrin) N3037 P y n/d n/d 
488 NBS1 (Nibrin) N3162 P y n/d y 
489 Nck-2 N2911 M y n/d y 
490 Nedd 8     N2786 M y n/d n/d 
491 Nerve Growth Factor-β  N3279 M y y n/d 
492 Nerve Growth Factor Receptor N5408 M y n/d n/d 
493 Nerve growth factor receptor (NGFR p75) N3908 P n/d n/d y 
494 Neurabin I  N4412 P n/d y y 
495 Neurabin II (C-terminal)  N5037 P n/d y y 
496 Neurabin-II  N5162 P n/d y y 
497 Neurofibromin N3662 M y y y 
498 Neurofilament 160  N2787 M y y y 
499 Neurofilament 200 N4142 P y y y 
500 Neurofilament 200 N0142 M y y y 
501 Neurofilament 200  N5389 M y n/d n/d 
502 Neurofilament 68  N5139 M y n/d n/d 
503 Neurofilament 160/200 N2912 M y y y 
504 Anti Cy3+Cy5 C0992 M NA NA NA 
505 NF-kB N8523 M y y n/d 
506 -Activating Kinase)  N2661 M y n/d y 
507 NG2  N8912 M n/d n/d y 
508 Nicastrin N1660 P y n/d n/d 
509 Nitric Oxide Synthase, Brain (b-NOS)  N2280 M y n/d y 
510 Nitric Oxide Synthase, Brain (b-NOS)  N7155 P y n/d y 
511 Nitric Oxide Synthase, Endothelial ( e-NOS) N9532 M y y y 
512 Nitric Oxide Synthase, Endothelial ( e-NOS) N3893 P y y y 
513 Nitric Oxide Synthase, Endothelial ( e-NOS) N2643 P y y n/d 
514 Nitric Oxide Synthase, Inducible (i-NOS)  N7782 P n/d y y 
515 Nitric Oxide Synthase, Inducible (i-NOS)  N9657 M n/d y y 
516 Notch1 N6786 M y y n/d 
517 Nitrotyrosin N0409 P y n/d n/d 
292 
 
518 NTF2         N9527 M y y y 
519 Nuf2  N5287 M y n/d n/d 
520 O-GlcNAc Transferase  O6264 P y y y 
521 OP-18/Stathmin  O0138 P y n/d y 
522 Ornithine Decarboxylase (ODC) O1136 M y y n/d 
523 p115/TAP  P3118 M n/d n/d Y 
524 p120
ctn
 P1870 P y n/d n/d 
525 p130
CAS
 C0354 P y y y 
526 p14
 arf 
  P2610 M y n/d n/d 
527 p16
INK4a/CDKN2
      P0968 M y n/d n/d 
528 Anti Cy3+Cy5 C0992 M NA NA NA 
529 p19
INK4d
 P4354 M y n/d n/d 
530 p21WAF1/Cip1 
 
 P1484 M y y n/d 
531 p300/CBP P2859 M y y y 
532 p34
cdc2  
 C3085 M y y n/d 
533 p35 (Cdk5 Regulator) P9489 P y n/d y 
534 p38 MAP Kinase, Non-Activated  M8432 M y y y 
535 p38 MAPK M0800 P n/d y y 
536 p38 MAPK activated (diphosphorylated p38)  M8177 M y y y 
537 Negative Control NA         
538 p53 P5813 M y n/d n/d 
539 p53 P6874 M y n/d n/d 
540 phospho-p53 (pSer
392
)  P8982 P y y n/d 
541 p53DINP1/SIP P4868 P y y y 
542 p53R2l P4993 P y y y 
543 p53 BP1 B4561 P y y y 
544 p53 BP1 B4436 P y y n/d 
545 p57
kip2     
 P2735 M y y n/d 
546 p63 P3362 M y y n/d 
547 p63         P3737 M y y y 
548 PABP P6246 M y n/d n/d 
549 PAD14 P4749 P y n/d n/d 
550 phospho-PAK1 (pThr
212
) P3237 M y y y 
551 Par-4 (Prostate Apoptosis Response-4) P5367 P y y y 
552 Anti Cy3+Cy5 C0992 M NA NA NA 
553 Parvin  P5746 M y n/d n/d 
554 Parkin P6248 M y y y 
555 PARP P7605 P y n/d n/d 
556 Paxillin P1093 M y n/d y 
557 PCAF  P7493 P y n/d n/d 
558 Proliferating Cell Nuclear Antigen (PCNA) P8825 M y n/d n/d 
559 PDK 1 P3110 P y n/d n/d 
560 Pen-2  P5622 P y n/d n/d 
561 Peripherin P5117 M y y y 
562 Peroxiredoxin 3 P1247 P y n/d n/d 
563 PERP P5243 P y n/d n/d 
564 Phospholipase A2 group V P5242 M y n/d n/d 
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565 Phosphoserine     P5747 M y y y 
566 Phosphothreonine   P6623 M y y y 
567 Phosphotyrosine    P1869 M y y y 
568 Phospholipase C 1 (PLC 1) P8104 P y y n/d 
569 PhosphatidylSerine Receptor (PSR)  P1495 P y y n/d 
570 Negative Control NA         
571 PIAS-x  P9498 M y n/d n/d 
572 Negative Control NA         
573 PINCH-1 P9371 M y y y 
574 Protein Kinase BAkt1 P2482 M y y y 
575 Protein Kinase BAkt1 P1601 P y y y 
576 Anti Cy3+Cy5 C0992 M NA NA NA 
577 phospho-PKB (pSer
473
) P4112 P n/d y y 
578 phospho-PKB (pThr
308
) P3862 P n/d y y 
579 Protein Kinase C (PKC)  P5704 M y y y 
580  P4334 P n/d y y 
581 Protein Kinase Cβ1  P3078 P n/d n/d y 
582 Protein Kinase Cβ1  P6959 M n/d n/d y 
583 Protein Kinase Cβ2  P3203 P n/d n/d y 
584 Protein Kinase Cβ2  P2584 M n/d n/d y 
585 Protein Kinase C P8083 M n/d n/d y 
586 Protein Kinase Cδ  P8333 P n/d n/d y 
587 Protein Kinase Cε  P8458 P n/d n/d y 
588 Protein Kinase Cζ  P0713 P n/d y y 
589 Protein Kinase Cη  P8090 P y n/d n/d 
590 Protein Kinase D P3987 P y y n/d 
591 PKR P0244 P y n/d n/d 
592 Plakoglobin (Catenin ) P8087 M y n/d n/d 
593 Platelet-Derived Growth Factor Receptor β  P7679 M y n/d n/d 
594 Plectin P9318 M n/d n/d y 
595 PML P6746 M y y n/d 
596 Presenilin-1 (S182) P7854 P y y y 
597 Prion Protein  P5999 M n/d y y 
598 PRMT1 P6871 P y n/d n/d 
599 PRMT1 P6996 P y y y 
600 Anti Cy3+Cy5 C0992 M NA NA NA 
601 PRMT2  P0748 M y n/d n/d 
602 PRMT3 P9370 M y y y 
603 PRMT4 P4995 P y n/d n/d 
604 PRMT5 P0493 M y y y 
605 PRMT6 P6495 P y n/d n/d 
606 PRMT6 P2996 M y n/d n/d 
607 Proliferating Cell Protein Ki-67  P6834 M y n/d n/d 
608 Protein Phosphatase 1 P7979 P y n/d n/d 
609 Protein Phosphatase 1 P7607 M y y y 
610 Protein Phosphatase 2A (PP2A) P8998 M y y n/d 
611 Protein S P4555 P y n/d n/d 
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612 Protein Tyrosine Phosphatase PEST  P9109 M y y y 
613 PSF P2860 M y y n/d 
614 PTEN P7482 P y n/d y 
615 PTEN  P3487 M y y y 
616 PUMA/bbc3, C-Terminal P4618 P y y n/d 
617 PUMA/bbc3, N-Terminal P4743 P y n/d n/d 
618 Pyk2 P3902 P y y y 
619 AP2 beta A6589 M y n/d n/d 
620 phospho-Pyk2 (pTyr
579/580
) P6989 P y n/d n/d 
621 AA2 ahpla A6659 M y n/d n/d 
622 Negative Control NA         
623 Rab5 R7904 M y y y 
624 Anti Cy3+Cy5 C0992 M NA NA NA 
625 Rab 7 R8779 M y y y 
626 Rab9 R5404 M y y y 
627 RAD1 R5029 P y n/d n/d 
628 Rad17 (C-terminal)  R8029 P y n/d n/d 
629 Raf-1/c-Raf  R2404 M y y y 
630 Raf-1 R5773 P y n/d y 
631 phospho-c-Raf (pSer
621
) R1151 P y y y 
632 RAIDD, Internal Domain  R9775 P y n/d n/d 
633 RAIDD R5275 P y n/d n/d 
634 RALAR R8529 M y y y 
635 Ran            R4777 M y y n/d 
636 PIASy P0104 M y n/d n/d 
637 RAP1 R8154 M y n/d n/d 
638 RbAp48/RbAp46  R3779 P y n/d n/d 
639 Reelin R4904 P n/d y y 
640 Retinoblastoma R6775 P y n/d n/d 
641 phospho-Retinoblastoma (pSer
795
)  R6878 M y y y 
642 RhoE R6153 M y y n/d 
643 RICK, C-Terminal  R9650 P y y y 
644 RIP (Receptor Interacting Protein) R8274 P y n/d n/d 
645 RNase L R3529 M y n/d n/d 
646 ROCK-1 R6028 P y y y 
647 ROCK-2 R8653 P y y n/d 
648 Anti Cy3+Cy5 C0992 M NA NA NA 
649 Rsk1             R5145 P y y y 
650 S-100 S2644 P y n/d y 
651 S-100 (Subunit) S2407 M y n/d n/d 
652 S-100 (β-Subunit)  S2532 M y n/d y 
653 S-Nitrosocysteine  N5411 P y y y 
654 S6 Kinase  S4047 P y y y 
655 SAPK3        S0315 P y y y 
656  S3396 M y n/d n/d 
657 Serine/Threonine Protein Phosphatase 2 A/A  P8109 P y y y 
658 Serine/Threonine Protein Phosphatase 1β  P7484 P y y y 
659  P7609 P y y y 
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660 Serine/Threonine Protein Phosphatase 2 A/B  P5359  P y y y 
661 
Serine/Threonine Protein Phosphatase 2 A/B′ 
pan2  P8359 P n/d n/d y 
662 Serine/Threonine Protein Phosphatase 2C  P8609 P y y n/d 
663 AP2 gamma A3108 M y n/d n/d 
664 SGK  S5188 P y n/d n/d 
665 SH-PTP2 (SHP-2)      S3056 P y n/d n/d 
666 Siah2  S7945 M y y n/d 
667 Sin3A, N-terminal  S4445 P y y y 
668 Sin3A, C-Terminal  S6695 P y n/d n/d 
669 Sir2 S5313 P n/d y n/d 
670 SIRP1 (SHPS-1)  S1311 P n/d y y 
671 Sirt1  S5196 M n/d y n/d 
672 Anti Cy3+Cy5 C0992 M NA NA NA 
673 SKM1 (Skeletal Muscle Type 1) S9568 M n/d y y 
674 Beta tubulin III (neuronal) T5855 M y y y 
675 SLIPR/MAGI-3  S1190 P n/d n/d y 
676 SLIPR/MAGI-3 S4191 M n/d n/d y 
677 Smad4 (DPC4)  S3934 M y n/d n/d 
678 SMC1L1 S6446 P y n/d n/d 
679 SMN  S2944 M y y n/d 
680 -SNAP, C-terminus  S9444 P y y y 
681 SNAP-23  S2194 P n/d y n/d 
682 SNAP-25 S9684 P n/d y y 
683 SNAP- 29 S2069 P n/d y y 
684 Sos1    S2937 P y n/d n/d 
685 Sp1 S9809 P y n/d n/d 
686 Spred-2 S7320 P y y y 
687 Striatin S0696 P n/d y y 
688 Substance P Receptor  S8305 P y y y 
689 SMAC/Diablo S0941 P y y n/d 
690 SUMO-1 S8070 P y n/d n/d 
691 SUMO-1 (C-terminal) S5446 P y n/d n/d 
692 Survivin  S8191 P y n/d n/d 
693 Synaptotagmin S2177 P y y n/d 
694 Synaptopodin S9442 P n/d n/d y 
695 Synaptopodin  S9567 P n/d n/d y 
696 Anti Cy3+Cy5 C0992 M NA NA NA 
697 SynCAM S4945 P n/d y y 
698 1 Syntrophin S4688 P n/d n/d y 
699 1 Syntrophin S4813 P n/d n/d y 
700 Syntaxin S0664 M n/d n/d y 
701 Syntaxin 6 S9067 M y y y 
702 Syntaxin 8 S8945 P n/d n/d y 
703 Synuclein  S3062 P y n/d y 
704 Negative Control NA         
705 Tal  T1075 P y y y 
706 Tal  T1200 P y y y 
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707 TAP T1076 M y n/d n/d 
708 Tau  T9450 M y y y 
709 phospho-Tau (pSer
199/202
)  T6819 P y y y 
710 Tau T5530 M y n/d n/d 
711 Tenascin T2551 M y n/d n/d 
712 Thimet Oligopeptidase 1 T7076 M y n/d n/d 
713 TIS7 T2576 M y y n/d 
714 Tumor Necrosis Factor Soluble Receptor II  T1815 M y n/d n/d 
715 Tob T2948 M y n/d n/d 
716 TOM22 T6319 M y n/d n/d 
717 Topoisomerase-I  T8573 M y n/d n/d 
718 TRAIL T3067 M y n/d n/d 
719 TRAIL T9191 P y n/d n/d 
720 Anti Cy3+Cy5 C0992 M NA NA NA 
721 Transforming Growth Factor-β, pan  T9429 P y n/d n/d 
722 Transportin 1 T0825 M y y y 
723 TRF1        T1948 M y n/d n/d 
724 Tropomyosin T2780 M y y y 
725 Tropomyosin (Sarcomeric) T9283 M y n/d y 
726 Tryptophane Hydroxylase T0678 M y n/d y 
727 TSG101 T5826 P y y y 
728 Tubulin T6074 M y y y 
729 Tubulin T6199 M y y y 
730 Tubulin T5201 M y y y 
731 β-Tubulin I T7816 M y y y 
732 Tubulin I+II T8535 M y y y 
733 Tubulin III T5076 M y n/d y 
734 β-Tubulin IV  T7941 M y y y 
735 Tubulin T5326 M y y y 
736 Tubulin T3559 P y n/d n/d 
737 Tubulin T3320 P y n/d y 
738 ε-Tubulin  T1323 M y y n/d 
739 Tubulin, Polyglutamylated  T9822 M y y y 
740 Tubulin, Tyrosine T9028 M y n/d n/d 
741 Tumor Necrosis Factor-  T8300 P y n/d n/d 
742 Tumor Necrosis Factor-  T2824 M n/d y y 
743 Nanog N3038 M y n/d n/d 
744 Anti Cy3+Cy5 C0992 M NA NA NA 
745 TWEAK Receptor/Fn-14  T9700 M y n/d n/d 
746 Tyrosin hydroxylase T2928 M y n/d y 
747 U2AF
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 U4758 M y y y 
748 Ubiquitin U0508 M y y y 
749 Ubiquitin C-terminal Hydrolase L1  U5133 P y y y 
750 Ubiquitin C-terminal Hydrolase L1  U5258 P y y y 
751 Pinin P0084 M y n/d n/d 
752 Vanilloid Receptor-1 V2764 P n/d n/d y 
753 VDAC/Porin V2139 P y y y 
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754 
Vascular Endothelial Growth Factor Receptor-
1 (VEGFR-1)  V4762 M y n/d n/d 
755 Vesicular GABA Transporter  V5764 P n/d y y 
756 VGLUT 1 V0389 P y n/d n/d 
757 VGLUT 2 V2639 P n/d n/d y 
758 Vimentin V6389 M y n/d y 
759 Vinculin V4505 M y y n/d 
760 Vitronectin V7881 M y n/d n/d 
761 WAVE W0392 P y y y 
762 WSTF  W3516 P y y n/d 
763 Y14 Y1253 M y n/d n/d 
764 ZAP-70  Z0627 M y y n/d 
765 Zip Kinase  Z0134 P y n/d n/d 
766 Zyxin Z0377 M y y y 
767 GAPDH G8795 M y y y 
768 Anti Cy3+Cy5 C0992 M NA NA NA 
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Protein ID Log ratio Fold change 
14-3-3 T5942 -1.658 -3.15 
BclXl B9429 1.362 2.57 
Calbindin D 28K C7354 -2.398 -5.27 
CDK5 C6118 -0.944 -1.92 
CUGBP1 C5112 -1.169 -2.24 
Cytokeratin Peptide 4 C5176 -1.328 -2.51 
Dystrophin D8043 0.914 1.88 
E2F6 E1532 -1.458 -2.74 
FAK pTyr577 F8926 -0.989 -1.98 
FANCD2 F0305 0.965 1.95 
HDAC2 H3159 0.846 1.79 
HDAC6 H2287 0.915 1.88 
ILK I1907 1.048 2.06 
MDMX M0445 0.852 1.8 
Mint2 M3319 -2.012 -4.03 
NFkB N8523 -0.905 -1.87 
p19INK4d P4354 -1.344 -2.53 
Pan Cytokeratin C2931 1.077 2.1 
PRMT2 P0748 -1.833 -3.56 
SynCAM S4945 -0.982 -1.97 
Tau pSer199 202 T6819 -0.99 -1.98 
Tranforming Growth factor beta pan T9429 -1.682 -3.2 
TWEAK Receptor T9700 -1.465 -2.76 
Zyxin Z0377 -1.108 -2.15 
Appendix 3: The list of differntially expressed proteins identified in the experiment #1c; 
sample #16B
CS
 vs #1B
CR
 (Half-Labelling Protocol). A total of n=24 proteins were identified 
with a fold change of ≥1.8 as listed below (Refer: Table 47 in thesis). 
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Protein ID Log ratio Fold Change 
PRMT2 P0748 -1.545 -2.91 
Anti Cy3/5 C0992 -1.43 -2.69 
FAK pTyr577 F8926 -1.038 -2.05 
FANCCD2 F0305 0.9 1.86 
G9a Methyltransferase G6919 -0.998 -1.99 
GRANZYME B G1044 0.869 1.826 
ILK I1907 1.037 2.05 
LIM Kinase 1 L2290 -0.858 -1.81 
MeCP2 M9317 0.898 1.86 
Pan cytokeratin C2931 1.484 2.79 
DR4 D3813 0.84 1.79 
ROCK1 R6028 0.975 1.96 
ZAP70 Z0627 -0.909 -1.87 
Appendix 4: The list of differntially expressed proteins identified from the combined 
experiments #2 and #2b (Full and Half-Labelling Proctocols); sample #38
CS
 vs #15. A total of 
n=13 proteins were identified with a fold change of ≥1.8 as listed below from both the 
experiments (Refer: Table 47 in thesis). 
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Proteins ID Log ratio Fold change 
14 3 3 T5942 -2.401 -5.28 
ARC A8344 0.921 1.89 
BclxL B9429 0.999 1.99 
Csk C7863 1.287 2.44 
DR4 D3813 1.468 2.76 
E2F6 E1532 -0.972 -1.96 
FANCD2 F0305 1.039 2.05 
G9a Methyltransfersase G6919 -1.203 -2.3 
MSK1 M5437 1.775 3.42 
p19INK4d P4354 -1.101 -2.14 
Pan Cytokeratin C2931 1.12 2.17 
Pinin P0084 1.182 2.26 
Rab7 R8779 -1.113 -2.16 
RNaseL R3529 -1.171 -2.25 
SNX6 S6324 2.416 5.33 
Appendix 5: The list of differntially expressed proteins identified in the experiment #3; 
sample #12B
CS
 vs #1
CR
 (Half-Labelling Protocol). A total of n=15 proteins were identified 
with a fold change of ≥1.8 as listed below (Refer: Table 47 in thesis). 
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Proteins Gene Names 
14- 3-3 YWHAQ 
Annexin V ANXA5 
Chondroitin sulfate ACAN 
Protein Kinase Ba AKT1 
Mint2 APBA2 
BclxL BCL2L1 
BID BID 
Calbindin D 28K CALB1 
CDK5 CDK5 
p19INK4d CDKN2D 
Centrin CETN1 
IKKa CHUK 
Csk CSK 
CUGBP1 CUGBP1 
Dystrophin DMD 
Desmosomal protein DSC1 
E2F6 E2F6 
Epidermal Growth Factor EGF 
G9a Methyl Transferase EHMT2 
FANCD2 FANCD2 
GRANZYME B GZMB 
Dimethyl Histone H3/Acetyl Histone H3 AcLys9 H3F3A 
HDAC4 HDAC4 
HDAC6 HDAC6 
ILK ILK 
Cytokeratin peptide 4 KRT4 
LIM Kinase 1 LIMK1 
PINCH 1 LIMS1 
SAPK3 MAPK12 
Tau pSer199 202 MAPT 
MDMX MDM4 
MeCP2 MECP2 
Ki-67 MKI67 
cMyc MYC 
MyD88 MYD88 
NFkB NFKB1 
ARC NOL3 
Pinin PNN 
Appendix 6: The list of 72 differentially expressed proteins identified and mapped onto 
IPA from the combined analysis #1 (9 x AbMA experiments TH+VH combined data). 
Refer to section 4.2.1 in the thesis. 
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Protein Kinase Cb2/Protein Kinase Cb1 PRKCB 
PRMT2 PRMT2 
FAKpTyr577 PTK2 
Rab7 RAB7A 
RALAR RALA 
Reelin RELN 
RIP RIPK1 
RNaseL RNASEL 
ROCK1 ROCK1 
Rsk1 RPS6KA1 
MSK1 RPS6KA5 
S6 Kinase RPS6KB1 
Sir2 SIRT1 
hSNF5 INI1 SMARCB1 
SNX6 SNX6 
Sp1 SP1 
DRAK1 STK17A 
TBP TBP 
Tranforming Growth factor beta pan TGFB1 
DR4 TNFRSF10A 
TWEAK receptor TNFRSF12A 
TRAIL TNFSF10 
Transportin 1 TNPO1 
Tropomyosin TPM1 
Munc13 1 UNC13A 
ZAP70 ZAP70 
Zyxin ZYX 
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Proteins Gene Names 
14 3 3 YWHAQ 
14-3-3 protein epsilon YWHAE 
14-3-3 protein gamma YWHAG 
14-3-3 protein theta YWHAQ 
14-3-3 protein zeta/delta YWHAZ 
Activator of 90 kDa heat shock protein ATPase homolog 1 AHSA1 
Adenine phosphoribosyltransferase APRT 
Annexin A3 ANXA3 
Annexin V ANXA5 
Apolipoprotein A1 APOA1 
ARC NOL3 
ATP synthase subunit beta, mitochondrial ATP5B 
Barrier-to-autointegration factor BANF1 
BclxL BCL2L1 
BID BID 
Calbindin D 28K CALB1 
CDK5 CDK5 
Cellular retinoic acid-binding protein 2 CRABP2 
Centrin CETN1 
Chloride intracellular channel protein 1 CLIC1 
Chondroitin sulfate ACAN 
cMyc MYC 
Coactosin-like protein COTL1 
Creatine kinase B-type CKB 
Csk CSK 
CUGBP1 CUGBP1 
Cytokeratin peptide 4 KRT4 
Cytokeratin 19 KRT19 
Desmosomal protein DSC1 
Dimethyl Histone H3/Acetyl Histone H3 AcLys9 H3F3A 
DR4 TNFRSF10A 
DRAK1 STK17A 
Dystrophin DMD 
E2F6 E2F6 
Epidermal Growth Factor EGF 
FAKpTyr577 PTK2 
FANCD2 FANCD2 
Appendix 7: The list of 125 differentially expressed proteins identified and loaded onto 
IPA from the combined analysis #2 (9 x AbMA experiments + 2x 2D-PAGE/MS + 3 
Literature proteins combined data). Refer to section 4.2.2 in the thesis. 
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Ferritin light chain FTL 
G9a Methyl Transferase EHMT2 
Glutathione S-transferase omega-1 GSTO1 
Glutathione S-transferase P GSTP1 
Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic GPD1 
GRANZYME B GZMB 
HDAC4 HDAC4 
HDAC6 HDAC6 
HEBP2 protein (fragment) HEBP2 
highly similar to Heat-shock protein beta-6 HSPB6 
Histone-binding protein RBBP4 RBBP4 
hSNF5 INI1 SMARCB1 
HSP27 HSBP1 
IKKa CHUK 
ILK ILK 
Inorganic pyrophosphatase PPA1 
Isoform 1 of Acyl-protein thioesterase 1 LYPLA1 
Isoform 1 of Alpha-1-antitrypsin SERPINA1 
Isoform 1 of Eukaryotic translation initiation factor 5A-1 EIF5A 
Isoform 1 of Nucleoside diphosphate kinase A NME1 
Isoform 2 of F-actin-capping protein subunit beta CAPZB 
Isoform 2 of Tropomyosin alpha-3 chain TPM3 
Isoform 2 of Tropomyosin alpha-4 chain TPM4 
Isoform 3 of Tropomyosin alpha-1 chain TPM1 
Isoform Long of 14-3-3 protein beta/alpha YWHAB 
Isoform Long of Proteasome subunit alpha type-1 PSMA1 
Keratin, type I cytoskeletal 19 KRT19 
Keratin, type II cytoskeletal 8 KRT8 
Ki-67 MKI67 
LIM Kinase 1 LIMK1 
Macrophage-capping protein CAPG 
MDMX MDM4 
MeCP2 MECP2 
Microfibril-associated glycoprotein 4 MFAP4 
Microtubule-associated protein RP/EB family member 1 MAPRE1 
Mint2 APBA2 
MSK1 RPS6KA5 
Munc13 1 UNC13A 
MyD88 MYD88 
Myosin regulatory light chain 12B MYL12B 
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NFkB NFKB1 
p19INK4d CDKN2D 
peroxiredoxin 3 isoform b PRDX3 
PINCH 1 LIMS1 
Pinin PNN 
Platelet-activating factor acetylhydrolase IB subunit beta PAFAH1B2 
PRMT2 PRMT2 
Prohibitin PHB 
Proteasome activator complex subunit 1 PSME1 
proteasome activator subunit 2 PSME2 
Proteasome subunit beta type-3 PSMB3 
Protein disulfide-isomerase P4HB 
Protein Kinase Ba AKT1 
Protein Kinase Cb2/Protein Kinase Cb1 PRKCB 
Protein SEC13 homolog SEC13 
Rab7 RAB7A 
RALAR RALA 
Reelin RELN 
Rho GDP-dissociation inhibitor 1 ARHGDIA 
Rho GDP-dissociation inhibitor 2 ARHGDIB 
Ribonuclease inhibitor RNH1 
RIP RIPK1 
RNaseL RNASEL 
ROCK1 ROCK1 
Rsk1 RPS6KA1 
S6 Kinase RPS6KB1 
SAPK3 MAPK12 
Serum amyloid P-component APCS 
Sir2 SIRT1 
SNX6 SNX6 
Sorcin GCL 
Sp1 SP1 
Stathmin STMN1 
Tau pSer199 202 MAPT 
TBP TBP 
T-complex protein 1 subunit beta CCT2 
TRAIL TNFSF10 
Tranforming Growth factor beta pan TGFB1 
Transportin 1 TNPO1 
Transthyretin TTR 
Tropomyosin TPM1 
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Tubulin-specific chaperone A TBCA 
Tumor protein, translationally-controlled 1 TPT1 
TWEAK receptor TNFRSF12A 
Vimentin VIM 
ZAP70 ZAP70 
Zyxin ZYX 
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